DICKKOPF-1 VARIANT ANTIBODIES AND METHODS OF USE

Abstract

Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding Dickkopf WNT signaling pathway inhibitor 1 (DKK1) antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Description

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Apr. 17, 2023, is named 44854-843_201_SL.xml and is 2,407,906 bytes in size.

BACKGROUND

Dickkopf WNT signaling pathway inhibitor 1 (also known as dickkopf-1 or DKK1) is a secreted glycoprotein characterized by two cysteine-rich domains that mediate protein-protein interactions. DKK1 is involved in embryonic development of the heart, head, and forelimbs through its inhibition of the WNT signaling pathway. In adults, elevated expression of this gene has been observed in numerous human cancers, and this protein may promote proliferation, invasion, and growth in cancer cell lines. Given the role of DKK1 in various diseases and disorders, there is a need for improved therapeutics.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF SUMMARY

Provided herein are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH), wherein the VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-98 or 919-1332; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 99-196 or 1333-1746; and (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 197-294 or 1747-2160. Further provided herein are antibodies or antibody fragments, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are antibodies or antibody fragments, wherein the antibody is a single domain antibody. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 50 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 25 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 10 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 5 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to DKK1.

Provided herein are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258, and wherein the VL comprises at least 90% sequence identity to any one of SEQ ID NOs 713-918. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 50 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 25 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 10 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 5 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are antibodies or antibody fragments, wherein the antibody is a single domain antibody.

Provided herein are nucleic acid compositions comprising: a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-98 or 919-1332; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 99-196 or 1333-1746; and (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 197-294 or 1747-2160; and an excipient.

Provided herein are nucleic acid compositions comprising: a) a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258; and an excipient.

Provided herein are antibodies or antibody fragments comprising a variable domain, light chain region (VL), wherein the VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 2259-2464; (b) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 2465-2521; and (c) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 2522-2727. Further provided herein are antibodies or antibody fragments, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are antibodies or antibody fragments, wherein the antibody is a single domain antibody. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 50 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 25 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 10 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 5 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to DKK1.

Provided herein are antibodies or antibody fragments comprising a variable domain, light chain region (VL) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 713-918. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 50 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 25 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 10 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_D of less than 5 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarily determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are antibodies or antibody fragments, wherein the antibody is a single domain antibody.

Provided herein are nucleic acid compositions comprising: a first nucleic acid encoding a variable domain, light chain region (VL) comprising complementarily determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 2259-2464; (b) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 2465-2521; and (c) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 2522-2727; and an excipient.

Provided herein are nucleic acid compositions comprising: a) a first nucleic acid encoding a variable domain, light chain region (VL) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 713-918; and an excipient.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1A depicts a first schematic of an immunoglobulin.

FIG. 1B depicts a second schematic of an immunoglobulin.

FIG. 2 depicts a schematic of a motif for placement in an immunoglobulin.

FIG. 3 presents a diagram of steps demonstrating an exemplary process workflow for gene synthesis as disclosed herein.

FIG. 4 illustrates an example of a computer system.

FIG. 5 is a block diagram illustrating an architecture of a computer system.

FIG. 6 is a diagram demonstrating a network configured to incorporate a plurality of computer systems, a plurality of cell phones and personal data assistants, and Network Attached Storage (NAS).

FIG. 7 is a block diagram of a multiprocessor computer system using a shared virtual address memory space.

FIG. 8A depicts a schematic of an immunoglobulin comprising a VH domain attached to a VL domain using a linker.

FIG. 8B depicts a schematic of a full-domain architecture of an immunoglobulin comprising a VH domain attached to a VL domain using a linker, a leader sequence, and pIII sequence.

FIG. 8C depicts a schematic of four framework elements (FW1, FW2, FW3, FW4) and the variable 3 CDR (L1, L2, L3) elements for a VL or VH domain.

FIG. 9A depicts long read NGS sequencing of the eluted phage pool for antibody pool A. The top portion of the figure shows the cluster enrichment number, the number of instances the antibody appears, plotted against the cluster rank, which lists the antibody rank order of the antibodies by size cluster. The bottom portion of the figure shows the parallel histogram showing the distribution of the HCDR3 lengths among the top 95 antibody clusters.

FIG. 9B depicts long read NGS sequencing of the eluted phage pool for antibody pool B. The top portion of the figure shows the cluster enrichment number, the number of instances the antibody appears, plotted against the cluster rank, which lists the antibody rank order of the antibodies by size cluster. The bottom portion of the figure shows the parallel histogram showing the distribution of the HCDR3 lengths among the top 95 antibody clusters.

FIG. 9C depicts long read NGS sequencing of the eluted phage pool for antibody pool C. The top portion of the figure shows the cluster enrichment number, the number of instances the antibody appears, plotted against the cluster rank, which lists the antibody rank order of the antibodies by size cluster. The bottom portion of the figure shows the parallel histogram showing the distribution of the HCDR3 lengths among the top 95 antibody clusters.

FIG. 10A depicts the distribution of antibody yields from 1.2 mL high-throughput antibody expression and purification among antibodies identified from the three library pools. Points are color-coded by whether the antibody was identified by phage ELISA screening (blue) or NGS enrichment data (green).

FIG. 10B depicts the distribution of antibody binding affinity to DKK1 as measured by SPR (Carterra). Points are color-coded by whether the antibody was identified by phage ELISA screening (blue) or NGS enrichment data (green).

FIG. 10C depicts the distribution of MFI ratio among antibodies identified from the three library pools. The MFI ratio is defined as the MFI measured of the antibody binding to HEK293 cells overexpressing DKK1 divided by the MFI measured of the antibody binding to HEK293 cells. Points are color-coded by whether the antibody was identified by phage ELISA screening (blue) or NGS enrichment data (green).

FIG. 11A depicts the relationship between the MFI ratio and binding affinity to DKK1 as measured by SPR. The size of each dot corresponds to the antibody yield from 1.2 ml high-throughput antibody expression and purification. Points are color-coded by the library pool used during panning.

FIG. 11B depicts the relationship between the MFI ratio and binding affinity to DKK1 as measured by SPR. The size of each dot corresponds to the antibody yield from 1.2 ml high-throughput antibody expression and purification. Points are color-coded by whether the antibody was identified by phage ELISA screening (blue) or NGS enrichment data (green).

FIG. 12A depicts Carterra SPR kinetic graphs showing VHH-Fc hits identified from NGS sequencing binding with high affinity to DKK1. Antibody lawn (10 ug/mL), 0-500 nM antigen, HBSTE+0.5 mg/mL BSA pH 7.4. FIG. 12B depicts Carterra SPR kinetic graphs showing VHH-Fc hits identified from ELISA screening binding with high affinity to DKK1. FIG. 12C depicts additional Carterra SPR kinetic graphs showing VHH-Fc hits identified from NGS sequencing binding with high affinity to DKK1. FIG. 12D depicts additional Carterra SPR kinetic graphs showing VHH-Fc hits identified from NGS sequencing binding with high affinity to DKK1.

FIG. 13 depicts the results of a TCF/LEF reporter (Wnt signaling) assay. Wnt signaling activation is plotted with SPR binding affinity.

FIGS. 14A-14D depict in vitro primary immune cell activation. FIG. 14A depicts an immune cell activation assay using peripheral blood mononuclear cells (PBMCs) and interferon gamma (IFN or IFN-γ). FIG. 14B depicts an immune cell activation assay using PBMCs and granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is the marker for NK cell activation. Human PBMC is treated with immune stimulator, mWnt3a, hDKK1, and Dkk1 leads from ML synthetic library (FIG. 14C) and ML from VHH library (FIG. 14D). Cytokine release of GM-CSF is measured by ELISA.

FIG. 15A depicts the outcomes of a tumor killing assay. Activated immune cells kill PC3, while hDKK1 treatment inhibits cytotoxicity. FIG. 15B depicts a graph of the results of a tumor killing assay. FIG. 15C highlights specific hits from the tumor killing assay that were also found in the TCF/LEF reporter (Wnt signaling) assay. FIG. 15D shows that ML synthetic library and ML from VHH library restore the cytotoxicity potency when DKK1 leads block the interaction of hDKK1 to the receptor. FIG. 15E shows PC3 tumor cell viability results. FIG. 15F shows top clones in a PC3 cytotoxicity assay. FIG. 15G shows a subset of the top clones in a PC3 cytotoxicity assay.

FIG. 16 depicts antibody yield results from 1 mL Expi293 cell culture.

FIGS. 17A-C show anti-DKK1 binding to hDKK1 by SPR analysis. FIG. 17A shows two epitope binds (activation of Wnt signaling vs immune response) apparent among DKK1 leads. FIG. 17B shows an example of a hDDK1 protein with CRD1 and CRD2 annotated. FIG. 17C shows that DKK1 leads which bind to hDKK1 CRD1 and/or hDKK1 CRD2 result in different activation pathways.

FIGS. 18A-18C depict Wnt TCF/LEF reporter assay screening. Wnt TCF/LEF signaling is blocked by DKK1 binding to LRP5/6. DKK1 leads were screened from a VHH library (FIG. 18A), a ML synthetic library (FIG. 18B), and a ML from VHH library (FIG. 18C).

FIGS. 19A-19D depict BsAb functional assays. DKK1-99 binds to DKK1 CRD1 and activates an immune response, while DKK1-100 binds to DKK1 CRD2 and activates Wnt signaling. A bispecific Ab of DKK1-99 and DKK1-100 (FIG. 19A) shows the potency of activating both Wnt (FIG. 19B) and immune response (FIG. 19C). FIG. 19D shows another graph of immune response activation.

FIGS. 20A-20D depict DKK1 leads in tumor regression. FIG. 20A shows a schematic of mice inoculation with PC3 cells. Dosing was initiated at tumor volume average of approximately 100 mm³ with 10 mg/kg via intraperitoneal injection once every 3 days for 8 cycles. Tumor sizes were measured 3 times a week. FIG. 20B shows that anti-DKK1 treatment downregulates tumor growth, showing its efficacy in tumor suppression. FIG. 20C shows that anti-DKK1 treatment downregulates tumor growth, showing efficacy in tumor suppression in days 1-7 of the study. FIG. 20D shows the mean tumor volume across days 1-7 of the study.

FIG. 21 depicts a schematic of the panning rounds for DKK1 antibody production.

FIGS. 22A-22C show that antagonism of DKK1 inhibition of WNT in TCF/LEF assays is biphasic. FIG. 22A shows a control DKN-01 antibody. FIG. 22B shows the results for DKK1-28. FIG. 22C shows the results for DKK1-100.

FIG. 23A shows that transient and cell line TCF/LEF reporter rankings match in functional assays. FIG. 23B shows a subset of the results of FIG. 23A.

FIG. 24 shows the development of a DKK1/LRP6 binding assay.

FIGS. 25A-25C show that functional antagonists DKN-01 (FIG. 25A), DKK1-100 (FIG. 25B), and DKK1-28 (FIG. 25C) enhance DKK1 binding to LRP6.

FIGS. 26A-26B show the results of primary immune cell reactivation assays. FIG. 26A shows results using the IFN-gamma marker of immune cell activation. FIG. 26B shows results using the GM-CSF marker for immune cell activation.

FIG. 27A shows the results for primary NK cell activation. FIG. 27B shows immune cell activation assay results for top clones. FIG. 27C shows a subset of the results of FIG. 27B.

FIG. 28A-28D show the identification of antagonists DKK1-473 (FIG. 28A), DKK1-478 (FIG. 28B), DKK1-477 (FIG. 28C), and DKK1-448 (FIG. 28D) through signaling titration assays.

FIG. 29A shows the results of an immune assay. FIG. 29B shows a subset of the results of FIG. 29A.

FIG. 30 depicts lung tumor organoid killing by immune cells with DKK1 inhibition.

DETAILED DESCRIPTION

The present disclosure employs, unless otherwise indicated, conventional molecular biology techniques, which are within the skill of the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art.

Definitions

Throughout this disclosure, various embodiments are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of any embodiments. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range to the tenth of the unit of the lower limit unless the context clearly dictates otherwise. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual values within that range, for example, 1.1, 2, 2.3, 5, and 5.9. This applies regardless of the breadth of the range. The upper and lower limits of these intervening ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, unless the context clearly dictates otherwise.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of any embodiment. As used herein, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, components, and/or groups, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.

Unless specifically stated or obvious from context, as used herein, the term “about” in reference to a number or range of numbers is understood to mean the stated number and numbers +/−10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range.

Unless specifically stated, as used herein, the term “nucleic acid” encompasses double- or triple-stranded nucleic acids, as well as single-stranded molecules. In double- or triple-stranded nucleic acids, the nucleic acid strands need not be coextensive (i.e., a double-stranded nucleic acid need not be double-stranded along the entire length of both strands). Nucleic acid sequences, when provided, are listed in the 5′ to 3′ direction, unless stated otherwise. Methods described herein provide for the generation of isolated nucleic acids. Methods described herein additionally provide for the generation of isolated and purified nucleic acids. A “nucleic acid” as referred to herein can comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or more bases in length. Moreover, provided herein are methods for the synthesis of any number of polypeptide-segments encoding nucleotide sequences, including sequences encoding non-ribosomal peptides (NRPs), sequences encoding non-ribosomal peptide-synthetase (NRPS) modules and synthetic variants, polypeptide segments of other modular proteins, such as antibodies, polypeptide segments from other protein families, including non-coding DNA or RNA, such as regulatory sequences e.g. promoters, transcription factors, enhancers, siRNA, shRNA, RNAi, miRNA, small nucleolar RNA derived from microRNA, or any functional or structural DNA or RNA unit of interest. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, intergenic DNA, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), small nucleolar RNA, ribozymes, complementary DNA (cDNA), which is a DNA representation of mRNA, usually obtained by reverse transcription of messenger RNA (mRNA) or by amplification; DNA molecules produced synthetically or by amplification, genomic DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. cDNA encoding for a gene or gene fragment referred herein may comprise at least one region encoding for exon sequences without an intervening intron sequence in the genomic equivalent sequence.

DKK1 Libraries

Provided herein are methods and compositions relating to dickkopf WNT signaling pathway inhibitor 1 (DKK1) variant immunoglobulins (e.g., antibody, VHH)comprising nucleic acids encoding for an immunoglobulin comprising a DKK1 binding domain. Immunoglobulins as described herein can stably support a DKK1 binding domain. Libraries as described herein may be further variegated to provide for variant libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries that may be generated when the nucleic acid libraries are translated. In some instances, nucleic acid libraries as described herein are transferred into cells to generate a cell library. Also provided herein are downstream applications for the libraries synthesized using methods described herein. Downstream applications include identification of variant nucleic acids or protein sequences with enhanced biologically relevant functions, e.g., improved stability, affinity, binding, functional activity, and for the treatment or prevention of a disease state associated with DKK1.

Provided herein are libraries comprising nucleic acids encoding for an immunoglobulin. In some instances, the immunoglobulin is an antibody. As used herein, the term antibody will be understood to include proteins having the characteristic two-armed, Y-shape of a typical antibody molecule as well as one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Exemplary antibodies include, but are not limited to, a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv) (including fragments in which the VL and VH are joined using recombinant methods by a synthetic or natural linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules, including single chain Fab and scFab), a single chain antibody, a Fab fragment (including monovalent fragments comprising the VL, VH, CL, and CH1 domains), a F(ab′)2 fragment (including bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region), a Fd fragment (including fragments comprising the VH and CH1 fragment), a Fv fragment (including fragments comprising the VL and VH domains of a single arm of an antibody), a single-domain antibody (dAb or sdAb) (including fragments comprising a VH domain), an isolated complementarity determining region (CDR), a diabody (including fragments comprising bivalent dimers such as two VL and VH domains bound to each other and recognizing two different antigens), a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. In some instances, the libraries disclosed herein comprise nucleic acids encoding for an immunoglobulin, wherein the immunoglobulin is a Fv antibody, including Fv antibodies comprised of the minimum antibody fragment which contains a complete antigen-recognition and antigen-binding site. In some embodiments, the Fv antibody consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association, and the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. In some embodiments, the six hypervariable regions confer antigen-binding specificity to the antibody. In some embodiments, a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen, including single domain antibodies isolated from camelid animals comprising one heavy chain variable domain such as VHH antibodies or nanobodies) has the ability to recognize and bind antigen. In some instances, the libraries disclosed herein comprise nucleic acids encoding for an immunoglobulin, wherein the immunoglobulin is a single-chain Fv or scFv, including antibody fragments comprising a VH, a VL, or both a VH and VL domain, wherein both domains are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains allowing the scFv to form the desired structure for antigen binding. In some instances, a scFv is linked to the Fc fragment or a VHH is linked to the Fc fragment (including minibodies). In some instances, the antibody comprises immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, e.g., molecules that contain an antigen binding site. Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG 2, IgG 3, IgG 4, IgA 1 and IgA 2), or subclass.

In some embodiments, libraries comprise immunoglobulins that are adapted to the species of an intended therapeutic target. Generally, these methods include “mammalization” and comprise methods for transferring donor antigen-binding information to a less immunogenic mammal antibody acceptor to generate useful therapeutic treatments. In some instances, the mammal is mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, or human. In some instances, provided herein are libraries and methods for felinization and caninization of antibodies.

“Humanized” forms of non-human antibodies can be chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human antibody (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. In some instances, these modifications are made to further refine antibody performance.

“Caninization” can comprise a method for transferring non-canine antigen-binding information from a donor antibody to a less immunogenic canine antibody acceptor to generate treatments useful as therapeutics in dogs. In some instances, caninized forms of non-canine antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-canine antibodies. In some instances, caninized antibodies are canine antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-canine species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties. In some instances, framework region (FR) residues of the canine antibody are replaced by corresponding non-canine FR residues. In some instances, caninized antibodies include residues that are not found in the recipient antibody or in the donor antibody. In some instances, these modifications are made to further refine antibody performance. The caninized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc) of a canine antibody.

“Felinization” can comprise a method for transferring non-feline antigen-binding information from a donor antibody to a less immunogenic feline antibody acceptor to generate treatments useful as therapeutics in cats. In some instances, felinized forms of non-feline antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-feline antibodies. In some instances, felinized antibodies are feline antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-feline species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties. In some instances, framework region (FR) residues of the feline antibody are replaced by corresponding non-feline FR residues. In some instances, felinized antibodies include residues that are not found in the recipient antibody or in the donor antibody. In some instances, these modifications are made to further refine antibody performance. The felinized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc) of a felinize antibody.

Provided herein are libraries comprising nucleic acids encoding for a non-immunoglobulin. For example, the non-immunoglobulin is an antibody mimetic. Exemplary antibody mimetics include, but are not limited to, anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, atrimers, DARPins, fynomers, Kunitz domain-based proteins, monobodies, anticalins, knottins, armadillo repeat protein-based proteins, and bicyclic peptides.

Libraries described herein comprising nucleic acids encoding for an immunoglobulin comprising variations in at least one region of the immunoglobulin. Exemplary regions of the antibody for variation include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain. In some instances, the CDR is CDR1, CDR2, or CDR3. In some instances, the CDR is a heavy domain including, but not limited to, CDRH1, CDRH2, and CDRH3. In some instances, the CDR is a light domain including, but not limited to, CDRL1, CDRL2, and CDRL3. In some instances, the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH). In some instances, the VL domain comprises kappa or lambda chains. In some instances, the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH).

Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for an immunoglobulin, wherein each nucleic acid encodes for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the variant library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.

In some instances, the at least one region of the immunoglobulin for variation is from heavy chain V-gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family. In some instances, the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL). Exemplary genes include, but are not limited to, IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV1-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, and IGLV3-1. In some instances, the gene is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the gene is IGHV1-69 and IGHV3-30. In some instances, the gene is IGHJ3, IGHJ6, IGHJ, IGHJ4, IGHJ5, IGHJ2, or IGH1. In some instances, the gene is IGHJ3, IGHJ6, IGHJ, or IGHJ4.

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins, wherein the libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the fragments comprise framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the immunoglobulin libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.

Libraries comprising nucleic acids encoding for immunoglobulins as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 amino acids to about 75 amino acids. In some instances, the immunoglobulins comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.

A number of variant sequences for the at least one region of the immunoglobulin for variation are de novo synthesized using methods as described herein. In some instances, a number of variant sequences is de novo synthesized for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is at least or about 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, or more than 8000 sequences. In some instances, the number of variant sequences is about 10 to 500, 25 to 475, 50 to 450, 75 to 425, 100 to 400, 125 to 375, 150 to 350, 175 to 325, 200 to 300, 225 to 375, 250 to 350, or 275 to 325 sequences.

Variant sequences for the at least one region of the immunoglobulin, in some instances, vary in length or sequence. In some instances, the at least one region that is de novo synthesized is for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, the at least one region that is de novo synthesized is for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more than 50 variant nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 additional nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 less nucleotides or amino acids as compared to wild-type. In some instances, the libraries comprise at least or about 10¹, 10², 10³, 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, or more than 10¹⁰ variants.

Following synthesis of libraries described herein, libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. In some instances, libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.

In some instances, the libraries are assayed for functional activity, structural stability (e.g., thermal stable or pH stable), expression, specificity, or a combination thereof. In some instances, the libraries are assayed for immunoglobulin (e.g., an antibody) capable of folding. In some instances, a region of the antibody is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof. For example, a VH region or VL region is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof.

DKK1 Libraries

Provided herein are DKK1 variant immunoglobulins (e.g., antibody, VHH)comprising nucleic acids encoding for immunoglobulins (e.g., antibodies) that bind to DKK1. In some instances, the immunoglobulin sequences for DKK1 binding domains are determined by interactions between the DKK1 binding domains and the DKK1.

Sequences of DKK1 binding domains based on surface interactions of DKK1 are analyzed using various methods. For example, multispecies computational analysis is performed. In some instances, a structure analysis is performed. In some instances, a sequence analysis is performed. Sequence analysis can be performed using a database known in the art. Non-limiting examples of databases include, but are not limited to, NCBI BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi), UCSC Genome Browser (genome.ucsc.edu/), UniProt (www.uniprot.org/), and IUPHAR/BPS Guide to PHARMACOLOGY (guidetopharmacology.org/).

Described herein are DKK1 binding domains designed based on sequence analysis among various organisms. For example, sequence analysis is performed to identify homologous sequences in different organisms. Exemplary organisms include, but are not limited to, mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, fish, fly, and human.

Following identification of DKK1 binding domains, libraries comprising nucleic acids encoding for the DKK1 binding domains may be generated. In some instances, libraries of DKK1 binding domains comprise sequences of DKK1 binding domains designed based on conformational ligand interactions, peptide ligand interactions, small molecule ligand interactions, extracellular domains of DKK1, or antibodies that target DKK1. In some instances, libraries of DKK1 binding domains comprise sequences of DKK1 binding domains designed based on peptide ligand interactions. Libraries of DKK1 binding domains may be translated to generate protein libraries. In some instances, libraries of DKK1 binding domains are translated to generate peptide libraries, immunoglobulin libraries, derivatives thereof, or combinations thereof. In some instances, libraries of DKK1 binding domains are translated to generate protein libraries that are further modified to generate peptidomimetic libraries. In some instances, libraries of DKK1 binding domains are translated to generate protein libraries that are used to generate small molecules.

Methods described herein provide for synthesis of libraries of DKK1 binding domains comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the libraries of DKK1 binding domains comprise varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a DKK1 binding domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a DKK1 binding domain. An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.

Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for the DKK1 binding domains, wherein the libraries comprise sequences encoding for variation of length of the DKK1 binding domains. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.

Provided herein are DKK1 variant immunoglobulins (e.g., antibody, VHH) comprising nucleic acids encoding for immunoglobulins comprising DKK1 binding domains comprising variation in domain type, domain length, or residue variation. In some instances, the domain is a region in the immunoglobulin comprising the DKK1 binding domains. For example, the region is the VH, CDRH1, CDRH2, CDRH3, VL, CDRL1, CDRL2, or CDRL3 domain. In some instances, the domain is the DKK1 binding domain.

Methods described herein provide for synthesis of a DKK1 binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the DKK1 binding library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a VH, CDRH1, CDRH2, CDRH3, VL, CDRL1, CDRL2, or CDRL3 domain. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a DKK1 binding domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a VH, CDRH1, CDRH2, CDRH3, VL, CDRL1, CDRL2, or CDRL3 domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a DKK1 binding domain. An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.

Methods described herein provide for synthesis of a DKK1 binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence, wherein the DKK1 binding library comprises sequences encoding for variation of length of a domain. In some instances, the domain is VH, CDRH1, CDRH2, CDRH3, VL, CDRL1, CDRL2, or CDRL3 domain. In some instances, the domain is the DKK1 binding domain. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.

Provided herein are DKK1 variant immunoglobulins (e.g., antibody, VHH) comprising nucleic acids encoding for immunoglobulins comprising DKK1 binding domains, wherein the DKK1 binding libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the VH, CDRH1, CDRH2, CDRH3, VL, CDRL1, CDRL2, or CDRL3 domain. In some instances, the DKK1 variant immunoglobulins (e.g., antibody, VHH) are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.

DKK1 variant immunoglobulins (e.g., antibody, VHH) comprising nucleic acids encoding for immunoglobulins comprising DKK1 binding domains as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 to about 75 amino acids.

DKK1 variant immunoglobulins (e.g., antibody, VHH) comprising de novo synthesized variant sequences encoding for immunoglobulins comprising DKK1 binding domains comprise a number of variant sequences. In some instances, a number of variant sequences is de novo synthesized for a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or a combination thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, a number of variant sequences is de novo synthesized for a GPCR binding domain. For example, the number of variant sequences is about 1 to about 10 sequences for the VH domain, about 108 sequences for the DKK1 binding domain, and about 1 to about 44 sequences for the VL domain. The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is about 10 to 300, 25 to 275, 50 to 250, 75 to 225, 100 to 200, or 125 to 150 sequences.

Described herein are antibodies or antibody fragments thereof that binds DKK1. In some embodiments, the antibody or antibody fragment thereof comprises a sequence as set forth in Tables 4-8. In some embodiments, the antibody or antibody fragment thereof comprises a sequence that is at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence as set forth in Tables 4-8.

In some instances, an antibody or antibody fragment described herein comprises a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332.

In some instances, an antibody or antibody fragment described herein comprises a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746.

In some instances, an antibody or antibody fragment described herein comprises a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160.

In some instances, an antibody or antibody fragment described herein comprises a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464.

In some instances, an antibody or antibody fragment described herein comprises a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521.

In some instances, an antibody or antibody fragment described herein comprises a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727.

Described herein, in some embodiments, are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 713-918. In some instances, the antibodies or antibody fragments comprise VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258. In some instances, the antibodies or antibody fragments comprise VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 713-918.

The term “sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software.

Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y, where Xis the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

The term “homology” or “similarity” between two proteins is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one protein sequence to the second protein sequence. Similarity may be determined by procedures which are well-known in the art, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information).

The terms “complementarity determining region,” and “CDR,” which are synonymous with “hypervariable region” or “HVR,” are known in the art to refer to non-contiguous sequences of amino acids within antibody variable regions, which confer antigen specificity and/or binding affinity. In general, there are three CDRs in each heavy chain variable region (CDRH1, CDRH2, CDRH3) and three CDRs in each light chain variable region (CDRL1, CDRL2, CDRL3). “Framework regions” and “FR” are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each full-length heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4). The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc M P et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 January; 27(1):55-77 (“IMGT” numbering scheme); Honegger A and Plückthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun. 8; 309(3):657-70, (“Aho” numbering scheme); and Whitelegg N R and Rees A R, “WAM: an improved algorithm for modelling antibodies on the WEB,” Protein Eng. 2000 December; 13(12):819-24 (“AbM” numbering scheme. In certain embodiments the CDRs of the antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM, or combinations thereof.

The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.

DKK1 variant immunoglobulins (e.g., antibody, VHH)comprising de novo synthesized variant sequences encoding for immunoglobulins comprising DKK1 binding domains comprise improved diversity. For example, variants are generated by placing DKK1binding domain variants in immunoglobulins comprising N-terminal CDRH3 variations and C-terminal CDRH3 variations. In some instances, variants include affinity maturation variants. Alternatively or in combination, variants include variants in other regions of the immunoglobulin including, but not limited to, CDRH1 and CDRH2. In some instances, the number of variants of the DKK1 variant immunoglobulins (e.g., antibody, VHH) is at least or about 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, 10¹⁹, 10²⁰, or more than 10²⁰ non-identical sequences.

In some instances, the at least one region of the antibody for variation is from heavy chain V-gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family. In some instances, the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL). Exemplary regions of the antibody for variation include, but are not limited to, IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV1-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, and IGLV3-1. In some instances, the gene is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the gene is IGHV1-69 and IGHV3-30. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, IGHJ4, IGHJ5, IGHJ2, or IGH1. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, or IGHJ4. In some instances, the at least one region of the antibody for variation is IGHV1-69, IGHV3-23, IGKV3-20, IGKV1-39, or combinations thereof. In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGKV3-20, In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGKV1-39. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV3-20. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV1-39.

Provided herein are libraries comprising nucleic acids encoding for a DKK1 antibody comprising variation in at least one region of the antibody, wherein the region is the CDR region. In some instances, the DKK1 antibody is a single domain antibody comprising one heavy chain variable domain such as a VHH antibody. In some instances, the VHH antibody comprises variation in one or more CDR regions. In some instances, libraries described herein comprise at least or about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2400, 2600, 2800, 3000, or more than 3000 sequences of a CDR1, CDR2, or CDR3. In some instances, libraries described herein comprise at least or about 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, 10¹⁹, 10²⁰, or more than 10²⁰ sequences of a CDR1, CDR2, or CDR3. For example, the libraries comprise at least 2000 sequences of a CDR1, at least 1200 sequences for CDR2, and at least 1600 sequences for CDR3. In some instances, each sequence is non-identical.

In some instances, the CDR1, CDR2, or CDR3 is of a variable domain, light chain (VL). CDR1, CDR2, or CDR3 of a variable domain, light chain (VL) can be referred to as CDRL1, CDRL2, or CDRL3, respectively. In some instances, libraries described herein comprise at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2400, 2600, 2800, 3000, or more than 3000 sequences of a CDR1, CDR2, or CDR3 of the VL. In some instances, libraries described herein comprise at least or about 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, 10¹⁹, 10²⁰, or more than 10²⁰ sequences of a CDR1, CDR2, or CDR3 of the VL. For example, the libraries comprise at least 20 sequences of a CDR1 of the VL, at least 4 sequences of a CDR2 of the VL, and at least 140 sequences of a CDR3 of the VL. In some instances, the libraries comprise at least 2 sequences of a CDR1 of the VL, at least 1 sequence of CDR2 of the VL, and at least 3000 sequences of a CDR3 of the VL. In some instances, the VL is IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, or IGLV3-1. In some instances, the VL is IGKV2-28. In some instances, the VL is IGLV1-51.

In some instances, the CDR1, CDR2, or CDR3 is of a variable domain, heavy chain (VH). CDR1, CDR2, or CDR3 of a variable domain, heavy chain (VH) can be referred to as CDRH1, CDRH2, or CDRH3, respectively. In some instances, libraries described herein comprise at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2400, 2600, 2800, 3000, or more than 3000 sequences of a CDR1, CDR2, or CDR3 of the VH. In some instances, libraries described herein comprise at least or about 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, 10¹⁹, 10²⁰, or more than 10²⁰ sequences of a CDR1, CDR2, or CDR3 of the VH. For example, the libraries comprise at least 30 sequences of a CDR1 of the VH, at least 570 sequences of a CDR2 of the VH, and at least 108 sequences of a CDR3 of the VH. In some instances, the libraries comprise at least 30 sequences of a CDR1 of the VH, at least 860 sequences of a CDR2 of the VH, and at least 107 sequences of a CDR3 of the VH. In some instances, the VH is IGHV1-18, IGHV1-69, IGHV1-8 IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV3-74, IGHV4-39, or IGHV4-59/61. In some instances, the VH is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the VH is IGHV1-69 or IGHV3-30. In some instances, the VH is IGHV3-23.

Libraries as described herein, in some embodiments, comprise varying lengths of a CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3. In some instances, the length of the CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 comprises at least or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or more than 90 amino acids in length. For example, the CDRH3 comprises at least or about 12, 15, 16, 17, 20, 21, or 23 amino acids in length. In some instances, the CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 comprises a range of about 1 to about 10, about 5 to about 15, about 10 to about 20, or about 15 to about 30 amino acids in length.

Libraries comprising nucleic acids encoding for antibodies having variant CDR sequences as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 amino acids to about 75 amino acids. In some instances, the antibodies comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.

Ratios of the lengths of a CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 may vary in libraries described herein. In some instances, a CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 comprising at least or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or more than 90 amino acids in length comprises about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90% of the library. For example, a CDRH3 comprising about 23 amino acids in length is present in the library at 40%, a CDRH3 comprising about 21 amino acids in length is present in the library at 30%, a CDRH3 comprising about 17 amino acids in length is present in the library at 20%, and a CDRH3 comprising about 12 amino acids in length is present in the library at 10%. In some instances, a CDRH3 comprising about 20 amino acids in length is present in the library at 40%, a CDRH3 comprising about 16 amino acids in length is present in the library at 30%, a CDRH3 comprising about 15 amino acids in length is present in the library at 20%, and a CDRH3 comprising about 12 amino acids in length is present in the library at 10%.

Libraries as described herein encoding for a VHH antibody comprise variant CDR sequences that are shuffled to generate a library with a theoretical diversity of at least or about 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, 10¹⁹, 10²⁰, or more than 10²⁰ sequences. In some instances, the library has a final library diversity of at least or about 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, 10¹⁹, 10²⁰, or more than 10²⁰ sequences.

Provided herein are DKK1 variant immunoglobulins (e.g., antibody, VHH)encoding for an immunoglobulin. In some instances, the DKK1 immunoglobulin is an antibody. In some instances, the DKK1 immunoglobulin is a VHH antibody. In some instances, the DKK1 immunoglobulin comprises a binding affinity (e.g., kD) to DKK1 of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 11 nm, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 1 nM. In some instances, the DKK1immunoglobulin comprises a kD of less than 1.2 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 2 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 5 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 10 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 13.5 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 15 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 20 nM. In some instances, the DKK1immunoglobulin comprises a kD of less than 25 nM. In some instances, the DKK1 immunoglobulin comprises a kD of less than 30 nM.

Provided herein are DKK1 variant immunoglobulins (e.g., antibody, VHH)encoding for an immunoglobulin, wherein the immunoglobulin comprises a long half-life. In some instances, the half-life of the DKK1 immunoglobulin is at least or about 12 hours, 24 hours 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 140 hours, 160 hours, 180 hours, 200 hours, or more than 200 hours. In some instances, the half-life of the DKK1 immunoglobulin is in a range of about 12 hours to about 300 hours, about 20 hours to about 280 hours, about 40 hours to about 240 hours, or about 60 hours to about 200 hours.

DKK1 immunoglobulins as described herein may comprise improved properties. In some instances, the DKK1 immunoglobulins are monomeric. In some instances, the DKK1 immunoglobulins are not prone to aggregation. In some instances, at least or about 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the DKK1 immunoglobulins are monomeric. In some instances, the DKK1 immunoglobulins are thermostable. In some instances, the DKK1 immunoglobulins result in reduced non-specific binding.

Following synthesis of DKK1 variant immunoglobulins (e.g., antibody, VHH)comprising nucleic acids encoding immunoglobulins comprising DKK1 binding domains, libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. In some instances, the DKK1 variant immunoglobulins (e.g., antibody, VHH)comprises nucleic acids encoding immunoglobulins with multiple tags such as GFP, FLAG, and Lucy as well as a DNA barcode. In some instances, libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.

Expression Systems

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins comprising DKK1 binding domains, wherein the libraries have improved specificity, stability, expression, folding, or downstream activity. In some instances, libraries described herein are used for screening and analysis.

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins comprising DKK1 binding domains, wherein the nucleic acid libraries are used for screening and analysis. In some instances, screening and analysis comprise in vitro, in vivo, or ex vivo assays. Cells for screening include primary cells taken from living subjects or cell lines. Cells may be from prokaryotes (e.g., bacteria and fungi) or eukaryotes (e.g., animals and plants). Exemplary animal cells include, without limitation, those from a mouse, rabbit, primate, and insect. In some instances, cells for screening include a cell line including, but not limited to, Chinese Hamster Ovary (CHO) cell line, human embryonic kidney (HEK) cell line, or baby hamster kidney (BHK) cell line. In some instances, nucleic acid libraries described herein may also be delivered to a multicellular organism. Exemplary multicellular organisms include, without limitation, a plant, a mouse, rabbit, primate, and insect.

Nucleic acid libraries or protein libraries encoded thereof described herein may be screened for various pharmacological or pharmacokinetic properties. In some instances, the libraries are screened using in vitro assays, in vivo assays, or ex vivo assays. For example, in vitro pharmacological or pharmacokinetic properties that are screened include, but are not limited to, binding affinity, binding specificity, and binding avidity. Exemplary in vivo pharmacological or pharmacokinetic properties of libraries described herein that are screened include, but are not limited to, therapeutic efficacy, activity, preclinical toxicity properties, clinical efficacy properties, clinical toxicity properties, immunogenicity, potency, and clinical safety properties.

Pharmacological or pharmacokinetic properties that may be screened include, but are not limited to, cell binding affinity and cell activity. For example, cell binding affinity assays or cell activity assays are performed to determine agonistic, antagonistic, or allosteric effects of libraries described herein. In some instances, libraries as described herein are compared to cell binding or cell activity of ligands of DKK1.

Libraries as described herein may be screened in cell-based assays or in non-cell-based assays. Examples of non-cell-based assays include, but are not limited to, using viral particles, using in vitro translation proteins, and using proteoliposomes with DKK1.

Nucleic acid libraries as described herein may be screened by sequencing. In some instances, next generation sequence is used to determine sequence enrichment of DKK1 binding variants. In some instances, V gene distribution, J gene distribution, V gene family, CDR3 counts per length, or a combination thereof is determined. In some instances, clonal frequency, clonal accumulation, lineage accumulation, or a combination thereof is determined. In some instances, number of sequences, sequences with VH clones, clones, clones greater than 1, clonotypes, clonotypes greater than 1, lineages, simpsons, or a combination thereof is determined. In some instances, a percentage of non-identical CDR3s is determined. For example, the percentage of non-identical CDR3s is calculated as the number of non-identical CDR3s in a sample divided by the total number of sequences that had a CDR3 in the sample.

Provided herein are nucleic acid libraries, wherein the nucleic acid libraries may be expressed in a vector. Expression vectors for inserting nucleic acid libraries disclosed herein may comprise eukaryotic or prokaryotic expression vectors. Exemplary expression vectors include, without limitation, mammalian expression vectors: pSF-CMV-NEO-NH2-PPT-3XFLAG, pSF-CMV-NEO—COOH-3XFLAG, pSF-CMV—PURO-NH2-GST-TEV, pSF-OXB20-COOH-TEV-FLAG(R)-6His, pCEP4 pDEST27, pSF-CMV-Ub-KrYFP, pSF-CMV-FMDV-daGFP, pEF1a-mCherry-N1 Vector, pEFla-tdTomato Vector, pSF-CMV-FMDV-Hygro, pSF-CMV-PGK-Puro, pMCP-tag(m), and pSF-CMV—PURO-NH2-CMYC; bacterial expression vectors: pSF-OXB20-BetaGal,pSF-OXB20-Fluc, pSF-OXB20, and pSF-Tac; plant expression vectors: pRI 101-AN DNA and pCambia2301; and yeast expression vectors: pTYB21 and pKLAC2, and insect vectors: pAc5.1/V5-His A and pDEST8. In some instances, the vector is pcDNA3 or pcDNA3.1.

Described herein are nucleic acid libraries that are expressed in a vector to generate a construct comprising an immunoglobulin comprising sequences of DKK1 binding domains. In some instances, a size of the construct varies. In some instances, the construct comprises at least or about 500, 600, 700, 800, 900, 1000, 1100, 1300, 1400, 1500, 1600, 1700, 1800, 2000, 2400, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200, 4400, 4600, 4800, 5000, 6000, 7000, 8000, 9000, 10000, or more than 10000 bases. In some instances, a the construct comprises a range of about 300 to 1,000, 300 to 2,000, 300 to 3,000, 300 to 4,000, 300 to 5,000, 300 to 6,000, 300 to 7,000, 300 to 8,000, 300 to 9,000, 300 to 10,000, 1,000 to 2,000, 1,000 to 3,000, 1,000 to 4,000, 1,000 to 5,000, 1,000 to 6,000, 1,000 to 7,000, 1,000 to 8,000, 1,000 to 9,000, 1,000 to 10,000, 2,000 to 3,000, 2,000 to 4,000, 2,000 to 5,000, 2,000 to 6,000, 2,000 to 7,000, 2,000 to 8,000, 2,000 to 9,000, 2,000 to 10,000, 3,000 to 4,000, 3,000 to 5,000, 3,000 to 6,000, 3,000 to 7,000, 3,000 to 8,000, 3,000 to 9,000, 3,000 to 10,000, 4,000 to 5,000, 4,000 to 6,000, 4,000 to 7,000, 4,000 to 8,000, 4,000 to 9,000, 4,000 to 10,000, 5,000 to 6,000, 5,000 to 7,000, 5,000 to 8,000, 5,000 to 9,000, 5,000 to 10,000, 6,000 to 7,000, 6,000 to 8,000, 6,000 to 9,000, 6,000 to 10,000, 7,000 to 8,000, 7,000 to 9,000, 7,000 to 10,000, 8,000 to 9,000, 8,000 to 10,000, or 9,000 to 10,000 bases.

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins, wherein the nucleic acid libraries are expressed in a cell. In some instances, the libraries are synthesized to express a reporter gene. Exemplary reporter genes include, but are not limited to, acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), cerulean fluorescent protein, citrine fluorescent protein, orange fluorescent protein, cherry fluorescent protein, turquoise fluorescent protein, blue fluorescent protein, horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), luciferase, and derivatives thereof. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), and antibiotic resistance determination.

Diseases and Disorders

Provided herein are DKK1 variant immunoglobulins (e.g., antibody, VHH)comprising nucleic acids encoding for immunoglobulins (e.g., antibodies) comprising DKK1 binding domains that may have therapeutic effects. In some instances, the DKK1 variant immunoglobulins (e.g., antibody, VHH)result in protein when translated that is used to treat a disease or disorder. In some instances, the protein is an immunoglobulin. In some instances, the protein is a peptidomimetic.

Exemplary diseases include, but are not limited to, cancer (e.g., gastro-esophageal cancer, endometrial cancer, ovarian cancer, prostate cancer, liver cancer, etc.), inflammatory diseases or disorders, a metabolic disease or disorder, a cardiovascular disease or disorder, a respiratory disease or disorder, pain, a digestive disease or disorder, a reproductive disease or disorder, an endocrine disease or disorder, or a neurological disease or disorder. In some instances, the cancer is a solid cancer or a hematologic cancer. In some instances, a modulator of DKK1 as described herein is used for treatment of weight gain (or for inducing weight loss), treatment of obesity, or treatment of Type II diabetes. In some instances, the DKK1 modulator is used for treating hypoglycemia. In some instances, the DKK1 modulator is used for treating post-bariatric hypoglycemia. In some instances, the DKK1 modulator is used for treating severe hypoglycemia. In some instances, the DKK1 modulator is used for treating hyperinsulinism. In some instances, the DKK1modulator is used for treating congenital hyperinsulinism.

DKK1 can be tumorigenic in cancer. DKK1 can also be immunosuppressive (e.g., via myeloid-derived suppressor cells (MDSCs) or natural killer (NK) cells). DKK1 can lead to immune suppression through T cell inactivation, MDSC accumulation, or NK cell clearance. DKK1 can inhibit Wnt binding to low-density lipoprotein (LDL) receptor related protein 5 (LRP5). DKK1 can inhibit Wnt binding to LDL receptor related protein 6 (LRP6). DKK1 can inhibit Wnt binding to an LRP5/6 complex. Mutations in Wnt activating genes can lead to increased DKK1 expression.

Antagonist mAb can activate an innate immune response with anti-angiogenic and direct antitumor effects, binding and removing DKK1 from the tumor microenvironment. Tumors with Wnt activating mutations can responded to DKK1 antagonism. For example, high tumoral DKK1 can be associated with longer progression-free survival in esophagogastic cancer patients.

In some instances, the subject is a mammal. In some instances, the subject is a mouse, rabbit, dog, or human. Subjects treated by methods described herein may be infants, adults, or children. Pharmaceutical compositions comprising antibodies or antibody fragments as described herein may be administered intravenously or subcutaneously.

Described herein are pharmaceutical compositions comprising antibodies or antibody fragment thereof that binds DKK1. In some embodiments, the antibody or antibody fragment thereof comprises a sequence as set forth in Tables 4-8. In some embodiments, the antibody or antibody fragment thereof comprises a sequence that is at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence as set forth in Tables 4-8.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-98 or 919-1332.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRH2 sequence of any one of SEQ ID NOs: 99-196 or 1333-1746.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRH3 sequence of any one of SEQ ID NOs: 197-294 or 1747-2160.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRL1 sequence of any one of SEQ ID NOs: 2259-2464.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRL2 sequence of any one of SEQ ID NOs: 2465-2521.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a C CDRL3 sequence of any one of SEQ ID NOs: 2522-2727. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRL3 sequence of any one of SEQ ID NOs: 2522-2727.

In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-98 or 919-1332; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 99-196 or 1333-1746; and (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 197-294 or 1747-2160. In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1-98; (b) an amino acid sequence of CDRH2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 99-196; and (c) an amino acid sequence of CDRH3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 197-294.

In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 2259-2464; (b) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 2465-2521; and (c) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 2522-2727. In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRL1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 2259-2464; (b) an amino acid sequence of CDRL2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 2465-2521; and (c) an amino acid sequence of CDRL3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 2522-2727.

Described herein, in some embodiments, are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258. In some instances, the antibodies or antibody fragments comprise VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258.

Described herein, in some embodiments, are antibodies or antibody fragments comprising a variable domain, light chain region (VL), wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 713-918. In some instances, the antibodies or antibody fragments comprise VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 713-918.

Variant Libraries

Codon Variation

Variant nucleic acid libraries described herein may comprise a plurality of nucleic acids, wherein each nucleic acid encodes for a variant codon sequence compared to a reference nucleic acid sequence. In some instances, each nucleic acid of a first nucleic acid population contains a variant at a single variant site. In some instances, the first nucleic acid population contains a plurality of variants at a single variant site such that the first nucleic acid population contains more than one variant at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding multiple codon variants at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding up to 19 or more codons at the same position. The first nucleic acid population may comprise nucleic acids collectively encoding up to 60 variant triplets at the same position, or the first nucleic acid population may comprise nucleic acids collectively encoding up to 61 different triplets of codons at the same position. Each variant may encode for a codon that results in a different amino acid during translation.

A nucleic acid population may comprise varied nucleic acids collectively encoding up to 20 codon variations at multiple positions. In such cases, each nucleic acid in the population comprises variation for codons at more than one position in the same nucleic acid. In some instances, each nucleic acid in the population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more codons in a single nucleic acid. In some instances, each variant long nucleic acid comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single long nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons in at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more codons in a single long nucleic acid.

Highly Parallel Nucleic Acid Synthesis

Provided herein is a platform approach utilizing miniaturization, parallelization, and vertical integration of the end-to-end process from polynucleotide synthesis to gene assembly within nanowells on silicon to create a revolutionary synthesis platform. Devices described herein provide, with the same footprint as a 96-well plate, a silicon synthesis platform capable of increasing throughput by a factor of up to 1,000 or more compared to traditional synthesis methods, with production of up to approximately 1,000,000 or more polynucleotides, or 10,000 or more genes in a single highly-parallelized run.

With the advent of next-generation sequencing, high resolution genomic data has become an important factor for studies that delve into the biological roles of various genes in both normal biology and disease pathogenesis. At the core of this research is the central dogma of molecular biology and the concept of “residue-by-residue transfer of sequential information.” Genomic information encoded in the DNA is transcribed into a message that is then translated into the protein that is the active product within a given biological pathway.

Another exciting area of study is on the discovery, development and manufacturing of therapeutic molecules focused on a highly-specific cellular target. High diversity DNA sequence libraries are at the core of development pipelines for targeted therapeutics. Gene mutants are used to express proteins in a design, build, and test protein engineering cycle that ideally culminates in an optimized gene for high expression of a protein with high affinity for its therapeutic target. As an example, consider the binding pocket of a receptor. The ability to test all sequence permutations of all residues within the binding pocket simultaneously will allow for a thorough exploration, increasing chances of success. Saturation mutagenesis, in which a researcher attempts to generate all possible mutations at a specific site within the receptor, represents one approach to this development challenge. Though costly and time- and labor-intensive, it enables each variant to be introduced into each position. In contrast, combinatorial mutagenesis, where a few selected positions or short stretch of DNA may be modified extensively, generates an incomplete repertoire of variants with biased representation.

To accelerate the drug development pipeline, a library with the desired variants available at the intended frequency in the right position available for testing—in other words, a precision library—enables reduced costs as well as turnaround time for screening. Provided herein are methods for synthesizing nucleic acid synthetic variant libraries which provide for precise introduction of each intended variant at the desired frequency. To the end user, this translates to the ability to not only thoroughly sample sequence space but also be able to query these hypotheses in an efficient manner, reducing cost and screening time. Genome-wide editing can elucidate important pathways, libraries where each variant and sequence permutation can be tested for optimal functionality, and thousands of genes can be used to reconstruct entire pathways and genomes to re-engineer biological systems for drug discovery.

In a first example, a drug itself can be optimized using methods described herein. For example, to improve a specified function of an antibody, a variant polynucleotide library encoding for a portion of the antibody is designed and synthesized. A variant nucleic acid library for the antibody can then be generated by processes described herein (e.g., PCR mutagenesis followed by insertion into a vector). The antibody is then expressed in a production cell line and screened for enhanced activity. Example screens include examining modulation in binding affinity to an antigen, stability, or effector function (e.g., ADCC, complement, or apoptosis). Exemplary regions to optimize the antibody include, without limitation, the Fc region, Fab region, variable region of the Fab region, constant region of the Fab region, variable domain of the heavy chain or light chain (V_H or V_L), and specific complementarity-determining regions (CDRs) of V_H or V_L.

Nucleic acid libraries synthesized by methods described herein may be expressed in various cells associated with a disease state. Cells associated with a disease state include cell lines, tissue samples, primary cells from a subject, cultured cells expanded from a subject, or cells in a model system. Exemplary model systems include, without limitation, plant and animal models of a disease state.

To identify a variant molecule associated with prevention, reduction or treatment of a disease state, a variant nucleic acid library described herein is expressed in a cell associated with a disease state, or one in which a cell a disease state can be induced. In some instances, an agent is used to induce a disease state in cells. Exemplary tools for disease state induction include, without limitation, a Cre/Lox recombination system, LPS inflammation induction, and streptozotocin to induce hypoglycemia. The cells associated with a disease state may be cells from a model system or cultured cells, as well as cells from a subject having a particular disease condition. Exemplary disease conditions include a bacterial, fungal, viral, autoimmune, or proliferative disorder (e.g., cancer). In some instances, the variant nucleic acid library is expressed in the model system, cell line, or primary cells derived from a subject, and screened for changes in at least one cellular activity. Exemplary cellular activities include, without limitation, proliferation, cycle progression, cell death, adhesion, migration, reproduction, cell signaling, energy production, oxygen utilization, metabolic activity, and aging, response to free radical damage, or any combination thereof

Substrates

Devices used as a surface for polynucleotide synthesis may be in the form of substrates which include, without limitation, homogenous array surfaces, patterned array surfaces, channels, beads, gels, and the like. Provided herein are substrates comprising a plurality of clusters, wherein each cluster comprises a plurality of loci that support the attachment and synthesis of polynucleotides. In some instances, substrates comprise a homogenous array surface. For example, the homogenous array surface is a homogenous plate. The term “locus” as used herein refers to a discrete region on a structure which provides support for polynucleotides encoding for a single predetermined sequence to extend from the surface. In some instances, a locus is on a two-dimensional surface, e.g., a substantially planar surface. In some instances, a locus is on a three-dimensional surface, e.g., a well, microwell, channel, or post. In some instances, a surface of a locus comprises a material that is actively functionalized to attach to at least one nucleotide for polynucleotide synthesis, or preferably, a population of identical nucleotides for synthesis of a population of polynucleotides. In some instances, polynucleotide refers to a population of polynucleotides encoding for the same nucleic acid sequence. In some cases, a surface of a substrate is inclusive of one or a plurality of surfaces of a substrate. The average error rates for polynucleotides synthesized within a library described here using the systems and methods provided are often less than 1 in 1000, less than about 1 in 2000, less than about 1 in 3000 or less often without error correction.

Provided herein are surfaces that support the parallel synthesis of a plurality of polynucleotides having different predetermined sequences at addressable locations on a common support. In some instances, a substrate provides support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more non-identical polynucleotides. In some cases, the surfaces provide support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more polynucleotides encoding for distinct sequences. In some instances, at least a portion of the polynucleotides have an identical sequence or are configured to be synthesized with an identical sequence. In some instances, the substrate provides a surface environment for the growth of polynucleotides having at least 80, 90, 100, 120, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 bases or more.

Provided herein are methods for polynucleotide synthesis on distinct loci of a substrate, wherein each locus supports the synthesis of a population of polynucleotides. In some cases, each locus supports the synthesis of a population of polynucleotides having a different sequence than a population of polynucleotides grown on another locus. In some instances, each polynucleotide sequence is synthesized with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more redundancy across different loci within the same cluster of loci on a surface for polynucleotide synthesis. In some instances, the loci of a substrate are located within a plurality of clusters. In some instances, a substrate comprises at least 10, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 20000, 30000, 40000, 50000 or more clusters. In some instances, a substrate comprises more than 2,000; 5,000; 10,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,100,000; 1,200,000; 1,300,000; 1,400,000; 1,500,000; 1,600,000; 1,700,000; 1,800,000; 1,900,000; 2,000,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; or 10,000,000 or more distinct loci. In some instances, a substrate comprises about 10,000 distinct loci. The amount of loci within a single cluster is varied in different instances. In some cases, each cluster includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 150, 200, 300, 400, 500 or more loci. In some instances, each cluster includes about 50-500 loci. In some instances, each cluster includes about 100-200 loci. In some instances, each cluster includes about 100-150 loci. In some instances, each cluster includes about 109, 121, 130 or 137 loci. In some instances, each cluster includes about 19, 20, 61, 64 or more loci. Alternatively or in combination, polynucleotide synthesis occurs on a homogenous array surface.

In some instances, the number of distinct polynucleotides synthesized on a substrate is dependent on the number of distinct loci available in the substrate. In some instances, the density of loci within a cluster or surface of a substrate is at least or about 1, 10, 25, 50, 65, 75, 100, 130, 150, 175, 200, 300, 400, 500, 1,000 or more loci per mm². In some cases, a substrate comprises 10-500, 25-400, 50-500, 100-500, 150-500, 10-250, 50-250, 10-200, or 50-200 mm². In some instances, the distance between the centers of two adjacent loci within a cluster or surface is from about 10-500, from about 10-200, or from about 10-100 um. In some instances, the distance between two centers of adjacent loci is greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some instances, the distance between the centers of two adjacent loci is less than about 200, 150, 100, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, each locus has a width of about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some cases, each locus has a width of about 0.5-100, 0.5-50, 10-75, or 0.5-50 um.

In some instances, the density of clusters within a substrate is at least or about 1 cluster per 100 mm², 1 cluster per 10 mm², 1 cluster per 5 mm², 1 cluster per 4 mm², 1 cluster per 3 mm², 1 cluster per 2 mm², 1 cluster per 1 mm², 2 clusters per 1 mm², 3 clusters per 1 mm², 4 clusters per 1 mm², 5 clusters per 1 mm², 10 clusters per 1 mm², 50 clusters per 1 mm² or more. In some instances, a substrate comprises from about 1 cluster per 10 mm² to about 10 clusters per 1 mm². In some instances, the distance between the centers of two adjacent clusters is at least or about 50, 100, 200, 500, 1000, 2000, or 5000 um. In some cases, the distance between the centers of two adjacent clusters is between about 50-100, 50-200, 50-300, 50-500, and 100-2000 um. In some cases, the distance between the centers of two adjacent clusters is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some cases, each cluster has a cross section of about 0.5 to about 2, about 0.5 to about 1, or about 1 to about 2 mm. In some cases, each cluster has a cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm. In some cases, each cluster has an interior cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm.

In some instances, a substrate is about the size of a standard 96 well plate, for example between about 100 and about 200 mm by between about 50 and about 150 mm. In some instances, a substrate has a diameter less than or equal to about 1000, 500, 450, 400, 300, 250, 200, 150, 100 or 50 mm. In some instances, the diameter of a substrate is between about 25-1000, 25-800, 25-600, 25-500, 25-400, 25-300, or 25-200 mm. In some instances, a substrate has a planar surface area of at least about 100; 200; 500; 1,000; 2,000; 5,000; 10,000; 12,000; 15,000; 20,000; 30,000; 40,000; 50,000 mm² or more. In some instances, the thickness of a substrate is between about 50-2000, 50-1000, 100-1000, 200-1000, or 250-1000 mm.

Surface Materials

Substrates, devices, and reactors provided herein are fabricated from any variety of materials suitable for the methods, compositions, and systems described herein. In certain instances, substrate materials are fabricated to exhibit a low level of nucleotide binding. In some instances, substrate materials are modified to generate distinct surfaces that exhibit a high level of nucleotide binding. In some instances, substrate materials are transparent to visible and/or UV light. In some instances, substrate materials are sufficiently conductive, e.g., are able to form uniform electric fields across all or a portion of a substrate. In some instances, conductive materials are connected to an electric ground. In some instances, the substrate is heat conductive or insulated. In some instances, the materials are chemical resistant and heat resistant to support chemical or biochemical reactions, for example polynucleotide synthesis reaction processes. In some instances, a substrate comprises flexible materials. For flexible materials, materials can include, without limitation: nylon, both modified and unmodified, nitrocellulose, polypropylene, and the like. In some instances, a substrate comprises rigid materials. For rigid materials, materials can include, without limitation: glass; fuse silica; silicon, plastics (for example polytetraflouroethylene, polypropylene, polystyrene, polycarbonate, and blends thereof, and the like); and metals (for example, gold, platinum, and the like). The substrate, solid support or reactors can be fabricated from a material selected from the group consisting of silicon, polystyrene, agarose, dextran, cellulosic polymers, polyacrylamides, polydimethylsiloxane (PDMS), and glass. The substrates/solid supports or the microstructures/reactors therein may be manufactured with a combination of materials listed herein or any other suitable material known in the art.

Surface Architecture

Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates have a surface architecture suitable for the methods, compositions, and systems described herein. In some instances, a substrate comprises raised and/or lowered features. One benefit of having such features is an increase in surface area to support polynucleotide synthesis. In some instances, a substrate having raised and/or lowered features is referred to as a three-dimensional substrate. In some cases, a three-dimensional substrate comprises one or more channels. In some cases, one or more loci comprise a channel. In some cases, the channels are accessible to reagent deposition via a deposition device such as a material deposition device. In some cases, reagents and/or fluids collect in a larger well in fluid communication one or more channels. For example, a substrate comprises a plurality of channels corresponding to a plurality of loci with a cluster, and the plurality of channels are in fluid communication with one well of the cluster. In some methods, a library of polynucleotides is synthesized in a plurality of loci of a cluster.

Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates are configured for polynucleotide synthesis. In some instances, the structure is configured to allow for controlled flow and mass transfer paths for polynucleotide synthesis on a surface. In some instances, the configuration of a substrate allows for the controlled and even distribution of mass transfer paths, chemical exposure times, and/or wash efficacy during polynucleotide synthesis. In some instances, the configuration of a substrate allows for increased sweep efficiency, for example by providing sufficient volume for a growing polynucleotide such that the excluded volume by the growing polynucleotide does not take up more than 50, 45, 40, 35, 30, 25, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1%, or less of the initially available volume that is available or suitable for growing the polynucleotide. In some instances, a three-dimensional structure allows for managed flow of fluid to allow for the rapid exchange of chemical exposure.

Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates comprise structures suitable for the methods, compositions, and systems described herein. In some instances, segregation is achieved by physical structure. In some instances, segregation is achieved by differential functionalization of the surface generating active and passive regions for polynucleotide synthesis. In some instances, differential functionalization is achieved by alternating the hydrophobicity across the substrate surface, thereby creating water contact angle effects that cause beading or wetting of the deposited reagents. Employing larger structures can decrease splashing and cross-contamination of distinct polynucleotide synthesis locations with reagents of the neighboring spots. In some cases, a device, such as a material deposition device, is used to deposit reagents to distinct polynucleotide synthesis locations. Substrates having three-dimensional features are configured in a manner that allows for the synthesis of a large number of polynucleotides (e.g., more than about 10,000) with a low error rate (e.g., less than about 1:500, 1:1000, 1:1500, 1:2,000, 1:3,000, 1:5,000, or 1:10,000). In some cases, a substrate comprises features with a density of about or greater than about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400 or 500 features per mm².

A well of a substrate may have the same or different width, height, and/or volume as another well of the substrate. A channel of a substrate may have the same or different width, height, and/or volume as another channel of the substrate. In some instances, the diameter of a cluster or the diameter of a well comprising a cluster, or both, is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.05-1, 0.05-0.5, 0.05-0.1, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some instances, the diameter of a cluster or well or both is less than or about 5, 4, 3, 2, 1, 0.5, 0.1, 0.09, 0.08, 0.07, 0.06, or 0.05 mm. In some instances, the diameter of a cluster or well or both is between about 1.0 and 1.3 mm. In some instances, the diameter of a cluster or well, or both is about 1.150 mm. In some instances, the diameter of a cluster or well, or both is about 0.08 mm. The diameter of a cluster refers to clusters within a two-dimensional or three-dimensional substrate.

In some instances, the height of a well is from about 20-1000, 50-1000, 100-1000, 200-1000, 300-1000, 400-1000, or 500-1000 um. In some cases, the height of a well is less than about 1000, 900, 800, 700, or 600 um.

In some instances, a substrate comprises a plurality of channels corresponding to a plurality of loci within a cluster, wherein the height or depth of a channel is 5-500, 5-400, 5-300, 5-200, 5-100, 5-50, or 10-50 um. In some cases, the height of a channel is less than 100, 80, 60, 40, or 20 um.

In some instances, the diameter of a channel, locus (e.g., in a substantially planar substrate) or both channel and locus (e.g., in a three-dimensional substrate wherein a locus corresponds to a channel) is from about 1-1000, 1-500, 1-200, 1-100, 5-100, or 10-100 um, for example, to about 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the diameter of a channel, locus, or both channel and locus is less than about 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the distance between the center of two adjacent channels, loci, or channels and loci is from about 1-500, 1-200, 1-100, 5-200, 5-100, 5-50, or 5-30, for example, to about 20 um.

Surface Modifications

Provided herein are methods for polynucleotide synthesis on a surface, wherein the surface comprises various surface modifications. In some instances, the surface modifications are employed for the chemical and/or physical alteration of a surface by an additive or subtractive process to change one or more chemical and/or physical properties of a substrate surface or a selected site or region of a substrate surface. For example, surface modifications include, without limitation, (1) changing the wetting properties of a surface, (2) functionalizing a surface, i.e., providing, modifying or substituting surface functional groups, (3) defunctionalizing a surface, i.e., removing surface functional groups, (4) otherwise altering the chemical composition of a surface, e.g., through etching, (5) increasing or decreasing surface roughness, (6) providing a coating on a surface, e.g., a coating that exhibits wetting properties that are different from the wetting properties of the surface, and/or (7) depositing particulates on a surface.

In some cases, the addition of a chemical layer on top of a surface (referred to as adhesion promoter) facilitates structured patterning of loci on a surface of a substrate. Exemplary surfaces for application of adhesion promotion include, without limitation, glass, silicon, silicon dioxide and silicon nitride. In some cases, the adhesion promoter is a chemical with a high surface energy. In some instances, a second chemical layer is deposited on a surface of a substrate. In some cases, the second chemical layer has a low surface energy. In some cases, surface energy of a chemical layer coated on a surface supports localization of droplets on the surface. Depending on the patterning arrangement selected, the proximity of loci and/or area of fluid contact at the loci are alterable.

In some instances, a substrate surface, or resolved loci, onto which nucleic acids or other moieties are deposited, e.g., for polynucleotide synthesis, are smooth or substantially planar (e.g., two-dimensional) or have irregularities, such as raised or lowered features (e.g., three-dimensional features). In some instances, a substrate surface is modified with one or more different layers of compounds. Such modification layers of interest include, without limitation, inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules, and the like.

In some instances, resolved loci of a substrate are functionalized with one or more moieties that increase and/or decrease surface energy. In some cases, a moiety is chemically inert. In some cases, a moiety is configured to support a desired chemical reaction, for example, one or more processes in a polynucleotide synthesis reaction. The surface energy, or hydrophobicity, of a surface is a factor for determining the affinity of a nucleotide to attach onto the surface. In some instances, a method for substrate functionalization comprises: (a) providing a substrate having a surface that comprises silicon dioxide; and (b) silanizing the surface using a suitable silanizing agent described herein or otherwise known in the art, for example, an organofunctional alkoxysilane molecule. Methods and functionalizing agents are described in U.S. Pat. No. 5,474,796, which is herein incorporated by reference in its entirety.

In some instances, a substrate surface is functionalized by contact with a derivatizing composition that contains a mixture of silanes, under reaction conditions effective to couple the silanes to the substrate surface, typically via reactive hydrophilic moieties present on the substrate surface. Silanization generally covers a surface through self-assembly with organofunctional alkoxysilane molecules. A variety of siloxane functionalizing reagents can further be used as currently known in the art, e.g., for lowering or increasing surface energy. The organofunctional alkoxysilanes are classified according to their organic functions.

Polynucleotide Synthesis

Methods of the current disclosure for polynucleotide synthesis may include processes involving phosphoramidite chemistry. In some instances, polynucleotide synthesis comprises coupling a base with phosphoramidite. Polynucleotide synthesis may comprise coupling a base by deposition of phosphoramidite under coupling conditions, wherein the same base is optionally deposited with phosphoramidite more than once, i.e., double coupling. Polynucleotide synthesis may comprise capping of unreacted sites. In some instances, capping is optional. Polynucleotide synthesis may also comprise oxidation or an oxidation step or oxidation steps. Polynucleotide synthesis may comprise deblocking, detritylation, and sulfurization. In some instances, polynucleotide synthesis comprises either oxidation or sulfurization. In some instances, between one or each step during a polynucleotide synthesis reaction, the device is washed, for example, using tetrazole or acetonitrile. Time frames for any one step in a phosphoramidite synthesis method may be less than about 2 min, 1 min, 50 sec, 40 sec, 30 sec, 20 sec and 10 sec.

Polynucleotide synthesis using a phosphoramidite method may comprise a subsequent addition of a phosphoramidite building block (e.g., nucleoside phosphoramidite) to a growing polynucleotide chain for the formation of a phosphite triester linkage. Phosphoramidite polynucleotide synthesis proceeds in the 3′ to 5′ direction. Phosphoramidite polynucleotide synthesis allows for the controlled addition of one nucleotide to a growing nucleic acid chain per synthesis cycle. In some instances, each synthesis cycle comprises a coupling step. Phosphoramidite coupling involves the formation of a phosphite triester linkage between an activated nucleoside phosphoramidite and a nucleoside bound to the substrate, for example, via a linker. In some instances, the nucleoside phosphoramidite is provided to the device activated. In some instances, the nucleoside phosphoramidite is provided to the device with an activator. In some instances, nucleoside phosphoramidites are provided to the device in a 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100-fold excess or more over the substrate-bound nucleosides. In some instances, the addition of nucleoside phosphoramidite is performed in an anhydrous environment, for example, in anhydrous acetonitrile. Following addition of a nucleoside phosphoramidite, the device is optionally washed. In some instances, the coupling step is repeated one or more additional times, optionally with a wash step between nucleoside phosphoramidite additions to the substrate. In some instances, a polynucleotide synthesis method used herein comprises 1, 2, 3 or more sequential coupling steps. Prior to coupling, in many cases, the nucleoside bound to the device is de-protected by removal of a protecting group, where the protecting group functions to prevent polymerization. A common protecting group is 4,4′-dimethoxytrityl (DMT).

Following coupling, phosphoramidite polynucleotide synthesis methods optionally comprise a capping step. In a capping step, the growing polynucleotide is treated with a capping agent. A capping step is useful to block unreacted substrate-bound 5′—OH groups after coupling from further chain elongation, preventing the formation of polynucleotides with internal base deletions. Further, phosphoramidites activated with 1H-tetrazole may react, to a small extent, with the 06 position of guanosine. Without being bound by theory, upon oxidation with I₂/water, this side product, possibly via O6-N7 migration, may undergo depurination. The apurinic sites may end up being cleaved in the course of the final deprotection of the polynucleotide thus reducing the yield of the full-length product. The O6 modifications may be removed by treatment with the capping reagent prior to oxidation with I₂/water. In some instances, inclusion of a capping step during polynucleotide synthesis decreases the error rate as compared to synthesis without capping. As an example, the capping step comprises treating the substrate-bound polynucleotide with a mixture of acetic anhydride and 1-methylimidazole. Following a capping step, the device is optionally washed.

In some instances, following addition of a nucleoside phosphoramidite, and optionally after capping and one or more wash steps, the device bound growing nucleic acid is oxidized. The oxidation step comprises a phosphite triester which is oxidized into a tetracoordinated phosphate triester, a protected precursor of the naturally occurring phosphate diester internucleoside linkage. In some instances, oxidation of the growing polynucleotide is achieved by treatment with iodine and water, optionally in the presence of a weak base (e.g., pyridine, lutidine, collidine). Oxidation may be carried out under anhydrous conditions using, e.g. tert-Butyl hydroperoxide or (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (CSO). In some methods, a capping step is performed following oxidation. A second capping step allows for device drying, as residual water from oxidation that may persist can inhibit subsequent coupling. Following oxidation, the device and growing polynucleotide are optionally washed. In some instances, the step of oxidation is substituted with a sulfurization step to obtain polynucleotide phosphorothioates, wherein any capping steps can be performed after the sulfurization. Many reagents are capable of the efficient sulfur transfer, including but not limited to 3-(Dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-3-thione, DDTT, 3H-1,2-benzodithiol-3-one 1,1-dioxide, also known as Beaucage reagent, and N,N,N′N′-Tetraethylthiuram disulfide (TETD).

In order for a subsequent cycle of nucleoside incorporation to occur through coupling, the protected 5′ end of the device bound growing polynucleotide is removed so that the primary hydroxyl group is reactive with a next nucleoside phosphoramidite. In some instances, the protecting group is DMT and deblocking occurs with trichloroacetic acid in dichloromethane. Conducting detritylation for an extended time or with stronger than recommended solutions of acids may lead to increased depurination of solid support-bound polynucleotide and thus reduces the yield of the desired full-length product. Methods and compositions of the disclosure described herein provide for controlled deblocking conditions limiting undesired depurination reactions. In some instances, the device bound polynucleotide is washed after deblocking. In some instances, efficient washing after deblocking contributes to synthesized polynucleotides having a low error rate.

Methods for the synthesis of polynucleotides typically involve an iterating sequence of the following steps: application of a protected monomer to an actively functionalized surface (e.g., locus) to link with either the activated surface, a linker or with a previously deprotected monomer; deprotection of the applied monomer so that it is reactive with a subsequently applied protected monomer; and application of another protected monomer for linking. One or more intermediate steps include oxidation or sulfurization. In some instances, one or more wash steps precede or follow one or all of the steps.

Methods for phosphoramidite-based polynucleotide synthesis comprise a series of chemical steps. In some instances, one or more steps of a synthesis method involve reagent cycling, where one or more steps of the method comprise application to the device of a reagent useful for the step. For example, reagents are cycled by a series of liquid deposition and vacuum drying steps. For substrates comprising three-dimensional features such as wells, microwells, channels and the like, reagents are optionally passed through one or more regions of the device via the wells and/or channels.

Methods and systems described herein relate to polynucleotide synthesis devices for the synthesis of polynucleotides. The synthesis may be in parallel. For example, at least or about at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 10000, 50000, 75000, 100000 or more polynucleotides can be synthesized in parallel. The total number polynucleotides that may be synthesized in parallel may be from 2-100000, 3-50000, 4-10000, 5-1000, 6-900, 7-850, 8-800, 9-750, 10-700, 11-650, 12-600, 13-550, 14-500, 15-450, 16-400, 17-350, 18-300, 19-250, 20-200, 21-150,22-100, 23-50, 24-45, 25-40, 30-35. Those of skill in the art appreciate that the total number of polynucleotides synthesized in parallel may fall within any range bound by any of these values, for example 25-100. The total number of polynucleotides synthesized in parallel may fall within any range defined by any of the values serving as endpoints of the range. Total molar mass of polynucleotides synthesized within the device or the molar mass of each of the polynucleotides may be at least or at least about 10, 20, 30, 40, 50, 100, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 25000, 50000, 75000, 100000 picomoles, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at least or about at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500 nucleotides, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at most or about at most 500, 400, 300, 200, 150, 100, 50, 45, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 nucleotides, or less. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall from 10-500, 9-400, 11-300, 12-200, 13-150, 14-100, 15-50, 16-45, 17-40, 18-35, 19-25. Those of skill in the art appreciate that the length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range bound by any of these values, for example 100-300. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range defined by any of the values serving as endpoints of the range.

Methods for polynucleotide synthesis on a surface provided herein allow for synthesis at a fast rate. As an example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, 200 nucleotides per hour, or more are synthesized. Nucleotides include adenine, guanine, thymine, cytosine, uridine building blocks, or analogs/modified versions thereof. In some instances, libraries of polynucleotides are synthesized in parallel on substrate. For example, a device comprising about or at least about 100; 1,000; 10,000; 30,000; 75,000; 100,000; 1,000,000; 2,000,000; 3,000,000; 4,000,000; or 5,000,000 resolved loci is able to support the synthesis of at least the same number of distinct polynucleotides, wherein polynucleotide encoding a distinct sequence is synthesized on a resolved locus. In some instances, a library of polynucleotides is synthesized on a device with low error rates described herein in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours, or less. In some instances, larger nucleic acids assembled from a polynucleotide library synthesized with low error rate using the substrates and methods described herein are prepared in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours, or less.

In some instances, methods described herein provide for generation of a library of nucleic acids comprising variant nucleic acids differing at a plurality of codon sites. In some instances, a nucleic acid may have 1 site, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites 18 sites, 19 sites, 20 sites, 30 sites, 40 sites, 50 sites, or more of variant codon sites.

In some instances, the one or more sites of variant codon sites may be adjacent. In some instances, the one or more sites of variant codon sites may not be adjacent but are separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more codons.

In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein all the variant codon sites are adjacent to one another, forming a stretch of variant codon sites. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein none the variant codon sites are adjacent to one another. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein some the variant codon sites are adjacent to one another, forming a stretch of variant codon sites, and some of the variant codon sites are not adjacent to one another.

Referring to the Figures, FIG. 3 illustrates an exemplary process workflow for synthesis of nucleic acids (e.g., genes) from shorter nucleic acids. The workflow is divided generally into phases: (1) de novo synthesis of a single stranded nucleic acid library, (2) joining nucleic acids to form larger fragments, (3) error correction, (4) quality control, and (5) shipment. Prior to de novo synthesis, an intended nucleic acid sequence or group of nucleic acid sequences is preselected. For example, a group of genes is preselected for generation.

Once large nucleic acids for generation are selected, a predetermined library of nucleic acids is designed for de novo synthesis. Various suitable methods are known for generating high density polynucleotide arrays. In the workflow example, a device surface layer is provided. In the example, chemistry of the surface is altered in order to improve the polynucleotide synthesis process. Areas of low surface energy are generated to repel liquid while areas of high surface energy are generated to attract liquids. The surface itself may be in the form of a planar surface or contain variations in shape, such as protrusions or microwells which increase surface area. In the workflow example, high surface energy molecules selected serve a dual function of supporting DNA chemistry, as disclosed in International Patent Application Publication WO/2015/021080, which is herein incorporated by reference in its entirety.

In situ preparation of polynucleotide arrays is generated on a solid support and utilizes single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is designed to release reagents in a step-wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 302. In some instances, polynucleotides are cleaved from the surface at this stage. Cleavage includes gas cleavage, e.g., with ammonia or methylamine.

The generated polynucleotide libraries are placed in a reaction chamber. In this exemplary workflow, the reaction chamber (also referred to as “nanoreactor”) is a silicon coated well, containing PCR reagents and lowered onto the polynucleotide library 303. Prior to or after the sealing 304 of the polynucleotides, a reagent is added to release the polynucleotides from the substrate. In the exemplary workflow, the polynucleotides are released subsequent to sealing of the nanoreactor 305. Once released, fragments of single stranded polynucleotides hybridize in order to span an entire long-range sequence of DNA. Partial hybridization 305 is possible because each synthesized polynucleotide is designed to have a small portion overlapping with at least one other polynucleotide in the pool.

After hybridization, a PCA reaction is commenced. During the polymerase cycles, the polynucleotides anneal to complementary fragments and gaps are filled in by a polymerase. Each cycle increases the length of various fragments randomly depending on which polynucleotides find each other. Complementarity amongst the fragments allows for formation of a complete large span of double stranded DNA 306.

After PCA is complete, the nanoreactor is separated from the device 307 and positioned for interaction with a device having primers for PCR 308. After sealing, the nanoreactor is subject to PCR 309 and the larger nucleic acids are amplified. After PCR 310, the nanochamber is opened 311, error correction reagents are added 312, the chamber is sealed 313 and an error correction reaction occurs to remove mismatched base pairs and/or strands with poor complementarity from the double stranded PCR amplification products 314. The nanoreactor is opened and separated 315. Error corrected product is next subject to additional processing steps, such as PCR and molecular bar coding, and then packaged 322 for shipment 323.

In some instances, quality control measures are taken. After error correction, quality control steps include for example interaction with a wafer having sequencing primers for amplification of the error corrected product 316, sealing the wafer to a chamber containing error corrected amplification product 317, and performing an additional round of amplification 318. The nanoreactor is opened 319 and the products are pooled 320 and sequenced 321. After an acceptable quality control determination is made, the packaged product 322 is approved for shipment 323.

In some instances, a nucleic acid generated by a workflow such as that in FIG. 3 is subject to mutagenesis using overlapping primers disclosed herein. In some instances, a library of primers is generated by in situ preparation on a solid support and utilize single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 302.

Computer Systems

Any of the systems described herein, may be operably linked to a computer and may be automated through a computer either locally or remotely. In various instances, the methods and systems of the disclosure may further comprise software programs on computer systems and use thereof. Accordingly, computerized control for the synchronization of the dispense/vacuum/refill functions such as orchestrating and synchronizing the material deposition device movement, dispense action and vacuum actuation are within the bounds of the disclosure. The computer systems may be programmed to interface between the user specified base sequence and the position of a material deposition device to deliver the correct reagents to specified regions of the substrate.

The computer system 400 illustrated in FIG. 4 may be understood as a logical apparatus that can read instructions from media 411 and/or a network port 405, which can optionally be connected to server 409 having fixed media 412. The system, such as shown in FIG. 4 can include a CPU 401, disk drives 403, optional input devices such as keyboard 415 and/or mouse 416 and optional monitor 407. Data communication can be achieved through the indicated communication medium to a server at a local or a remote location. The communication medium can include any means of transmitting and/or receiving data. For example, the communication medium can be a network connection, a wireless connection or an internet connection. Such a connection can provide for communication over the World Wide Web. It is envisioned that data relating to the present disclosure can be transmitted over such networks or connections for reception and/or review by a party 422 as illustrated in FIG. 4.

FIG. 5 is a block diagram illustrating a first example architecture of a computer system 500 that can be used in connection with example instances of the present disclosure. As depicted in FIG. 5, the example computer system can include a processor 502 for processing instructions. Non-limiting examples of processors include: Intel Xeon™ processor, AMD Opteron™ processor, Samsung 32-bit RISC ARM 1176JZ(F)-S v1.0™ processor, ARM Cortex-A8 Samsung S5PC100™ processor, ARM Cortex-A8 Apple A4™ processor, Marvell PXA 930™ processor, or a functionally-equivalent processor. Multiple threads of execution can be used for parallel processing. In some instances, multiple processors or processors with multiple cores can also be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, and/or personal data assistant devices.

As illustrated in FIG. 5, a high-speed cache 504 can be connected to, or incorporated in, the processor 502 to provide a high speed memory for instructions or data that have been recently, or are frequently, used by the processor 502. The processor 502 is connected to a north bridge 506 by a processor bus 508. The north bridge 506 is connected to random access memory (RAM) 510 by a memory bus 512 and manages access to the RAM 510 by the processor 502. The north bridge 506 is also connected to a south bridge 514 by a chipset bus 516. The south bridge 514 is, in turn, connected to a peripheral bus 518. The peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus. The north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 518. In some alternative architectures, the functionality of the north bridge can be incorporated into the processor instead of using a separate north bridge chip. In some instances, system 500 can include an accelerator card 522 attached to the peripheral bus 518. The accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing. For example, an accelerator can be used for adaptive data restructuring or to evaluate algebraic expressions used in extended set processing.

Software and data are stored in external storage 524 and can be loaded into RAM 510 and/or cache 504 for use by the processor. The system 500 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux, Windows™, MACOS™, BlackBerry OS™, iOS™, and other functionally-equivalent operating systems, as well as application software running on top of the operating system for managing data storage and optimization in accordance with example instances of the present disclosure. In this example, system 500 also includes network interface cards (NICs) 520 and 521 connected to the peripheral bus for providing network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing.

FIG. 6 is a diagram showing a network 600 with a plurality of computer systems 602a, and 602b, a plurality of cell phones and personal data assistants 602c, and Network Attached Storage (NAS) 604a, and 604b. In example instances, systems 602a, 602b, and 602c can manage data storage and optimize data access for data stored in Network Attached Storage (NAS) 604a and 604b. A mathematical model can be used for the data and be evaluated using distributed parallel processing across computer systems 602a, and 602b, and cell phone and personal data assistant systems 602c. Computer systems 602a, and 602b, and cell phone and personal data assistant systems 602c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 604a and 604b. FIG. 6 illustrates an example only, and a wide variety of other computer architectures and systems can be used in conjunction with the various instances of the present disclosure. For example, a blade server can be used to provide parallel processing. Processor blades can be connected through a back plane to provide parallel processing. Storage can also be connected to the back plane or as Network Attached Storage (NAS) through a separate network interface. In some example instances, processors can maintain separate memory spaces and transmit data through network interfaces, back plane or other connectors for parallel processing by other processors. In other instances, some or all of the processors can use a shared virtual address memory space.

FIG. 7 is a block diagram of a multiprocessor computer system 700 using a shared virtual address memory space in accordance with an example instance. The system includes a plurality of processors 702a-f that can access a shared memory subsystem 704. The system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 706a-f in the memory subsystem 704. Each MAP 706a-f can comprise a memory 708a-f and one or more field programmable gate arrays (FPGAs) 710a-f The MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 710a-f for processing in close coordination with a respective processor. For example, the MAPs can be used to evaluate algebraic expressions regarding the data model and to perform adaptive data restructuring in example instances. In this example, each MAP is globally accessible by all of the processors for these purposes. In one configuration, each MAP can use Direct Memory Access (DMA) to access an associated memory 708a-f, allowing it to execute tasks independently of, and asynchronously from the respective microprocessor 702a-f. In this configuration, a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms.

The above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example instances, including systems using any combination of general processors, co-processors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements. In some instances, all or part of the computer system can be implemented in software or hardware. Any variety of data storage media can be used in connection with example instances, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.

In example instances, the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems. In other instances, the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in FIG. 5, system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements. For example, the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such as accelerator card 522 illustrated in FIG. 5.

The following examples are set forth to illustrate more clearly the principle and practice of embodiments disclosed herein to those skilled in the art and are not to be construed as limiting the scope of any claimed embodiments. Unless otherwise stated, all parts and percentages are on a weight basis.

EXAMPLES

The following examples are given for the purpose of illustrating various embodiments of the disclosure and are not meant to limit the present disclosure in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the disclosure. Changes therein and other uses which are encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art.

Example 1: Functionalization of a Device Surface

A device was functionalized to support the attachment and synthesis of a library of polynucleotides. The device surface was first wet cleaned using a piranha solution comprising 90% H₂SO₄ and 10% H₂O₂ for 20 minutes. The device was rinsed in several beakers with DI water, held under a DI water gooseneck faucet for 5 min, and dried with N₂. The device was subsequently soaked in NH₄OH (1:100; 3 mL:300 mL) for 5 min, rinsed with DI water using a handgun, soaked in three successive beakers with DI water for 1 min each, and then rinsed again with DI water using the handgun. The device was then plasma cleaned by exposing the device surface to O₂. A SAMCO PC-300 instrument was used to plasma etch O₂ at 250 watts for 1 min in downstream mode.

The cleaned device surface was actively functionalized with a solution comprising N-(3-triethoxysilylpropyl)-4-hydroxybutyramide using a YES-1224P vapor deposition oven system with the following parameters: 0.5 to 1 torr, 60 min, 70° C., 135° C. vaporizer. The device surface was resist coated using a Brewer Science 200× spin coater. SPR™ 3612 photoresist was spin coated on the device at 2500 rpm for 40 sec. The device was pre-baked for 30 min at 90° C. on a Brewer hot plate. The device was subjected to photolithography using a Karl Suss MA6 mask aligner instrument. The device was exposed for 2.2 sec and developed for 1 min in MSF 26A. Remaining developer was rinsed with the handgun and the device soaked in water for 5 min. The device was baked for 30 min at 100° C. in the oven, followed by visual inspection for lithography defects using a Nikon L200. A descum process was used to remove residual resist using the SAMCO PC-300 instrument to O₂ plasma etch at 250 watts for 1 min.

The device surface was passively functionalized with a 100 μL, solution of perfluorooctyltrichlorosilane mixed with 10 μL, light mineral oil. The device was placed in a chamber, pumped for 10 min, and then the valve was closed to the pump and left to stand for 10 min. The chamber was vented to air. The device was resist stripped by performing two soaks for 5 min in 500 mL NMP at 70° C. with ultrasonication at maximum power (9 on Crest system). The device was then soaked for 5 min in 500 mL isopropanol at room temperature with ultrasonication at maximum power. The device was dipped in 300 mL of 200 proof ethanol and blown dry with N₂. The functionalized surface was activated to serve as a support for polynucleotide synthesis.

Example 2: Synthesis of a 50-Mer Sequence on an Oligonucleotide Synthesis Device

A two-dimensional oligonucleotide synthesis device was assembled into a flowcell, which was connected to a flowcell (Applied Biosystems (ABI394 DNA Synthesizer”). The two-dimensional oligonucleotide synthesis device was uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE (Gelest) which was used to synthesize an exemplary polynucleotide of 50 bp (“50-mer polynucleotide”) using polynucleotide synthesis methods described herein.

The sequence of the 50-mer was as described in SEQ ID NO: 393. 5′AGACAATCAACCATTTGGGGTGGACAGCCTTGACCTCTAGACTTCGGCAT##TTTTTTT TTT3′ (SEQ ID NO.: 393), where #denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes), which is a cleavable linker enabling the release of oligos from the surface during deprotection.

The synthesis was done using standard DNA synthesis chemistry (coupling, capping, oxidation, and deblocking) according to the protocol in Table 1 and an ABI synthesizer.

TABLE 1
Synthesis protocols
General DNA Synthesis		Time
Process Name	Process Step	(sec)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	23
	N2 System Flush	4
	Acetonitrile System Flush	4
DNA BASE ADDITION	Activator Manifold Flush	2
(Phosphoramidite +	Activator to Flowcell	6
Activator Flow)	Activator +	6
	Phosphoramidite to
	Flowcell
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to
	Flowcell
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to
	Flowcell
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to
	Flowcell
	Incubate for 25 sec	25
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
DNA BASE ADDITION	Activator Manifold Flush	2
(Phosphoramidite +	Activator to Flowcell	5
Activator Flow)	Activator +	18
	Phosphoramidite to
	Flowcell
	Incubate for 25 sec	25
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
CAPPING (CapA + B, 1:1,	CapA + B to Flowcell	15
Flow)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	15
	Acetonitrile System Flush	4
OXIDATION (Oxidizer	Oxidizer to Flowcell	18
Flow)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	23
	N2 System Flush	4
	Acetonitrile System Flush	4
DEBLOCKING (Deblock	Deblock to Flowcell	36
Flow)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	18
	N2 System Flush	4.13
	Acetonitrile System Flush	4.13
	Acetonitrile to Flowcell	15

The phosphoramidite/activator combination was delivered similarly to the delivery of bulk reagents through the flowcell. No drying steps were performed as the environment stays “wet” with reagent the entire time.

The flow restrictor was removed from the ABI 394 synthesizer to enable faster flow. Without flow restrictor, flow rates for amidites (0.1M in ACN), Activator, (0.25M Benzoylthiotetrazole (“BTT”; 30-3070-xx from GlenResearch) in ACN), and Ox (0.02M I2 in 20% pyridine, 10% water, and 70% THF) were roughly ˜100 uL/sec, for acetonitrile (“ACN”) and capping reagents (1:1 mix of CapA and CapB, wherein CapA is acetic anhydride in THF/Pyridine and CapB is 16% 1-methylimidizole in THF), roughly ˜200 uL/sec, and for Deblock (3% dichloroacetic acid in toluene), roughly −300 uL/sec (compared to ˜50 uL/sec for all reagents with flow restrictor). The time to completely push out Oxidizer was observed, the timing for chemical flow times was adjusted accordingly and an extra ACN wash was introduced between different chemicals. After polynucleotide synthesis, the chip was deprotected in gaseous ammonia overnight at 75 psi. Five drops of water were applied to the surface to recover polynucleotides. The recovered polynucleotides were then analyzed on a BioAnalyzer small RNA chip.

Example 3: Synthesis of a 100-Mer Sequence on an Oligonucleotide Synthesis Device

The same process as described in Example 2 for the synthesis of the 50-mer sequence was used for the synthesis of a 100-mer polynucleotide (“100-mer polynucleotide”; 5′ CGGGATCCTTATCGTCATCGTCGTACAGATCCCGACCCATTTGCTGTCCACCAGTCATG CTAGCCATACCATGATGATGATGATGATGAGAACCCCGCAT ##TTTTTTTTTT3′, where #denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes); SEQ ID NO.: 2161) on two different silicon chips, the first one uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE and the second one functionalized with 5/95 mix of 11-acetoxyundecyltriethoxysilane and n-decyltriethoxysilane, and the polynucleotides extracted from the surface were analyzed on a BioAnalyzer instrument.

All ten samples from the two chips were further PCR amplified using a forward (5′ATGCGGGGTTCTCATCATC3′; SEQ ID NO.: 2162) and a reverse (5′CGGGATCCTTATCGTCATCG3; SEQ ID NO.: 2163) primer in a 50 uL PCR mix (25 uL NEB Q5 mastermix, 2.5 uL 10 uM Forward primer, 2.5 uL 10 uM Reverse primer, luL polynucleotide extracted from the surface, and water up to 50 uL) using the following thermalcycling program:

• • 98° C., 30 sec
  • 98° C., 10 sec; 63° C., 10 sec; 72° C., 10 sec; repeat 12 cycles
  • 72° C., 2 min

The PCR products were also run on a BioAnalyzer, demonstrating sharp peaks at the 100-mer position. Next, the PCR amplified samples were cloned, and Sanger sequenced. Table 2 summarizes the results from the Sanger sequencing for samples taken from spots 1-5 from chip 1 and for samples taken from spots 6-10 from chip 2.

TABLE 2
Sequencing results
Spot	Error rate	Cycle efficiency
1	1/763 bp	99.87%
2	1/824 bp	99.88%
3	1/780 bp	99.87%
4	1/429 bp	99.77%
5	1/1525 bp	99.93%
6	1/1615 bp	99.94%
7	1/531 bp	99.81%
8	1/1769 bp	99.94%
9	1/854 bp	99.88%
10	1/1451 bp	99.93%

Thus, the high quality and uniformity of the synthesized polynucleotides were repeated on two chips with different surface chemistries. Overall, 89% of the 100-mers that were sequenced were perfect sequences with no errors, corresponding to 233 out of 262.

Table 3 summarizes error characteristics for the sequences obtained from the polynucleotide samples from spots 1-10.

TABLE 3
Error characteristics
	Sample ID/Spot no.
	OSA_0046/1	OSA_0047/2	OSA_0048/3	OSA_0049/4	OSA_0050/5
Total Sequences	32	32	32	32	32
Sequencing Quality	25 of 28	27 of 27	26 of 30	21 of 23	25 of 26
Oligo Quality	23 of 25	25 of 27	22 of 26	18 of 21	24 of 25
ROI Match Count	2500	2698	2561	2122	2499
ROI Mutation	2	2	1	3	1
ROI Multi Base	0	0	0	0	0
Deletion
ROI Small Insertion	1	0	0	0	0
ROI Single Base	0	0	0	0	0
Deletion
Large Deletion Count	0	0	1	0	0
Mutation: G > A	2	2	1	2	1
Mutation: T > C	0	0	0	1	0
ROI Error Count	3	2	2	3	1
ROI Error Rate	Err: ~1 in 834	Err: ~1 in 1350	Err: ~1 in 1282	Err: ~1 in 708	Err: ~1 in 2500
ROI Minus Primer	MP Err: ~1 in 763	MP Err: ~1 in 824	MP Err: ~1 in 780	MP Err: ~1 in 429	MP Err: ~1 in 1525
Error Rate
	Sample ID/Spot no.
	OSA_0051/6	OSA_0052/7	OSA_0053/8	OSA_0054/9	OSA_0055/10
Total Sequences	32	32	32	32	32
Sequencing Quality	29 of 30	27 of 31	29 of 31	28 of 29	25 of 28
Oligo Quality	25 of 29	22 of 27	28 of 29	26 of 28	20 of 25
ROI Match Count	2666	2625	2899	2798	2348
ROI Mutation	0	2	1	2	1
ROI Multi Base	0	0	0	0	0
Deletion
ROI Small Insertion	0	0	0	0	0
ROI Single Base	0	0	0	0	0
Deletion
Large Deletion Count	1	1	0	0	0
Mutation: G > A	0	2	1	2	1
Mutation: T > C	0	0	0	0	0
ROI Error Count	1	3	1	2	1
ROI Error Rate	Err: ~1 in 2667	Err: ~1 in 876	Err: ~1 in 2900	Err: ~1 in 1400	Err: ~1 in 2349
ROI Minus Primer	MP Err: ~1 in 1615	MP Err: ~1 in 531	MP Err: ~1 in 1769	MP Err: ~1 in 854	MP Err: ~1 in 1451
Error Rate

Example 4: Exemplary Sequences

TABLE 4
Variable Heavy Chain CDRs
DKK1	SEQ		SEQ		SEQ
Variant	ID NO	CDR1 Sequence	ID NO	CDR2 Sequence	ID NO	CDR3 Sequence
DKK1-1	1	GRTFSRFAM	99	EGVASITSGGTTNY	197	AADDGARGSW
DKK1-2	2	GSAFSSTVM	100	EFVATINSLGGTSY	198	AAAYSGHFSGRVSDFLW
DKK1-3	3	GSTFSTYAM	101	EFVASINWGGGNTYY	199	AAKKVSFGDW
DKK1-4	4	GNIFRINAM	102	ELVAAISRSGGSTNY	200	AKDKNGPW
DKK1-5	5	GGLTFSTYAM	103	EFVAAVSWSGGNTYY	201	AAEIGYYSGGTYYSSEAW
DKK1-6	6	GIPFSTRTM	104	EFVAAISSGATTLY	202	AAGNGGRAYGYSRARYEW
DKK1-7	7	GISGSVFSRTPM	105	EFVAALSKDGARTYY	203	ARDLVGTDAFDIW
DKK1-8	8	GFTFSNYAM	106	EFVAAISWSDGSTYY	204	AAEGGYSGTYYYTGDFDW
DKK1-9	9	GRSFSMYAM	107	ELVAAISWSGGSTVY	205	AAEGGYSGTYYYTGDFDW
DKK1-10	10	GRTISNYAM	108	EFVAAISWRGGSTYY	206	AAAPRPKYVSVSYFSTSSNYDW
DKK1-11	11	GPTVDAYAM	109	EFVSAISWSGSATFY	207	AAAPRPKRVSVRYFSTSSNYDW
DKK1-12	12	GRTFNSRPM	110	EFVAAISSSASSTYY	208	AAGNGGRLYGHSRARYDW
DKK1-13	13	GFLMYDRAM	111	EIVAAISRTGSSIYY	209	AAGNGGRKYGHHRARYDW
DKK1-14	14	GSIFSRLAM	112	EFVAAISSSGISTIY	210	ARGQRGRWLEPLTGW
DKK1-15	15	GFTFGTTTM	113	ELVAAITSGGGTTYY	211	AKDLAAAGYYYYYGMDVW
DKK1-16	16	GNIFTRNVM	114	EFVGAINWSGGNTVY	212	ARHDHNNRGLDYW
DKK1-17	17	GGTFSRYAM	115	EFVAGISWTLGRTYY	213	ARDPFGKW
DKK1-18	18	GITFRFKAM	116	EFVAAINRSGRSTRY	214	AAESHGSTSPRNPLQYDW
DKK1-19	19	GRTYGM	117	EFVAGISWTLGRTYY	215	ASDESDAANW
DKK1-20	20	GPTFSIYDM	118	EFVTGSNTGGTTY	216	ATCTDFEYDW
DKK1-21	21	GIPSSIRAM	119	EWVSGISISDSSTYY	217	AAGKRYGYYDW
DKK1-22	22	GSTLSINAM	120	ELVAAISWSGGTAY	218	AAQSRYRSNYYDHDKYAW
DKK1-23	23	GYNFSTFCM	121	EWVAAISGGGSTMY	219	AASKWYGGFGDTDIEW
DKK1-24	24	GSSFSAYGM	122	EFVAGISWTLGRTYY	220	AADGVPEYSDYASGPVW
DKK1-25	25	GSTSRSYGM	123	EFVAGISWTLGRTYY	221	ARDPSGKW
DKK1-26	26	GFSLDYYGM	124	EVVASIRWNAKPYY	222	AAGKRYGYYDW
DKK1-27	27	GRTFSNYAM	125	EWVASISTSGKTTYY	223	AAGNGGRNYGHSRARYEW
DKK1-28	28	GLTTVYTM	126	EFVAAISWYVSTTFY	224	AAEGGYSGTYYYTGDFDW
DKK1-29	29	GSIGGLNAM	127	EFVAAINYSGRSTVY	225	AAGAGRDRGFSRAQYAW
DKK1-30	30	GRTFSKYAM	128	EFVAAISWSGESTYY	226	AAAPRPKRVSVSYFYTSSNYDW
DKK1-31	31	GRTLSRSAM	129	ELVAAISWSGGSTYY	227	AAGNGGRTYGHSRARYEW
DKK1-32	32	GRTFSNGPM	130	EFVAAISRGGKISHY	228	AAGNGGRYYGHSRARYDW
DKK1-33	33	GRSLNTYTM	131	ELVAVIISGGSTAY	229	AAGNGGRSYGHSRARYDW
DKK1-34	34	GFTFDDRAM	132	EFVAAISWSGGSTYY	230	AAAPRPKRVSVSYFYTSSNYDW
DKK1-35	35	GRTFTTYPM	133	EFVAAISSSGSSTVY	231	AAGNGGRQYGHSRARYDW
DKK1-36	36	GIPSTLRAM	134	EFVAAINWSGASTVY	232	AAGNGGRQYGHSRARYDW
DKK1-37	37	GRTFSSYSM	135	EFIAAINLSSGSTYY	233	AAGNGGRNYGHSRARYEW
DKK1-38	38	GTSFSIGAM	136	EWVSSISPGGLFPYY	234	AARDAIVGVTDTSGYRW
DKK1-39	39	GTVFSISDM	137	EWVSAISPGGGYTVY	235	ARSSWFDCGVQGRDLGNEYDW
DKK1-40	40	GRTISSFRM	138	EFVAAISRGGNVTPY	236	AANSDSGFDSYSVWAAYEW
DKK1-41	41	GRTLSRS	139	SWSGGS	237	GNGGRTYGHSRARYE
DKK1-42	42	GRTFSSL	140	TSGGR	238	GNGGRTYGHSRARYE
DKK1-43	43	GTSFSVG	141	SWSGGT	239	GNGGRQYGHSRARYD
DKK1-44		GRG	142	NRSGKS	240	GNGGRSYGHSRARYD
DKK1-45	45	GRTFSNF	143	SATGS	241	GNGGRQYGHSRARYD
DKK1-46	46	GRTLSSI	144	TRAGS	242	GNGGRYYGHSRARYD
DKK1-47	47	GRTFSSL	145	SSGGS	243	GNGGRTYGHSRARYD
DKK1-48	48	GRSFGNF	146	TSGGS	244	GNGGRSYGHSRARYD
DKK1-49	49	GFTFTNY	147	NWSGRR	245	APRPKRVSVQYFSTSSNYD
DKK1-50	50	GRTFSLY	148	NRSGKS	246	GNGGRQYGHSRARYD
DKK1-51	51	GRTFSTS	149	NRSGKT	247	GNGGRAYGYSRARYE
DKK1-52	52	GRTFSIS	150	SPSGN	248	GNGGRAYGYSRARYE
DKK1-53	53	GRTFSSY	151	SRSGT	249	GNGGRTYGHSRARYE
DKK1-54	54	GFTFDDR	152	STGGT	250	GNGGRTYGHSRARYE
DKK1-55	55	GFTFGDY	153	DWSGRR	251	APRPKRVSVSYFSTASNYD
DKK1-56	56	GRTFSSL	154	SSSGGT	252	GNGGRLYGHSRARYD
DKK1-57	57	GSTFSKA	155	TFSGAR	253	GNGGRTYGHSRARYD
DKK1-58	58	GRRFSAD	156	RSGGT	254	GNGGRQYGHSRARYD
DKK1-59	59	GFTVSNY	157	SWSGGS	255	APRPKRVSVRYFSTSSNYD
DKK1-60	60	GRAFSSS	158	NRGGKI	256	GNGGRLYGHSRARYD
DKK1-61	61	GRTFSSN	159	SRSGGS	257	GNGGRTYGHSRARYD
DKK1-62	62	GRTFSYN	160	NRSGKS	258	GNGGRHYGHSRARYD
DKK1-63	63	GFRMYDR	161	SRSGGR	259	GNGGRLYGHSRARYD
DKK1-64	64	GRTSSAY	162	SRSGAS	260	GNGGRSYGHSRARYD
DKK1-65	65	GRTFSRF	163	SARGM	261	GNGGRTYGHSRARYE
DKK1-66	66	GRTFSSY	164	NLSSGS	262	GNGGRNYGHSRARYE
DKK1-67	67	GRTFRSY	165	SMSGKE	263	GNGGRTYGHSRARYE
DKK1-68	68	GRTFSNY	166	STSGKT	264	GNGGRNYGHSRARYE
DKK1-69	69	GRTFSSY	167	SRSGGS	265	GNGGRHYGHSRARYD
DKK1-70	70	GTSFSIG	168	SRSGAS	266	GNGGRTYGHSRARYD
DKK1-71	71	GRTISNA	169	RSGGT	267	GNGGRQYGHSRARYD
DKK1-72	72	GGIYRVN	170	NWSGGS	268	GNGGRKYGHHRARYD
DKK1-73	73	GRTFSSK	171	NWSGGL	269	GNGGRAYGYSRARYE
DKK1-74	74	GIPFSSR	172	SRSGTG	270	GNGGRTYGHSRARYD
DKK1-75	75	GPTVDAY	173	SWSGSA	271	APRPKRVSVRYFSTSSNYD
DKK1-76	76	GIPFSTR	174	SSGAT	272	GNGGRAYGYSRARYE
DKK1-77	77	GRTFNSR	175	SSSASS	273	GNGGRLYGHSRARYD
DKK1-78	78	GFTFSSS	176	LRGGS	274	GNGGRHYGHSRARYD
DKK1-79	79	SIGIAFSSR	177	TRSGGK	275	GNGGRTYGHSRARYE
DKK1-80	80	GFLMYDR	178	SRTGSS	276	GNGGRKYGHHRARYD
DKK1-81	81	GIAFQGY	179	DTNGGH	277	EGGYRGTYYYTGDFD
DKK1-82	82	GRTFSNT	180	TSGGS	278	GNGGRHYGHNRPRYD
DKK1-83	83	GSTSSLR	181	SWSLSR	279	APRPKRVSVSYFSTASNYD
DKK1-84	84	GRTFTNY	182	NRGGST	280	GNRRRPYGYSHSRYD
DKK1-85	85	GITFKRY	183	TSRDGTT	281	GNGGRNYGHSRSRYE
DKK1-86	86	GRTFINY	184	IWTGVS	282	APRPNRVSVRYFSTNNNYD
DKK1-87	87	GRTFSGY	185	SWSGGS	283	GNGGRHYGHSRARYD
DKK1-88	88	GLTFSTY	186	ASNGN	284	GNGGRAYGYSRARYE
DKK1-89	89	GFTSDDY	187	SWSGGR	285	APRPKRVSVRYFSTSSNYD
DKK1-90	90	GRTFRSY	188	SWSPGR	286	APRPKRISVQYFTTSSNYD
DKK1-91	91	GFTVSSY	189	SWSGGR	287	APRPKRVSFSYFSTSSNYE
DKK1-92	92	GFGFGSY	190	SWTGGS	288	APRPKRVSVRYFNTSSNYD
DKK1-93	93	GRTFSRY	191	SWSGGS	289	GNGGRYYNHSRTRYE
DKK1-94	94	GRIFGGY	192	SWSGAS	290	GNGGSRYGHSRARYD
DKK1-95	95	GSIENIN	193	SSGGGI	291	GNGGRKYGHHRARYD
DKK1-96	96	GFTFSSFGNF	194	NWSSRS	292	GNGGRQYGHSRARYD
DKK1-97	97	GNIDRLY	195	SWSVSS	293	EGGYSGTYYYTGDFD
DKK1-98	98	GRTFSNF	196	LRGGS	294	APRPKRVSVSYFSTASNYD
DKK1-99	919	GRTFSNF	1333	LRGGS	1747	APRPKRVSVSYFSTASNYD
DKK1-100	920	GNIDRLY	1334	SWSVSS	1748	EGGYSGTYYYTGDFD
DKK1-101	921	GFTFSSFGNF	1335	NWSSRS	1749	GNGGRQYGHSRARYD
DKK1-102	922	GSIENIN	1336	SSGGGI	1750	GNGGRKYGHHRARYD
DKK1-103	923	GRIFGGY	1337	SWSGAS	1751	GNGGSRYGHSRARYD
DKK1-104	924	GRTFSRY	1338	SWSGGS	1752	GNGGRYYNHSRTRYE
DKK1-105	925	GFGFGSY	1339	SWTGGS	1753	APRPKRVSVRYFNTSSNYD
DKK1-106	926	GFTVSSY	1340	SWSGGR	1754	APRPKRVSFSYFSTSSNYE
DKK1-107	927	GRTFRSY	1341	SWSPGR	1755	APRPKRISVQYFTTSSNYD
DKK1-108	928	GFTSDDY	1342	SWSGGR	1756	APRPKRVSVRYFSTSSNYD
DKK1-109	929	GLTFSTY	1343	ASNGN	1757	GNGGRAYGYSRARYE
DKK1-110	930	GRTFSGY	1344	SWSGGS	1758	GNGGRHYGHSRARYD
DKK1-111	931	GRTFINY	1345	IWTGVS	1759	APRPNRVSVRYFSTNNNYD
DKK1-112	932	GITFKRY	1346	TSRDGTT	1760	GNGGRNYGHSRSRYE
DKK1-113	933	GRTFTNY	1347	NRGGST	1761	GNRRRPYGYSHSRYD
DKK1-114	934	GSTSSLR	1348	SWSLSR	1762	APRPKRVSVSYFSTASNYD
DKK1-115	935	GRTFSNT	1349	TSGGS	1763	GNGGRHYGHNRPRYD
DKK1-116	936	GIAFQGY	1350	DTNGGH	1764	EGGYRGTYYYTGDFD
DKK1-117	937	GFLMYDR	1351	SRTGSS	1765	GNGGRKYGHHRARYD
DKK1-118	938	SIGIAFSSR	1352	TRSGGK	1766	GNGGRTYGHSRARYE
DKK1-119	939	GFTFSSS	1353	LRGGS	1767	GNGGRHYGHSRARYD
DKK1-120	940	GRTFNSR	1354	SSSASS	1768	GNGGRLYGHSRARYD
DKK1-121	941	GIPFSTR	1355	SSGAT	1769	GNGGRAYGYSRARYE
DKK1-122	942	GPTVDAY	1356	SWSGSA	1770	APRPKRVSVRYFSTSSNYD
DKK1-123	943	GIPFSSR	1357	SRSGTG	1771	GNGGRTYGHSRARYD
DKK1-124	944	GRTFSSK	1358	NWSGGL	1772	GNGGRAYGYSRARYE
DKK1-125	945	GGIYRVN	1359	NWSGGS	1773	GNGGRKYGHHRARYD
DKK1-126	946	GRTISNA	1360	RSGGT	1774	GNGGRQYGHSRARYD
DKK1-127	947	GTSFSIG	1361	SRSGAS	1775	GNGGRTYGHSRARYD
DKK1-128	948	GRTFSSY	1362	SRSGGS	1776	GNGGRHYGHSRARYD
DKK1-129	949	GRTFSNY	1363	STSGKT	1777	GNGGRNYGHSRARYE
DKK1-130	950	GRTFRSY	1364	SMSGKE	1778	GNGGRTYGHSRARYE
DKK1-131	951	GRTFSSY	1365	NLSSGS	1779	GNGGRNYGHSRARYE
DKK1-132	952	GRTFSRF	1366	SARGM	1780	GNGGRTYGHSRARYE
DKK1-133	953	GRTSSAY	1367	SRSGAS	1781	GNGGRSYGHSRARYD
DKK1-134	954	GFRMYDR	1368	SRSGGR	1782	GNGGRLYGHSRARYD
DKK1-135	955	GRTFSYN	1369	NRSGKS	1783	GNGGRHYGHSRARYD
DKK1-136	956	GRTFSSN	1370	SRSGGS	1784	GNGGRTYGHSRARYD
DKK1-137	957	GRAFSSS	1371	NRGGKI	1785	GNGGRLYGHSRARYD
DKK1-138	958	GFTVSNY	1372	SWSGGS	1786	APRPKRVSVRYFSTSSNYD
DKK1-139	959	GRRFSAD	1373	RSGGT	1787	GNGGRQYGHSRARYD
DKK1-140	960	GSTFSKA	1374	TFSGAR	1788	GNGGRTYGHSRARYD
DKK1-141	961	GRTFSSL	1375	SSSGGT	1789	GNGGRLYGHSRARYD
DKK1-142	962	GFTFGDY	1376	DWSGRR	1790	APRPKRVSVSYFSTASNYD
DKK1-143	963	GFTFDDR	1377	STGGT	1791	GNGGRTYGHSRARYE
DKK1-144	964	GRTFSSY	1378	SRSGT	1792	GNGGRTYGHSRARYE
DKK1-145	965	GRTFSIS	1379	SPSGN	1793	GNGGRAYGYSRARYE
DKK1-146	966	GRTFSTS	1380	NRSGKT	1794	GNGGRAYGYSRARYE
DKK1-147	967	GRTFSLY	1381	NRSGKS	1795	GNGGRQYGHSRARYD
DKK1-148	968	GFTFTNY	1382	NWSGRR	1796	APRPKRVSVQYFSTSSNYD
DKK1-149	969	GRSFGNF	1383	TSGGS	1797	GNGGRSYGHSRARYD
DKK1-150	970	GRTFSSL	1384	SSGGS	1798	GNGGRTYGHSRARYD
DKK1-151	971	GRTLSSI	1385	TRAGS	1799	GNGGRYYGHSRARYD
DKK1-152	972	GRTFSNF	1386	SATGS	1800	GNGGRQYGHSRARYD
DKK1-153		GRG	1387	NRSGKS	1801	GNGGRSYGHSRARYD
DKK1-154	974	GTSFSVG	1388	SWSGGT	1802	GNGGRQYGHSRARYD
DKK1-155	975	GRTFSSL	1389	TSGGR	1803	GNGGRTYGHSRARYE
DKK1-156	976	GRTLSRS	1390	SWSGGS	1804	GNGGRTYGHSRARYE
DKK1-157	977	GRTISNY	1391	SWRGGS	1805	APRPKYVSVSYFSTSSNYD
DKK1-158	978	GHTFRGY	1392	SGRSGN	1806	GNGGRLYGHSRARYD
DKK1-159	979	GSIVRGN	1393	SSSGSS	1807	GNGGRTYGHSRARYE
DKK1-160	980	GRTFSSY	1394	SRSGGS	1808	GNGGRTYGHSRARYE
DKK1-161	981	GNIFGVN	1395	SGTGGS	1809	GNGGRTYGHSRARYE
DKK1-162	982	GHTFRGY	1396	NRSGSS	1810	GNGGRAYGYSRARYE
DKK1-163	983	GRTLRRY	1397	ISDGN	1811	GNGGRQYGHSRARYD
DKK1-164	984	GRALSSS	1398	WSGGR	1812	GNGGRYYGHSRARYD
DKK1-165	985	GRTFSNG	1399	TSTGS	1813	GNGGRLYGHSRARYD
DKK1-166	986	GLTFGSA	1400	TSGGR	1814	GNGGRQYGHSRARYD
DKK1-167	987	GFTFGST	1401	NWSGRR	1815	APRPKRVSVSYFYTSSNYD
DKK1-168	988	GRFTSSS	1402	TSGGR	1816	GNGGRAYGYSRARYE
DKK1-169	989	GRTFNSR	1403	TSDGS	1817	GNGGRQYGHSRARYD
DKK1-170	990	GRTLSS	1404	SQRG	1818	GNGGRQYGHSRARYD
DKK1-171	991	GGTFSRY	1405	NRSGKS	1819	GNGGRQYGHSRARYD
DKK1-172	992	GRTFNSR	1406	SSGST	1820	GNGGRSYGHSRARYD
DKK1-173	993	GSTFRGA	1407	TSAGGT	1821	GNGGRQYGHSRARYD
DKK1-174	994	GSTFSKA	1408	LSSGA	1822	GNGGRHYGHSRARYD
DKK1-175	995	GTTFRIN	1409	SRSGGS	1823	GNGGRSYGHSRARYD
DKK1-176	996	GFPVNRY	1410	SRSGGS	1824	GNGGRQYGHSRARYD
DKK1-177	997	GHTFNTY	1411	TSNGR	1825	GNGGRAYGYSRARYE
DKK1-178	998	GRTFGRR	1412	NWSGGS	1826	GNGGRHYGHSRARYD
DKK1-179	999	GFTFSSY	1413	SRSGGT	1827	GNGGRNYGHSRARYD
DKK1-180	1000	GRTFSNF	1414	SSGGR	1828	GNGGRHYGHSRARYD
DKK1-181	1001	GLTTVY	1415	SRTGGS	1829	GNGGRTYGHSRARYE
DKK1-182	1002	GTTFRIN	1416	NRSGKS	1830	GNGGRQYGHSRARYD
DKK1-183	1003	GRTFSTH	1417	TRLGV	1831	GNGGRAYGYSRARYE
DKK1-184	1004	GIPSTLR	1418	NWSGAS	1832	GNGGRQYGHSRARYD
DKK1-185	1005	GRTFSSY	1419	DWSGSR	1833	APRPKRVSVSYFYTSSNYD
DKK1-186	1006	GRTFSDI	1420	NWSGAR	1834	APRPKRVSVQYFSTSSNYD
DKK1-187	1007	GIPFSTR	1421	SWSGGS	1835	GNGGRQYGHSRARYD
DKK1-188	1008	GFTFDEY	1422	DWSGRR	1836	APRPKRISVSYFSTSSNYD
DKK1-189	1009	GFTFSNY	1423	SWSGGS	1837	APRPKRVSFSYFSTSSNYE
DKK1-190	1010	GITFKRY	1424	NWSGAS	1838	GNGGRQYGHSRARYD
DKK1-191	1011	GFTFGHY	1425	SWSLTR	1839	APRPKRVSVQYFSTSSNYD
DKK1-192	1012	GSITSIN	1426	SRSGAS	1840	GNGGRTYGHSRARYE
DKK1-193	1013	GGRIFSNY	1427	SWSGGS	1841	APRPKRVSVSYFSTASNYD
DKK1-194	1014	GRTF	1428	NWRSGGS	1842	GNGGRTYGHSRARYE
DKK1-195	1015	GGTFNGR	1429	SRSGGG	1843	GNGGRQYGHSRARYD
DKK1-196	1016	GFNFDDY	1430	SWSLSR	1844	APRPKRVSVSYFSTASNYD
DKK1-197	1017	SIGIAFSSR	1431	TRSGGK	1845	GNGGRSYGHSRARYD
DKK1-198	1018	GSTFRIN	1432	SASGS	1846	GNGGRTYGHSRARYE
DKK1-199	1019	GGIYRVN	1433	NWSGGS	1847	GNGGRQYGHSRARYD
DKK1-200	1020	GRSLNTY	1434	ISGGS	1848	GNGGRSYGHSRARYD
DKK1-201	1021	GRTFSNY	1435	STSGKT	1849	GNGGRQYGHSRARYD
DKK1-202	1022	GTTVRIR	1436	NGGGN	1850	GNGGRQYGHSRARYD
DKK1-203	1023	GRTFSTY	1437	NWSGSS	1851	GNGGRHYGHSRARYD
DKK1-204	1024	GIPFSTR	1438	SSGAT	1852	GNGGRHYGHSRARYD
DKK1-205	1025	GRTFSRY	1439	RIKDGS	1853	GNGGRQYGHSRARYD
DKK1-206	1026	GHTFNTY	1440	SRSGGK	1854	GNGGRNYGHSRARYE
DKK1-207	1027	GRSFSEY	1441	SRDGAA	1855	GNGGRKYGHHRARYD
DKK1-208	1028	GRTFTTY	1442	SSSGSS	1856	GNGGRQYGHSRARYD
DKK1-209	1029	GRTFSRY	1443	SWSGGS	1857	GNGGRQYGHSRARYD
DKK1-210	1030	GSIFTIN	1444	NWSGSS	1858	GNGGRKYGHHRARYD
DKK1-211	1031	GTSISNR	1445	SSGGNL	1859	GNGGRQYGHSRARYD
DKK1-212	1032	GFTFRRYV	1446	IEGAGSDT	1860	AKQIPGRKWTANGRKDY
DKK1-213	1033	GFTFNKYP	1447	ISPSGKKK	1861	AKYPKNFDY
DKK1-214	1034	GFTFSSAA	1448	ISGGGADT	1862	ARLPKRGPRFDY
DKK1-215	1035	GFTFNKYP	1449	IQQRGLKT	1863	AKGIRGWIGHDTQPFDY
DKK1-216	1036	GFTFDRYR	1450	ISPSGKKK	1864	AKYPKNFDY
DKK1-217	1037	GFTSNNFA	1451	ISGGGADT	1865	AKLQKRGPRFDY
DKK1-218	1038	GFTFGNYA	1452	ISSSGGET	1866	VKAPLRSGGVDY
DKK1-219	1039	GFTFDRYR	1453	ISPSGKKK	1867	AKFPSTHGKFDY
DKK1-220	1040	GLTFPNYG	1454	IDDRGRYT	1868	ARVIAAAGAFDY
DKK1-221	1041	GFTFNKYP	1455	ISNSGST	1869	AKRTRSKFDY
DKK1-222	1042	GFTFTHYS	1456	ITRSGST	1870	AKRTENRGVSFDY
DKK1-223	1043	GFTFEEKE	1457	ISSSGLWT	1871	AKGWRRFDY
DKK1-224	1044	GFTFDRYR	1458	ISPSGKKK	1872	AKYTWNGY
DKK1-225	1045	GFTFHKYG	1459	ISPSGKKK	1873	ASLSRGY
DKK1-226	1046	GFTFGNYA	1460	IWPRGQKT	1874	AKFRGRGFDY
DKK1-227	1047	GFTFAKYK	1461	ISPSGKKK	1875	AKAHNAFDY
DKK1-228	1048	GFTFSSYF	1462	ISGGGADT	1876	ARGNYFDY
DKK1-229	1049	GFTFDRYR	1463	ISGYGSTT	1877	AKFRGRGFDY
DKK1-230	1050	GFTFSRYA	1464	IGANGAPT	1878	AKDKRYRGSQHYFDY
DKK1-231	1051	GFTFRSYT	1465	ISNSGGST	1879	AKAGRKFDY
DKK1-232	1052	GFTFSDYD	1466	IGASGSAT	1880	AKQSGSEDHFDY
DKK1-233	1053	GFTFRRYV	1467	ISPSGKKK	1881	AKWRREGYTGSKFDY
DKK1-234	1054	GGFSLSRY	1468	INQAGLRT	1882	AKSRTGRYFDY
DKK1-235	1055	GFTFHKYG	1469	INPSRGYT	1883	AKGYRHFDY
DKK1-236	1056	GFTFNKYP	1470	ISSSGGET	1884	AKDLGQGFDY
DKK1-237	1057	GFTFNKYP	1471	ISSSGSST	1885	AKRTRSKFDY
DKK1-238	1058	GFTFRRYV	1472	ISGGGADT	1886	AGLPKRGPRFDY
DKK1-239	1059	GFTFSRYA	1473	IGPSGGKT	1887	ARLPKRGPWFDY
DKK1-240	1060	GFTFRRYV	1474	ISGGGADT	1888	AKPSRRFDY
DKK1-241	1061	GFTFSSYV	1475	IQQRGLKT	1889	ARSGPYYFDY
DKK1-242	1062	GFTFEDYQ	1476	ITGTGGET	1890	AKPGHRFDY
DKK1-243	1063	GFTFRRYV	1477	IYPSGGST	1891	AKDRYSQVHYALDY
DKK1-244	1064	GFTFKAYE	1478	ISPSGGIT	1892	ARHRAGSSGWYSDY
DKK1-245	1065	GFTFEVYT	1479	ISGRGDNT	1893	AKRTENRGVSFDY
DKK1-246	1066	GFTFGNYS	1480	IWPRGQKT	1894	AKVTGRGFDY
DKK1-247	1067	GFTFRRYV	1481	VNPNSGTS	1895	AKGPGTRGDY
DKK1-248	1068	GFTFSNYG	1482	ISPSGGWT	1896	ARYGAYFGLDY
DKK1-249	1069	GFTFAHEP	1483	INYAGNT	1897	AKKDYDYVWGSPYFDY
DKK1-250	1070	GFTFHEST	1484	ISSSGGET	1898	ARIRVGPSGGAFDY
DKK1-251	1071	GFTFNKYP	1485	ISPSGKKK	1899	AKFPSSQFRFDY
DKK1-252	1072	GFTFNKYP	1486	ISPSGKKK	1900	AKYPKNFNY
DKK1-253	1073	GFTFHKYG	1487	INYAGNT	1901	AKDKRYRGSQHYFDY
DKK1-254	1074	GLTFPNYG	1488	ISPSGKKK	1902	AREGLWAFDY
DKK1-255	1075	GFTFKAYE	1489	IIPNGGIT	1903	GRHRAGSIGWYSDY
DKK1-256	1076	GFTFRRYV	1490	IGASGSAT	1904	AKRTRSKFDY
DKK1-257	1077	GFTFRRYV	1491	ISGGGADT	1905	AKGRRRFDY
DKK1-258	1078	GFTSNNFA	1492	ISGGGADT	1906	AKLQKRGPRFDY
DKK1-259	1079	GFTFGNYA	1493	IWARGQKT	1907	AHLPGRGFEY
DKK1-260	1080	GFTFEDET	1494	IISSGGLT	1908	AKGFRIFDY
DKK1-261	1081	GFTFSNSY	1495	ITPKGDHT	1909	AKGARRFDY
DKK1-262	1082	GFTFSGYD	1496	IGRHGGRT	1910	AKSLGRFDY
DKK1-263	1083	GFTFRRYV	1497	IEGAGSDT	1911	ARLPKRGPRFDY
DKK1-264	1084	GFTFKSYG	1498	IWPRGQKT	1912	AKSGTRIKQGFDY
DKK1-265	1085	GFTFRRYV	1499	ISGGGADT	1913	ARLPKRGPRFDY
DKK1-266	1086	GFTFVAYN	1500	ISNSGGST	1914	AKNRAKFDY
DKK1-267	1087	GFTFRRYV	1501	ISSSGGET	1915	AKLPKRGPRFDY
DKK1-268	1088	GFTFRRYV	1502	IEGAGSDT	1916	AKFRGRGFDY
DKK1-269	1089	GFTFSRYG	1503	ISYGGSNK	1917	AKGVRKGFDY
DKK1-270	1090	GFTFGNYA	1504	IQQRGLKT	1918	ARGYRGYFDY
DKK1-271	1091	GYSISSGYH	1505	IDDRGRYT	1919	AKSNGRFDY
DKK1-272	1092	GFTFRRYV	1506	ISGSGGGT	1920	AKYFHGKFDY
DKK1-273	1093	GFTFHKYG	1507	ISPSGKKK	1921	AKGRWSIFDY
DKK1-274	1094	GFTFRRYV	1508	VNPNSGAS	1922	AKGPGTRGDY
DKK1-275	1095	GFTFNKYP	1509	IYPSGGST	1923	AKWSSRAFDY
DKK1-276	1096	GFTFRRYV	1510	IEGAGSDT	1924	ARLPKRGPRFDY
DKK1-277	1097	GFTFRRYV	1511	IEGAGSDT	1925	ARLPKRGPRFDY
DKK1-278	1098	GFTFSSYV	1512	ISPSGKKK	1926	AKYPKNFDY
DKK1-279	1099	GFTFRRYV	1513	ISGGGADT	1927	ARLPKRGPRFDY
DKK1-280	1100	GFTSNNFA	1514	INPSRGYT	1928	AKRTENRGVSFDY
DKK1-281	1101	GFTFNKYP	1515	ISPSGKKK	1929	AKFRGRGFDY
DKK1-282	1102	GFTFFPYA	1516	ISGGGADT	1930	ARLPKRGPRFDY
DKK1-283	1103	GFTFDQYD	1517	ITGSGGST	1931	ATAESDDTYDY
DKK1-284	1104	GFTFRRYV	1518	IEGAGSDT	1932	ARLPKRGPRFDY
DKK1-285	1105	GFTFRSYT	1519	ITGTGGET	1933	ARLPKRGPRFDY
DKK1-286	1106	GFTFRRYV	1520	IEARGGGT	1934	AKFRGRGFDY
DKK1-287	1107	GFTFGNYA	1521	IWPSGGQT	1935	AKDKRYRGSQHYFDY
DKK1-288	1108	GFTFNKYP	1522	SNSGST	1936	AKRTRSKFDY
DKK1-289	1109	GFTFHKYG	1523	IGRHGGRT	1937	AKAGSGFDY
DKK1-290	1110	GFTFSSYW	1524	IGPSGTST	1938	AESFRSRYFDY
DKK1-291	1111	GFTFGNYA	1525	IWPRGQKT	1939	ASLSRGY
DKK1-292	1112	GFTFRSYT	1526	ISGGGADT	1940	AKLPKRGPRFDY
DKK1-293	1113	GFTFSRYF	1527	ISGRGDNT	1941	AKRTENRGVSFDY
DKK1-294	1114	GFTFNKYP	1528	IQQRGLKT	1942	ARWTSGLDY
DKK1-295	1115	GFTFSRYF	1529	IDALGTDT	1943	AKGLRRFDY
DKK1-296	1116	GFTFDRYR	1530	ISSTGFKT	1944	AKFRGRGFDY
DKK1-297	1117	GFTFTHYS	1531	INGTGGET	1945	ARLPKRGPRFDY
DKK1-298	1118	GFTFSPYL	1532	IGPSGTST	1946	AKGRRIFDY
DKK1-299	1119	GFTFSNYF	1533	IDDRGRYT	1947	ARGGDYGSGDY
DKK1-300	1120	GFTFRRYV	1534	ISGGGADT	1948	ARPPKRGPRFDY
DKK1-301	1121	GFTFNKYP	1535	ISSSGGET	1949	AKRTRSKFDY
DKK1-302	1122	GFTFKSYG	1536	IGRHGGRT	1950	ARGGDYGSGDY
DKK1-303	1123	GFTFNKYP	1537	IGPSGGKT	1951	AKRTRSKFDY
DKK1-304	1124	GFTFRRYV	1538	ISGGGADT	1952	ARPPKRGPRFDY
DKK1-305	1125	GFTFEDET	1539	IISSGGLT	1953	AKGFRIFDY
DKK1-306	1126	GFTFNKYP	1540	ITRSGST	1954	AKWSSRAFDY
DKK1-307	1127	GFTFRRYV	1541	ISGGGADT	1955	AKHSKSSHRQSFDY
DKK1-308	1128	GFTFNKYP	1542	ISPSGKKK	1956	AKLTGRFDY
DKK1-309	1129	GFTFSRYF	1543	ISPSGKKK	1957	AKSGAYFDY
DKK1-310	1130	GFTFNKYP	1544	IEGRGTET	1958	AKRTRSKFDY
DKK1-311	1131	GFTFHKYG	1545	ISPSGKKK	1959	AKYPKNFDY
DKK1-312	1132	GFTFRRYV	1546	ISPSGKKK	1960	AKGVRKKFDY
DKK1-313	1133	GFTFRRYV	1547	ISGGGADT	1961	ARLPKRGPRFDY
DKK1-314	1134	GFTFGNYA	1548	ISPIGPRT	1962	AKRTENRGVSFDY
DKK1-315	1135	GFTLDYLA	1549	ISPSGKKK	1963	AKYTGRWEPFDY
DKK1-316	1136	GFTFTHYS	1550	ISGGGADT	1964	ARLPKRGPRFDY
DKK1-317	1137	GFTFRRYV	1551	ITGTGGET	1965	ARLPKRGPRFDY
DKK1-318	1138	GFTFRRYV	1552	ISPSGHGT	1966	ARRTGREYGGGWYFDY
DKK1-319	1139	GFTFPVYN	1553	ISESGTTT	1967	AKNRAKFDY
DKK1-320	1140	GFTFRRYV	1554	ISGGGADT	1968	ARLPKRGPRFDY
DKK1-321	1141	GFSFSAYA	1555	ISTSGGST	1969	ARGRAGADY
DKK1-322	1142	GFTFSRFA	1556	ISGSGAYT	1970	ARDIAAASFDY
DKK1-323	1143	GFTFTSYA	1557	VSGSGGTT	1971	AISYHFDYYFDY
DKK1-324	1144	GFTFSSYA	1558	ISGGGGAT	1972	ARECSGGSCSYYYGMDV
DKK1-325	1145	GSTFNNYA	1559	ISGSGSTT	1973	ARLAVSTSDYYYYGMDV
DKK1-326	1146	GFTFGRFA	1560	ITGSGTST	1974	ARDDRVRFSPVRRWFDP
DKK1-327	1147	GFTFSKYA	1561	ISATGGST	1975	ARVRSSSWYGDY
DKK1-328	1148	GFTFSRYA	1562	ISGSGVTT	1976	ARKTGGHYPFDY
DKK1-329	1149	GFTFSRSA	1563	ISASGANT	1977	ARDQARYYGMDV
DKK1-330	1150	GFTFRNYA	1564	ITSSGGST	1978	ASGLRARNGFDI
DKK1-331	1151	GFTFSNYA	1565	ISGSGGST	1979	ARGAILAY
DKK1-332	1152	GFTFSSYA	1566	VSGTGGTT	1980	ARDVGFGELHP
DKK1-333	1153	GFTFSSYA	1567	ISGSGYST	1981	ARGRTGTLYGMDV
DKK1-334	1154	GFSFNNYA	1568	ISGGGSNT	1982	ARVAASGSYYRAFDQ
DKK1-335	1155	GFTFRRYA	1569	ISSSGGNT	1983	ARDRGFGWFDP
DKK1-336	1156	GFTFRSYG	1570	ISGSGGRT	1984	AKVSYDSSGYYYDAFDI
DKK1-337	1157	GFTFANYA	1571	ISGSGGSA	1985	ARSGSFLSFDS
DKK1-338	1158	GFTFGRFA	1572	ISGSGGRT	1986	ARVDYKKKSYYNAMDA
DKK1-339	1159	GFTFRTSA	1573	ISSGGGGT	1987	ARGPRGRGAFDV
DKK1-340	1160	GFTFSSYA	1574	ISGSGGST	1988	ARDDRVRFSPVRRWFDP
DKK1-341	1161	GIHLSSYA	1575	ISGGGGGT	1989	ARGGHVGIRRPFDV
DKK1-342	1162	GFTFSKYA	1576	ISGSGGTT	1990	ARHAHGAGSYPFDY
DKK1-343	1163	GFPFSSYA	1577	ISGSGGRT	1991	GRAPRKYYGMDV
DKK1-344	1164	GFSFSAYA	1578	ISGRDTST	1992	ARVPLRGSGRLSFDY
DKK1-345	1165	GSPFSNYA	1579	ISGSGGST	1993	ARAPRSPILGVRRGLDP
DKK1-346	1166	GFSFSGYA	1580	ISGSSGRT	1994	VRGGTRGLGY
DKK1-347	1167	GFTFRTYG	1581	ISGSGETT	1995	ARLDHDSSGFYEAFDV
DKK1-348	1168	GLTFSRYA	1582	ISGRGGNT	1996	ARGGMRLGKSYYYYGMDV
DKK1-349	1169	GFAFSTSA	1583	ISASGGST	1997	ARLSVARGAYGMDV
DKK1-350	1170	GFTFGAYA	1584	ISGSGART	1998	ARRGRPPQYYFDS
DKK1-351	1171	GFTFRRYA	1585	VSGSGGTT	1999	ARGWEPGIAAN
DKK1-352	1172	GFTFSKHA	1586	ISGSGDTT	2000	ARHQYSGSGSFRY
DKK1-353	1173	GFTFRRSA	1587	IGGSGDNT	2001	AKHRGSFWFDP
DKK1-354	1174	GFSFRSYA	1588	ISGSGGNT	2002	TTMFGSGTFYTGFDF
DKK1-355	1175	GFTFSSSS	1589	ISGSGGTT	2003	ARAGARFVGFDY
DKK1-356	1176	GFTFSRFA	1590	ISGSGRNT	2004	ATFNPVGLFY
DKK1-357	1177	GFSFSTYA	1591	ISGSAVST	2005	ARSGSFLSFDS
DKK1-358	1178	GFTFSRYT	1592	VSGSGGRT	2006	ARSRNGRWFDP
DKK1-359	1179	GLTFRSYA	1593	ISGSGGST	2007	ARGASFDS
DKK1-360	1180	GFTFSNYA	1594	ISGSGART	2008	ARGRQRQRSTPLGRY
DKK1-361	1181	GFNFRDYA	1595	ISGRGSV	2009	ARGGDWVAFDY
DKK1-362	1182	GFTFSGYV	1596	ISGSGGRT	2010	ARRKGPTYGMDV
DKK1-363	1183	GFTFSTFA	1597	LSGSGGRT	2011	ARVTRYQGWLSHFDY
DKK1-364	1184	GFTLSTYA	1598	ISTSGGST	2012	ARVFVSSGWYDGMDV
DKK1-365	1185	GLTFNNYA	1599	ISGSGART	2013	ARGASLDV
DKK1-366	1186	GFTFGRYA	1600	ISGSGTTT	2014	ARAIGGRTAY
DKK1-367	1187	GFSFSAYA	1601	ISGRDTST	2015	ARVPLRGSGRLSFDY
DKK1-368	1188	GFTFGRYA	1602	ITASGGST	2016	ARVVTAMGYYYGMDV
DKK1-369	1189	GFTFSNYG	1603	ISAGGGNT	2017	ARDLGMRGPYYYYYGMDV
DKK1-370	1190	GFTFSYYG	1604	ISGGGAGT	2018	VASRNYLLDF
DKK1-371	1191	GFTFTKYA	1605	ISGRGGST	2019	ARGDLTVTRKYDS
DKK1-372	1192	GFTFRSYG	1606	ISRSGGNT	2020	ARTYSYGSFDY
DKK1-373	1193	GFNFRSYA	1607	ISGSGTTT	2021	ASWRAAPFDY
DKK1-374	1194	GFSFSAYA	1608	ISGRDTST	2022	ARVPLRGSGRLSFDY
DKK1-375	1195	GFTFGNYA	1609	ITGSGGST	2023	AKGKFHLDP
DKK1-376	1196	GFSFSSYA	1610	ISGRGGST	2024	TTDYGAIMDV
DKK1-377	1197	GFTFGRFA	1611	ISGSGTST	2025	ARDSRNYFGMGV
DKK1-378	1198	GFTFGNYA	1612	ISRSGGNT	2026	GRDGTRFGAFDI
DKK1-379	1199	GFTFNKFA	1613	ISGSGSRT	2027	ARGRSWYNH
DKK1-380	1200	GLTFSSYA	1614	ISGSGGNT	2028	ARFQPRPLRLFDY
DKK1-381	1201	GFTLRSYA	1615	ISGSGGYT	2029	ARASYGSGSYPLIH
DKK1-382	1202	GFTFSSFA	1616	VSGSGGST	2030	AGHRSNIGWDV
DKK1-383	1203	GSTFSSYA	1617	ISASGGRT	2031	ARDDRVRFSPVRRWFDP
DKK1-384	1204	GFTFRRSA	1618	ISGSGSGT	2032	ARSARGRWFDP
DKK1-385	1205	GFTFAGYA	1619	ISRSGDRT	2033	AKGQRAHQQLVRGAMDV
DKK1-386	1206	GFTFRTFA	1620	ISASGGTT	2034	AHRRRSKFWSGFGV
DKK1-387	1207	GFTFSRYA	1621	ISGSGVTT	2035	ARKTGGHYPFDY
DKK1-388	1208	GFTFDNYA	1622	ISGSGGSI	2036	VKGAPAGYLDS
DKK1-389	1209	GFRFSSYA	1623	ISGRGGST	2037	ARHNRERRAFDI
DKK1-390	1210	GFTFRSYA	1624	ISGGGGTT	2038	ARDSRVRGTHDYYYYGMDV
DKK1-391	1211	GFTFSKFA	1625	ISASGGRT	2039	ARGSLRFTP
DKK1-392	1212	GFTFSSSG	1626	ISPSGGST	2040	ARLSADRVFAFDI
DKK1-393	1213	GFSFSSFA	1627	ISGSGDVT	2041	AGHRSNIGWDV
DKK1-394	1214	GFTFGRFA	1628	ITGSGTST	2042	ARVPLRGSGRLSFDY
DKK1-395	1215	GFGFSSYA	1629	ITGSGGNT	2043	AKSRRPRYSYGFAFES
DKK1-396	1216	GVTFRNYA	1630	ISASGGSP	2044	ARDTSVGWFDP
DKK1-397	1217	GFTFRNYA	1631	ISGGGGRT	2045	VRDLTRRAAMDV
DKK1-398	1218	GFTFRSSA	1632	ISGSGRST	2046	ARNGAGSHYYAMDV
DKK1-399	1219	GFTFSRFA	1633	ISGSGGRT	2047	ASSKVTRSALDY
DKK1-400	1220	GFTFGNYA	1634	ISGSGSST	2048	GRESGRGSGT
DKK1-401	1221	GFTYSSYA	1635	ISGSGGST	2049	ARERELYYFYYGMDV
DKK1-402	1222	GFTFSTYG	1636	ITGSGGST	2050	ARHHNRRSSLDY
DKK1-403	1223	GFTFSSSG	1637	ISSTGGTT	2051	ARRGRRQLRYYYGMDV
DKK1-404	1224	GFSFSSSA	1638	ISGSGGTT	2052	ARARRRSFDW
DKK1-405	1225	GFTFSRYA	1639	ISGGRVST	2053	ARSLRGNAFDI
DKK1-406	1226	GFTFSGYA	1640	IRGSGGST	2054	AKDLQSRGY
DKK1-407	1227	GFTFNKFA	1641	ISVSGGNT	2055	ARHSRLAALLA
DKK1-408	1228	GFTFSSHV	1642	ISGSGAGT	2056	AVTGTTGWFDP
DKK1-409	1229	GFTFGRYA	1643	ISSSRGST	2057	ARVGIAGRGMDV
DKK1-410	1230	GFTFNTYG	1644	ISGRRT	2058	ARVSRGYPRRSDS
DKK1-411	1231	GFTVSSYA	1645	ISGGGGTT	2059	VRSSNWKFDQ
DKK1-412	1232	GFTFSRSA	1646	ISASGANT	2060	ARDQARYYGMDV
DKK1-413	1233	GFTFRSYD	1647	ISGSGVTT	2061	ARGRRLDY
DKK1-414	1234	GFAFTTYA	1648	ISGSGSTT	2062	ARSGSFLSFDS
DKK1-415	1235	GFTFSSYD	1649	ISGSGRNT	2063	ARGGGASNWFDP
DKK1-416	1236	GFSFSAYA	1650	ISGRDTST	2064	ARVPLRGSGRLSFDY
DKK1-417	1237	GFTFSRFA	1651	ISGTGSST	2065	ARVPGN
DKK1-418	1238	GIPFSSR	1652	SRSGTG	2066	GNGGRTYGHSRARYD
DKK1-419	1239	GGIYRVN	1653	NWSGGS	2067	GNGGRKYGHHRARYD
DKK1-420	1240	GFLMYDR	1654	SRTGSS	2068	GNGGRKYGHHRARYD
DKK1-421	1241	GRTFSRF	1655	SARGM	2069	GNGGRTYGHSRARYE
DKK1-422	1242	GTTFRIN	1656	NWNGGS	2070	GNGGRQYGHSRARYD
DKK1-423	1243	GRTFSNN	1657	LSGGS	2071	GNGGRNYGHSRARYD
DKK1-424	1244	GRTFSDI	1658	NWSGAR	2072	APRPKRVSVQYFSTSSNYD
DKK1-425	1245	GHTYNTY	1659	LRGGS	2073	GNGGRHYGHSRARYD
DKK1-426	1246	GRSLYDR	1660	SRTGSS	2074	GNGGRSYGHSRARYD
DKK1-427	1247	GRTFNNY	1661	SWSTGS	2075	EGGYSGTYYYTGDFD
DKK1-428	1248	GRTLYSY	1662	SWSAGS	2076	GNGGSKYGHSRARYD
DKK1-429	1249	GTFRDY	1663	YGTGGEL	2077	GNGGRQYGHSRARYD
DKK1-430	1250	GGGTFGSY	1664	TWNGTR	2078	APRPKRVSVSYFSTASNYD
DKK1-431	1251	GRTFSNY	1665	SWSGGS	2079	GNGGRTYGHSRARYD
DKK1-432	1252	GRTFTNY	1666	SRGGSA	2080	GNGGRHYGHSRARYD
DKK1-433	1253	GRTFSTH	1667	TRLGV	2081	GNGGRAYGYSRARYE
DKK1-434	1254	GRSFSMY	1668	SRDGAA	2082	GNGGRLYGHSRARYD
DKK1-435	1255	GLTFRNY	1669	SWSLSR	2083	APRPKRASVQYFSTSSNYD
DKK1-436	1256	GFTFDDR	1670	RWSGGI	2084	GNGGRSYGHSRARYD
DKK1-437	1257	GRTFSS	1671	NWSGAS	2085	GNGGRYYNHSRTRYE
DKK1-438	1258	GHTFNTY	1672	NSGGSY	2086	GNGGRNYGHSRARYE
DKK1-439	1259	GRIF	1673	SGSGVY	2087	GNGGRYYGHSRARYD
DKK1-440	1260	GRSFSEY	1674	SRDGAA	2088	GNGGRKYGHHRARYD
DKK1-441	1261	GFNSGSY	1675	SWSLSR	2089	APRPKRVSVSYFSTASNYD
DKK1-442	1262	GGTAY	1676	SWSLTR	2090	APRPKRVSVRYFSTSSNYD
DKK1-443	1263	GRTFTSY	1677	SGSGDD	2091	GNGGRQYGHSRARYD
DKK1-444	1264	GSTFRIN	1678	SASGS	2092	GNGGRTYGHSRARYE
DKK1-445	1265	GGTLNNNPM	1679	NWSGAR	2093	APRPKRISVQYFTTSSNYD
DKK1-446	1266	GRTFSTY	1680	GTRGA	2094	GNGGRQYGHSRARYD
DKK1-447	1267	GRTFNSY	1681	TRLGV	2095	GNGGRYYGHSRARYD
DKK1-448	1268	GIPFSSR	1682	GWYGS	2096	GNGGRQYGHSRARYD
DKK1-449	1269	GIDVNRN	1683	SWSGGR	2097	APRPKRVSVHYFSTSSNYD
DKK1-450	1270	GINFSRY	1684	DWSGSR	2098	APRPKRVSVSYFSTASNYD
DKK1-451	1271	GGTLRGY	1685	DWSGSR	2099	APRPKYVSVRYFSTSSNYD
DKK1-452	1272	GQTF	1686	NWNGDS	2100	GNGGRKYGHHRARYD
DKK1-453	1273	GYTFRAY	1687	TSGGS	2101	GNGGRTYGHSRARYE
DKK1-454	1274	GNIFTLN	1688	NSGGSY	2102	GNGGRKYGHHRARYD
DKK1-455	1275	GFRMYDR	1689	SGRSGN	2103	GNGGRNYGHSRARYD
DKK1-456	1276	GFTFSMW	1690	SRSGGS	2104	GNGGRYYNHSRTRYE
DKK1-457	1277	GFTFRSY	1691	HTGGG	2105	GNGGRNYGHSRARYD
DKK1-458	1278	GLPFSTK	1692	SSGGR	2106	GNGGRHYGHSRARYD
DKK1-459	1279	GNIFRIN	1693	NSGGSS	2107	GNGGRAYGYSRARYE
DKK1-460	1280	GGTFGHY	1694	SWSLTR	2108	APRPKRVSFSYFSTSSNYE
DKK1-461	1281	GRTFNSY	1695	TWGGST	2109	GNGGRSYGHSRARYD
DKK1-462	1282	GITFRRY	1696	NWGGGS	2110	GNGGRAYGYSRARYE
DKK1-463	1283	GRTFSYN	1697	SIGGR	2111	GNGGRSYGHSRARYD
DKK1-464	1284	GRTFSSL	1698	RSSGG	2112	GNGGRTYGHSRARYE
DKK1-465	1285	GPTFSTN	1699	YSGVRSGVS	2113	GNGGRHYGHSRARYD
DKK1-466	1286	GRTFSNY	1700	YGTGGEL	2114	GNGGRKYGHHRARYD
DKK1-467	1287	GRAIGSY	1701	TFSGAR	2115	APRPKRASVQYFSTSSNYD
DKK1-468	1288	GRTLSRN	1702	RSGA	2116	GNGGRHYGHSRARYD
DKK1-469	1289	GRTFIGY	1703	KFSGGT	2117	GNGGRYYGHSRARYD
DKK1-470	1290	GRTISNY	1704	SWRGGS	2118	APRPKYVSVSYFSTSSNYD
DKK1-471	1291	GRTISNY	1705	SWALSR	2119	APRPKRVSFSYFSTSSNYE
DKK1-472	1292	GTFTSY	1706	SWTGGS	2120	GNGGRYYNHSRTRYE
DKK1-473	1293	GRSFSMY	1707	SWSGGS	2121	EGGYSGTYYYTGDFD
DKK1-474	1294	GLTFRNY	1708	NWSGAR	2122	APRPKSISVRYFSTSSNYE
DKK1-475	1295	GFTFSSY	1709	SADGSD	2123	GKRYGYYD
DKK1-476	1296	GRTHSIY	1710	RWGTTD	2124	APRPTRVSVRYFSTRSNYN
DKK1-477	1297	GFSLDYV	1711	KPSGDT	2125	YLSFYSDYEVYD
DKK1-478	1298	GSIFRVN	1712	SMSGAN	2126	GNGGRQYGHSRARYD
DKK1-479	1299	GRTFSSL	1713	NWSGGN	2127	GNGGRKYGHHRARYD
DKK1-480	1300	GFLMYDR	1714	SRTGSS	2128	GNGGRAYGYSRARYE
DKK1-481	1301	GDISSY	1715	TWNGGTH	2129	GNGGRKYGHHRARYD
DKK1-482	1302	GRTHSIY	1716	NWNGDS	2130	GNGGRTYGHSRARYE
DKK1-483	1303	GIPFSSR	1717	SRSGTG	2131	GNGGRAYGYSRARYE
DKK1-484	1304	GRTFSNY	1718	VNGGS	2132	GNGGRAYGYSRARYE
DKK1-485	1305	GMTTIG	1719	SWDGGN	2133	GNGGRQYGHSRARYD
DKK1-486	1306	GRASGDY	1720	SWRGGN	2134	APRPKRVSFSYFSTSSNYE
DKK1-487	1307	GRTFSSY	1721	LSGGS	2135	GNGGRAYGYSRARYE
DKK1-488	1308	GRTFSEV	1722	HWSGGS	2136	GNGGRSYGHSRARYD
DKK1-489	1309	GSTFSIN	1723	TPRGL	2137	GNGGRAYGYSRARYE
DKK1-490	1310	GRTF	1724	IWRGGS	2138	GNGGRQYGHSRARYD
DKK1-491	1311	GGTFSSY	1725	SWSGSA	2139	GNGGRSYGHSRARYD
DKK1-492	1312	GRTFSNF	1726	LRGGS	2140	APRPKRVSVSYFSTASNYD
DKK1-493	1313	GGTFSRY	1727	SWSLTR	2141	APRPKRVSVQYFVTSSNYD
DKK1-494	1314	GRTLSRS	1728	RIKDGS	2142	GNGGRQYGHSRARYD
DKK1-495	1315	GRTFSSG	1729	SRSGTL	2143	APRPKRVSVQYFSTSSNYD
DKK1-496	1316	GRTFNSY	1730	NVGGG	2144	GNGGRTYGHSRARYD
DKK1-497	1317	GYTLKNYY	1731	SRSGGT	2145	APRPKRASVQYFSTSSNYD
DKK1-498	1318	GHTFNTY	1732	SYSG	2146	GNGGRAYGYSRARYE
DKK1-499	1319	GFTFDDR	1733	STSGTR	2147	GNGGRQYGHSRARYD
DKK1-500	1320	GRTLSSY	1734	GTSGP	2148	GNGGRTYGHSRARYE
DKK1-501	1321	GRIFTNT	1735	SWGGGL	2149	GNGGSRYGHSRARYD
DKK1-502	1322	GRIF	1736	SWTAGT	2150	GNGGRNYGHSRARYD
DKK1-503	1323	GNIFTRH	1737	NTGGGS	2151	GNGGRTYGHSRARYE
DKK1-504	1324	GRTFSNY	1738	SWSSGN	2152	GNGGRQYGHSRARYD
DKK1-505	1325	GRTFTSY	1739	GTHGT	2153	GNGGRQYGHSRARYD
DKK1-506		GQT	1740	SRSG	2154	GNGGRAYGYSRARYE
DKK1-507	1327	GRSFSEY	1741	TWSGDM	2155	GNGGRHYGHSRARYD
DKK1-508	1328	GRSFSSY	1742	NTAGW	2156	GNGGRSYGHSRARYD
DKK1-509	1329	GLTFRNY	1743	SWSGGK	2157	APRPKRISVSYFSTTSNYD
DKK1-510	1330	GSTFSSY	1744	HTGG	2158	GNGGRQYGHSRARYD
DKK1-511	1331	GIDVNRN	1745	SWSGGT	2159	APRPKRVSVSYFSTASNYD
DKK1-512	1332	GGTFNVY	1746	NRSGKS	2160	APRPKRVSVRYFSTSSNYD

TABLE 5
Variable Heavy Chain Domain Sequences
DKK1	SEQ
Variant	ID NO	VH Sequence
DKK1-	295	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRFAMGWFRQAPGKEREGVASITSGGTTNYADSV
1		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADDGARGSWGQGTLVTVSS
DKK1-	296	EVQLVESGGGLVQPGGSLRLSCAASGSAFSSTVMGWFRQAPGKEREFVATINSLGGTSYADSV
2		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAYSGHFSGRVSDFLWGQGTLVTVSS
DKK1-	297	EVQLVESGGGLVQPGGSLRLSCAASGSTFSTYAMGWFRQAPGKEREFVASINWGGGNTYYADS
3		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAKKVSFGDWGQGTLVTVSS
DKK1-	298	EVQLVESGGGLVQPGGSLRLSCAASGNIFRINAMGWFRQAPGKERELVAAISRSGGSTNYADSV
4		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKDKNGPWGQGTLVTVSS
DKK1-	299	EVQLVESGGGLVQPGGSLRLSCAASGGLTFSTYAMGWFRQAPGKEREFVAAVSWSGGNTYYA
5		DSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEIGYYSGGTYYSSEAWGQGTLVTVSS
DKK1-	300	EVQLVESGGGLVQPGGSLRLSCAASGIPFSTRTMGWFRQAPGKEREFVAAISSGATTLYADSVK
6		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	301	EVQLVESGGGLVQPGGSLRLSCAASGISGSVFSRTPMGWFRQAPGKEREFVAALSKDGARTYY
7		ADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCARDLVGTDAFDIWGQGTLVTVSS
DKK1-	302	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMGWFRQAPGKEREFVAAISWSDGSTYYADS
8		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	303	EVQLVESGGGLVQPGGSLRLSCAASGRSFSMYAMGWFRQAPGKERELVAAISWSGGSTVYAD
9		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	304	EVQLVESGGGLVQPGGSLRLSCAASGRTISNYAMGWFRQAPGKEREFVAAISWRGGSTYYADS
10		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKYVSVSYFSTSSNYDWGQGTLVTVSS
DKK1-	305	EVQLVESGGGLVQPGGSLRLSCAASGPTVDAYAMGWFRQAPGKEREFVSAISWSGSATFYADS
11		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	306	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSRPMGWFRQAPGKEREFVAAISSSASSTYYADSV
12		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	307	EVQLVESGGGLVQPGGSLRLSCAASGFLMYDRAMGWFRQAPGKEREIVAAISRTGSSIYYADS
13		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	308	EVQLVESGGGLVQPGGSLRLSCAASGSIFSRLAMGWFRQAPGKEREFVAAISSSGISTIYADSVK
14		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCARGQRGRWLEPLTGWGQGTLVTVSS
DKK1-	309	EVQLVESGGGLVQPGGSLRLSCAASGFTFGTTTMGWFRQAPGKERELVAAITSGGGTTYYADS
15		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKDLAAAGYYYYYGMDVWGQGTLVTVSS
DKK1-	310	EVQLVESGGGLVQPGGSLRLSCAASGNIFTRNVMGWFRQAPGKEREFVGAINWSGGNTVYADS
16		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCARHDHNNRGLDYWGQGTLVTVSS
DKK1-	311	EVQLVESGGGLVQPGGSLRLSCAASGGTFSRYAMGWFRQAPGKEREFVAGISWTLGRTYYADS
17		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCARDPFGKWGQGTLVTVSS
DKK1-	312	EVQLVESGGGLVQPGGSLRLSCAASGITFRFKAMGWFRQAPGKEREFVAAINRSGRSTRYADSV
18		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAESHGSTSPRNPLQYDWGQGTLVTVSS
DKK1-	313	EVQLVESGGGLVQPGGSLRLSCAASGRTYGMGWFRQAPGKEREFVAGISWTLGRTYYADSVK
19		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCASDESDAANWGQGTLVTVSS
DKK1-	314	EVQLVESGGGLVQPGGSLRLSCAASGPTFSIYDMGWFRQAPGKEREFVTGSNTGGTTYADSVK
20		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCATCTDFEYDWGQGTLVTVSS
DKK1-	315	EVQLVESGGGLVQPGGSLRLSCAASGIPSSIRAMGWFRQAPGKEREWVSGISISDSSTYYADSVK
21		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGKRYGYYDWGQGTLVTVSS
DKK1-	316	EVQLVESGGGLVQPGGSLRLSCAASGSTLSINAMGWFRQAPGKERELVAAISWSGGTAYADSV
22		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAQSRYRSNYYDHDKYAWGQGTLVTVSS
DKK1-	317	EVQLVESGGGLVQPGGSLRLSCAASGYNFSTFCMGWFRQAPGKEREWVAAISGGGSTMYADS
23		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASKWYGGFGDTDIEWGQGTLVTVSS
DKK1-	318	EVQLVESGGGLVQPGGSLRLSCAASGSSFSAYGMGWFRQAPGKEREFVAGISWTLGRTYYADS
24		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADGVPEYSDYASGPVWGQGTLVTVSS
DKK1-	319	EVQLVESGGGLVQPGGSLRLSCAASGSTSRSYGMGWFRQAPGKEREFVAGISWTLGRTYYADS
25		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCARDPSGKWGQGTLVTVSS
DKK1-	320	EVQLVESGGGLVQPGGSLRLSCAASGFSLDYYGMGWFRQAPGKEREVVASIRWNAKPYYADS
26		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGKRYGYYDWGQGTLVTVSS
DKK1-	321	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREWVASISTSGKTTYYADS
27		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	322	EVQLVESGGGLVQPGGSLRLSCAASGLTTVYTMGWFRQAPGKEREFVAAISWYVSTTFYADSV
28		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	323	EVQLVESGGGLVQPGGSLRLSCAASGSIGGLNAMGWFRQAPGKEREFVAAINYSGRSTVYADS
29		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGAGRDRGFSRAQYAWGQGTLVTVSS
DKK1-	324	EVQLVESGGGLVQPGGSLRLSCAASGRTFSKYAMGWFRQAPGKEREFVAAISWSGESTYYADS
30		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFYTSSNYDWGQGTLVTVSS
DKK1-	325	EVQLVESGGGLVQPGGSLRLSCAASGRTLSRSAMGWFRQAPGKERELVAAISWSGGSTYYADS
31		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	326	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNGPMGWFRQAPGKEREFVAAISRGGKISHYADS
32		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	327	EVQLVESGGGLVQPGGSLRLSCAASGRSLNTYTMGWFRQAPGKERELVAVIISGGSTAYADSV
33		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	328	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDRAMGWFRQAPGKEREFVAAISWSGGSTYYADS
34		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFYTSSNYDWGQGTLVTVSS
DKK1-	329	EVQLVESGGGLVQPGGSLRLSCAASGRTFTTYPMGWFRQAPGKEREFVAAISSSGSSTVYADSV
35		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	330	EVQLVESGGGLVQPGGSLRLSCAASGIPSTLRAMGWFRQAPGKEREFVAAINWSGASTVYADS
36		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	331	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFIAAINLSSGSTYYADSV
37		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	332	EVQLVESGGGLVQPGGSLRLSCAASGTSFSIGAMGWFRQAPGKEREWVSSISPGGLFPYYADSV
38		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAARDAIVGVTDTSGYRWGQGTLVTVSS
DKK1-	333	EVQLVESGGGLVQPGGSLRLSCAASGTVFSISDMGWFRQAPGKEREWVSAISPGGGYTVYADS
39		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCARSSWFDCGVQGRDLGNEYDWGQGTLVTVSS
DKK1-	334	EVQLVESGGGLVQPGGSLRLSCAASGRTISSFRMGWFRQAPGKEREFVAAISRGGNVTPYADSV
40		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANSDSGFDSYSVWAAYEWGQGTLVTVSS
DKK1-	335	EVQLVESGGGLVQPGGSLRLSCAASGRTLSRSAMGWFRQAPGKERELVAAISWSGGSTYYADS
41		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	336	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVAAITSGGRTYADSVK
42		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	337	EVQLVESGGGLVQPGGSLRLSCAASGTSFSVGAMGWFRQAPGKEREFVGAVSWSGGTTVYAD
43		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	338	EVQLVESGGGLVQPGGSLRLSCAASGRGAMGWFRQAPGKEREFVAAINRSGKSTYYADSVKG
44		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	339	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNFAMGWFRQAPGKEREFVAAISATGSTYYADSV
45		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	340	EVQLVESGGGLVQPGGSLRLSCAASGRTLSSITMGWFRQAPGKERELVATITRAGSTNYADSVK
46		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	341	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVASISSGGSTYYADSVK
47		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	342	EVQLVESGGGLVQPGGSLRLSCAASGRSFGNFPMGWFRQAPGKERELVAAVTSGGSTYYADSV
48		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	343	EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYAMGWFRQAPGKEREVVAVVNWSGRRTYYA
49		DSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFSTSSNYDWGQGTLVTVSS
DKK1-	344	EVQLVESGGGLVQPGGSLRLSCAASGRTFSLYTMGWFRQAPGKEREFVAAINRSGKSTYYADS
50		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	345	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTSAMGWFRQAPGKEREFVAVINRSGKTTYYADS
51		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	346	EVQLVESGGGLVQPGGSLRLSCAASGRTFSISAMGWFRQAPGKEREFVAAISPSGNTYYADSVK
52		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	347	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYPMGWFRQAPGKEREFVASISRSGTTYYADSVK
53		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	348	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDRAMGWFRQAPGKEREFVAAISTGGTTVYADSV
54		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	349	EVQLVESGGGLVQPGGSLRLSCAASGFTFGDYAMGWFRQAPGKEREFVGAIDWSGRRITYADS
55		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	350	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVARISSSGGTTYYADSV
56		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	351	EVQLVESGGGLVQPGGSLRLSCAASGSTFSKAVMGWFRQAPGKEREFVATITFSGARTHYADS
57		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	352	EVQLVESGGGLVQPGGSLRLSCAASGRRFSADVMGWFRQAPGKEREFVAAIRSGGTTLYADSV
58		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	353	EVQLVESGGGLVQPGGSLRLSCAASGFTVSNYAMGWFRQAPGKEREFVAAISWSGGSTYYADS
59		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	354	EVQLVESGGGLVQPGGSLRLSCAASGRAFSSSAMGWFRQAPGKEREFVAAINRGGKISHYADS
60		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	355	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSNVMGWFRQAPGKEREFVSAISRSGGSTVYADSV
61		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	356	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKEREFVAAINRSGKSTYYADS
62		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	357	EVQLVESGGGLVQPGGSLRLSCAASGFRMYDRVMGWFRQAPGKEREFVATISRSGGRTYYADS
63		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	358	EVQLVESGGGLVQPGGSLRLSCAASGRTSSAYAMGWFRQAPGKEREFVAAISRSGASAYYADS
64		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	359	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRFAMGWFRQAPGKERELVAAISARGMPAYADSV
65		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	360	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFIAAINLSSGSTYYADSV
66		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	361	EVQLVESGGGLVQPGGSLRLSCAASGRTFRSYPMGWFRQAPGKEREFVAAISMSGKETWYADS
67		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	362	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREWVASISTSGKTTYYADS
68		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	363	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYPMGWFRQAPGKEREFVAAISRSGGSTVYADSV
69		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	364	EVQLVESGGGLVQPGGSLRLSCAASGTSFSIGAMGWFRQAPGKERELLAAISRSGASAYYADSV
70		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	365	EVQLVESGGGLVQPGGSLRLSCAASGRTISNAAMGWFRQAPGKERELVAVIRSGGTTLYADSV
71		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	366	EVQLVESGGGLVQPGGSLRLSCAASGGIYRVNTMGWFRQAPGKEREFVAAINWSGGSTIYADS
72		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	367	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSKTMGWFRQAPGKEREFVAAINWSGGLTVYADS
73		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	368	EVQLVESGGGLVQPGGSLRLSCAASGIPFSSRTMGWFRQAPGKEREFVAAISRSGTGTYYADSV
74		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	369	EVQLVESGGGLVQPGGSLRLSCAASGPTVDAYAMGWFRQAPGKEREFVSAISWSGSATFYADS
75		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	370	EVQLVESGGGLVQPGGSLRLSCAASGIPFSTRTMGWFRQAPGKEREFVAAISSGATTLYADSVK
76		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	371	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSRPMGWFRQAPGKEREFVAAISSSASSTYYADSV
77		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	372	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSPMGWFRQAPGKERELVAVILRGGSTNYADSVK
78		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	373	EVQLVESGGGLVQPGGSLRLSCAASSIGIAFSSRTMGWFRQAPGKEREFVAAVTRSGGKSYYAD
79		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	374	EVQLVESGGGLVQPGGSLRLSCAASGFLMYDRAMGWFRQAPGKEREIVAAISRTGSSIYYADS
80		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	375	EVQLVESGGGLVQPGGSLRLSCAASGIAFQGYAMGWFRQAPGKERELVAAIDTNGGHTLYADS
81		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYRGTYYYTGDFDWGQGTLVTVSS
DKK1-	376	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNTLMGWFRQAPGKEREWVARITSGGSTHYADNV
82		KGRFTIITDNSKNTAYLLMISLKPQNTAEYYWSAGNGGRHYGHNRPRYDWCHGGLVTVIT
DKK1-	377	EVQLVESGGGLVQPGGSLRLSCAASGSTSSLRTMGWFRQAPGKEREFVAAISWSLSRTHYADS
83		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	378	EVQLVESGGGLVQPGGSLRLSCAASGRTFTNYPMGWFRQAPGKEREFVAAINRGGSTTYYADS
84		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNRRRPYGYSHSRYDWGQGTLVTVSS
DKK1-	379	EVQLVESGGGLVQPGGSLRLSCAASGITFKRYVMGWFRQAPGKEREFVATITSRDGTTYYYAD
85		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYWAAGNGGRNYGHSRSRYEWGQGTLVTVSS
DKK1-	380	EVQLVESGGGLVQPGGSLRLSCAASGRTFINYAMGWFRQAPGKEREFVAAIIWTGVSTYYADS
86		VKGRFTIIADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPNRVSVRYFSTNNNYDWGQGTLVTVSS
DKK1-	381	EVQLVESGGGLVQPGGSLRLSCAASGRTFSGYTMGWFRQAPGKEREFVAAISWSGGSTYYADS
87		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYHCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	382	EVQLVESGGGLVQPGGSLRLSCAASGLTFSTYPMGWFRQAPGKERELVALIASNGNTHYADSV
88		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	383	EVQLVESGGGLVQPGGSLRLSCAASGFTSDDYAMGWFRQAPGKEREFVAAISWSGGRTYYAD
89		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	384	EVQLVESGGGLVQPGGSLRLSCAASGRTFRSYAMGWFRQAPGKEREFVAAISWSPGRTHYADS
90		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRISVQYFTTSSNYDWGQGTLVTVSS
DKK1-	385	EVQLVESGGGLVQPGGSLRLSCAASGFTVSSYTMGWFRQAPGKEREFVAAISWSGGRTYYADS
91		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSFSYFSTSSNYEWGQGTLVTVSS
DKK1-	386	EVQLVESGGGLVQPGGSLRLSCAASGFGFGSYNMGWFRQAPGKEREFVAMISWTGGSTYYAD
92		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFNTSSNYDWGQGTLVTVSS
DKK1-	387	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRYPMGWFRQAPGKEREFVAAISWSGGSTVYADS
93		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYNHSRTRYEWGQGTLVTVSS
DKK1-	388	EVQLVESGGGLVQPGGSLRLSCAASGRIFGGYAMGWFRQAPGKEREFVAAISWSGASAIYADS
94		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGSRYGHSRARYDWGQGTLVTVSS
DKK1-	389	EVQLVESGGGLVQPGGSLRLSCAASGSIENINAMGWFRQAPGKEREFVAAISSGGGITIYADSVK
95		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	390	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGNFPMGWFRQAPGKEREFVAAINWSSRSTVYA
96		DSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	391	EVQLVESGGGLVQPGGSLRLSCAASGNIDRLYAMGWFRQAPGKEREFVAAISWSVSSTYYADS
97		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	392	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNFAMGWFRQAPGKEREFVAVILRGGSTNYADSV
98		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS

TABLE 6
Additional Variable Heavy Chain Domain Sequences
	SEQ
DKK1	ID
Variant	NO	VH Sequence
DKK1-	394	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNFAMGWFRQAPGKEREFVAVILRGGSTNYADSVK
99		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	395	EVQLVESGGGLVQPGGSLRLSCAASGNIDRLYAMGWFRQAPGKEREFVAAISWSVSSTYYADSV
100		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	396	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGNFPMGWFRQAPGKEREFVAAINWSSRSTVYA
101		DSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	397	EVQLVESGGGLVQPGGSLRLSCAASGSIENINAMGWFRQAPGKEREFVAAISSGGGITIYADSVK
102		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	398	EVQLVESGGGLVQPGGSLRLSCAASGRIFGGYAMGWFRQAPGKEREFVAAISWSGASAIYADSV
103		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGSRYGHSRARYDWGQGTLVTVSS
DKK1-	399	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRYPMGWFRQAPGKEREFVAAISWSGGSTVYADSV
104		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYNHSRTRYEWGQGTLVTVSS
DKK1-	400	EVQLVESGGGLVQPGGSLRLSCAASGFGFGSYNMGWFRQAPGKEREFVAMISWTGGSTYYADS
105		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFNTSSNYDWGQGTLVTVSS
DKK1-	401	EVQLVESGGGLVQPGGSLRLSCAASGFTVSSYTMGWFRQAPGKEREFVAAISWSGGRTYYADS
106		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSFSYFSTSSNYEWGQGTLVTVSS
DKK1-	402	EVQLVESGGGLVQPGGSLRLSCAASGRTFRSYAMGWFRQAPGKEREFVAAISWSPGRTHYADS
107		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRISVQYFTTSSNYDWGQGTLVTVSS
DKK1-	403	EVQLVESGGGLVQPGGSLRLSCAASGFTSDDYAMGWFRQAPGKEREFVAAISWSGGRTYYADS
108		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	404	EVQLVESGGGLVQPGGSLRLSCAASGLTFSTYPMGWFRQAPGKERELVALIASNGNTHYADSVK
109		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	405	EVQLVESGGGLVQPGGSLRLSCAASGRTFSGYTMGWFRQAPGKEREFVAAISWSGGSTYYADS
110		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYHCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	406	EVQLVESGGGLVQPGGSLRLSCAASGRTFINYAMGWFRQAPGKEREFVAAIIWTGVSTYYADSV
111		KGRFTIIADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPNRVSVRYFSTNNNYDWGQGTLVTVSS
DKK1-	407	EVQLVESGGGLVQPGGSLRLSCAASGITFKRYVMGWFRQAPGKEREFVATITSRDGTTYYYADS
112		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYWAAGNGGRNYGHSRSRYEWGQGTLVTVSS
DKK1-	408	EVQLVESGGGLVQPGGSLRLSCAASGRTFTNYPMGWFRQAPGKEREFVAAINRGGSTTYYADSV
113		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNRRRPYGYSHSRYDWGQGTLVTVSS
DKK1-	409	EVQLVESGGGLVQPGGSLRLSCAASGSTSSLRTMGWFRQAPGKEREFVAAISWSLSRTHYADSV
114		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	410	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNTLMGWFRQAPGKEREWVARITSGGSTHYADNV
115		KGRFTIITDNSKNTAYLLMISLKPQNTAEYYWSAGNGGRHYGHNRPRYDWCHGGLVTVIT
DKK1-	411	EVQLVESGGGLVQPGGSLRLSCAASGIAFQGYAMGWFRQAPGKERELVAAIDTNGGHTLYADS
116		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYRGTYYYTGDFDWGQGTLVTVSS
DKK1-	412	EVQLVESGGGLVQPGGSLRLSCAASGFLMYDRAMGWFRQAPGKEREIVAAISRTGSSIYYADSV
117		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	413	EVQLVESGGGLVQPGGSLRLSCAASSIGIAFSSRTMGWFRQAPGKEREFVAAVTRSGGKSYYAD
118		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	414	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSPMGWFRQAPGKERELVAVILRGGSTNYADSVK
119		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	415	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSRPMGWFRQAPGKEREFVAAISSSASSTYYADSV
120		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	416	EVQLVESGGGLVQPGGSLRLSCAASGIPFSTRTMGWFRQAPGKEREFVAAISSGATTLYADSVKG
121		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	417	EVQLVESGGGLVQPGGSLRLSCAASGPTVDAYAMGWFRQAPGKEREFVSAISWSGSATFYADS
122		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	418	EVQLVESGGGLVQPGGSLRLSCAASGIPFSSRTMGWFRQAPGKEREFVAAISRSGTGTYYADSVK
123		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	419	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSKTMGWFRQAPGKEREFVAAINWSGGLTVYADS
124		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	420	EVQLVESGGGLVQPGGSLRLSCAASGGIYRVNTMGWFRQAPGKEREFVAAINWSGGSTIYADSV
125		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	421	EVQLVESGGGLVQPGGSLRLSCAASGRTISNAAMGWFRQAPGKERELVAVIRSGGTTLYADSVK
126		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	422	EVQLVESGGGLVQPGGSLRLSCAASGTSFSIGAMGWFRQAPGKERELLAAISRSGASAYYADSV
127		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	423	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYPMGWFRQAPGKEREFVAAISRSGGSTVYADSV
128		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	424	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREWVASISTSGKTTYYADS
129		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	425	EVQLVESGGGLVQPGGSLRLSCAASGRTFRSYPMGWFRQAPGKEREFVAAISMSGKETWYADS
130		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	426	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFIAAINLSSGSTYYADSVK
131		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	427	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRFAMGWFRQAPGKERELVAAISARGMPAYADSV
132		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	428	EVQLVESGGGLVQPGGSLRLSCAASGRTSSAYAMGWFRQAPGKEREFVAAISRSGASAYYADSV
133		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	429	EVQLVESGGGLVQPGGSLRLSCAASGFRMYDRVMGWFRQAPGKEREFVATISRSGGRTYYADS
134		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	430	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKEREFVAAINRSGKSTYYADSV
135		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	431	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSNVMGWFRQAPGKEREFVSAISRSGGSTVYADSV
136		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	432	EVQLVESGGGLVQPGGSLRLSCAASGRAFSSSAMGWFRQAPGKEREFVAAINRGGKISHYADSV
137		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	433	EVQLVESGGGLVQPGGSLRLSCAASGFTVSNYAMGWFRQAPGKEREFVAAISWSGGSTYYADS
138		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	434	EVQLVESGGGLVQPGGSLRLSCAASGRRFSADVMGWFRQAPGKEREFVAAIRSGGTTLYADSV
139		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	435	EVQLVESGGGLVQPGGSLRLSCAASGSTFSKAVMGWFRQAPGKEREFVATITFSGARTHYADSV
140		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	436	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVARISSSGGTTYYADSV
141		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	437	EVQLVESGGGLVQPGGSLRLSCAASGFTFGDYAMGWFRQAPGKEREFVGAIDWSGRRITYADS
142		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	438	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDRAMGWFRQAPGKEREFVAAISTGGTTVYADSV
143		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	439	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYPMGWFRQAPGKEREFVASISRSGTTYYADSVK
144		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	440	EVQLVESGGGLVQPGGSLRLSCAASGRTFSISAMGWFRQAPGKEREFVAAISPSGNTYYADSVK
145		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	441	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTSAMGWFRQAPGKEREFVAVINRSGKTTYYADSV
146		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	442	EVQLVESGGGLVQPGGSLRLSCAASGRTFSLYTMGWFRQAPGKEREFVAAINRSGKSTYYADSV
147		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	443	EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYAMGWFRQAPGKEREVVAVVNWSGRRTYYAD
148		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFSTSSNYDWGQGTLVTVSS
DKK1-	444	EVQLVESGGGLVQPGGSLRLSCAASGRSFGNFPMGWFRQAPGKERELVAAVTSGGSTYYADSV
149		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	445	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVASISSGGSTYYADSVK
150		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	446	EVQLVESGGGLVQPGGSLRLSCAASGRTLSSITMGWFRQAPGKERELVATITRAGSTNYADSVK
151		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	447	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNFAMGWFRQAPGKEREFVAAISATGSTYYADSVK
152		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	448	EVQLVESGGGLVQPGGSLRLSCAASGRGAMGWFRQAPGKEREFVAAINRSGKSTYYADSVKGR
153		FTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	449	EVQLVESGGGLVQPGGSLRLSCAASGTSFSVGAMGWFRQAPGKEREFVGAVSWSGGTTVYADS
154		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	450	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVAAITSGGRTYADSVKG
155		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	451	EVQLVESGGGLVQPGGSLRLSCAASGRTLSRSAMGWFRQAPGKERELVAAISWSGGSTYYADS
156		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	452	EVQLVESGGGLVQPGGSLRLSCAASGRTISNYAMGWFRQAPGKEREFVAAISWRGGSTYYADS
157		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKYVSVSYFSTSSNYDWGQGTLVTVSS
DKK1-	453	EVQLVESGGGLVQPGGSLRLSCAASGHTFRGYVMGWFRQAPGKEREFVAAISGRSGNTYYADS
158		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	454	EVQLVESGGGLVQPGGSLRLSCAASGSIVRGNTMGWFRQAPGKEREFVAAISSSGSSTVYADSV
159		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	455	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYPMGWFRQAPGKEREFVAAISRSGGSTLYADSV
160		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	456	EVQLVESGGGLVQPGGSLRLSCAASGNIFGVNPMGWFRQAPGKEREFVAFISGTGGSTYYADSV
161		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	457	EVQLVESGGGLVQPGGSLRLSCAASGHTFRGYAMGWFRQAPGKEREFVAAINRSGSSTVYADS
162		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	458	EVQLVESGGGLVQPGGSLRLSCAASGRTLRRYVMGWFRQAPGKERELVARIISDGNTYYADSVK
163		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	459	EVQLVESGGGLVQPGGSLRLSCAASGRALSSSVMGWFRQAPGKERELVALLWSGGRTLYADSV
164		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	460	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNGPMGWFRQAPGKEREWVASITSTGSTYADSVKG
165		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	461	EVQLVESGGGLVQPGGSLRLSCAASGLTFGSAPMGWFRQAPGKERELVAAITSGGRTYADSVKG
166		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	462	EVQLVESGGGLVQPGGSLRLSCAASGFTFGSTTMGWFRQAPGKEREFVAAVNWSGRRELYADS
167		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFYTSSNYDWGQGTLVTVSS
DKK1-	463	EVQLVESGGGLVQPGGSLRLSCAASGRFTSSSPMGWFRQAPGKERELVASITSGGRTSYADSVK
168		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	464	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSRPMGWFRQAPGKERELVASITSDGSTYYADSVK
169		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	465	EVQLVESGGGLVQPGGSLRLSCAASGRTLSSVMGWFRQAPGKEREFVATISQRGRRYADSVKGR
170		FTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	466	EVQLVESGGGLVQPGGSLRLSCAASGGTFSRYAMGWFRQAPGKEREFVAAINRSGKSTYYADS
171		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	467	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSRPMGWFRQAPGKERELVATISSGSTTYYADSVK
172		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	468	EVQLVESGGGLVQPGGSLRLSCAASGSTFRGAAMGWFRQAPGKEREFVAAITSAGGTTYYADS
173		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	469	EVQLVESGGGLVQPGGSLRLSCAASGSTFSKAVMGWFRQAPGKERELVAGILSSGATVYADSVK
174		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	470	EVQLVESGGGLVQPGGSLRLSCAASGTTFRINVMGWFRQAPGKEREFVGAISRSGGSTYYADSV
175		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	471	EVQLVESGGGLVQPGGSLRLSCAASGFPVNRYSMGWFRQAPGKEREFVAAISRSGGSTYYADSV
176		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	472	EVQLVESGGGLVQPGGSLRLSCAASGHTFNTYPMGWFRQAPGKERELVAAITSNGRPSYADSVK
177		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	473	EVQLVESGGGLVQPGGSLRLSCAASGRTFGRRAMGWFRQAPGKEREFVAAINWSGGSTVYADS
178		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	474	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYPMGWFRQAPGKEREFVALISRSGGTTFYADSVK
179		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYDWGQGTLVTVSS
DKK1-	475	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNFAMGWFRQAPGKERELVAFSSSGGRTIYADSVK
180		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	476	EVQLVESGGGLVQPGGSLRLSCAASGLTTVYTMGWFRQAPGKEREVVAAISRTGGSTYYADSV
181		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	477	EVQLVESGGGLVQPGGSLRLSCAASGTTFRINVMGWFRQAPGKEREFVAAINRSGKSTYYADSV
182		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	478	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTHAMGWFRQAPGKEREFVAHITRLGVTYYADSV
183		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	479	EVQLVESGGGLVQPGGSLRLSCAASGIPSTLRAMGWFRQAPGKEREFVAAINWSGASTVYADSV
184		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	480	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYVMGWFRQAPGKEREFVAAIDWSGSRSYYADS
185		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFYTSSNYDWGQGTLVTVSS
DKK1-	481	EVQLVESGGGLVQPGGSLRLSCAASGRTFSDIAMGWFRQAPGKEREFVAAINWSGARTYYADS
186		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFSTSSNYDWGQGTLVTVSS
DKK1-	482	EVQLVESGGGLVQPGGSLRLSCAASGIPFSTRTMGWFRQAPGKEREFVAAISWSGGSTIYADSVK
187		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	483	EVQLVESGGGLVQPGGSLRLSCAASGFTFDEYAMGWFRQAPGKEREFVGAIDWSGRRITYADSV
188		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRISVSYFSTSSNYDWGQGTLVTVSS
DKK1-	484	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMGWFRQAPGKEREFVAAISWSGGSTVYADS
189		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSFSYFSTSSNYEWGQGTLVTVSS
DKK1-	485	EVQLVESGGGLVQPGGSLRLSCAASGITFKRYAMGWFRQAPGKEREFVAAINWSGASTVYADS
190		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	486	EVQLVESGGGLVQPGGSLRLSCAASGFTFGHYAMGWFRQAPGKEREFVAAISWSLTRTHYADS
191		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFSTSSNYDWGQGTLVTVSS
DKK1-	487	EVQLVESGGGLVQPGGSLRLSCAASGSITSINPMGWFRQAPGKEREFVAAISRSGASAYYADSVK
192		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	488	EVQLVESGGGLVQPGGSLRLSCAASGGRIFSNYAMGWFRQAPGKEREFVAAISWSGGSTYYADS
193		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	489	EVQLVESGGGLVQPGGSLRLSCAASGRTFTMGWFRQAPGKEREFVAAINWRSGGSTYYADSVK
194		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	490	EVQLVESGGGLVQPGGSLRLSCAASGGTFNGRAMGWFRQAPGKEREFVAAISRSGGGIYYADSV
195		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	491	EVQLVESGGGLVQPGGSLRLSCAASGFNFDDYAMGWFRQAPGKERELVAAISWSLSRTHYADS
196		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	492	EVQLVESGGGLVQPGGSLRLSCAASSIGIAFSSRTMGWFRQAPGKEREFVAAVTRSGGKSYYAD
197		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	493	EVQLVESGGGLVQPGGSLRLSCAASGSTFRINVMGWFRQAPGKEREFVAAISASGSALYADSVK
198		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	494	EVQLVESGGGLVQPGGSLRLSCAASGGIYRVNTMGWFRQAPGKEREFVAAINWSGGSTVYADS
199		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	495	EVQLVESGGGLVQPGGSLRLSCAASGRSLNTYTMGWFRQAPGKERELVAVIISGGSTAYADSVK
200		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	496	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREWVASISTSGKTTYYADS
201		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	497	EVQLVESGGGLVQPGGSLRLSCAASGTTVRIRTMGWFRQAPGKEREFVAAINGGGNTYYADSV
202		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	498	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTYSMGWFRQAPGKEREFVAAINWSGSSTVYADSV
203		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	499	EVQLVESGGGLVQPGGSLRLSCAASGIPFSTRTMGWFRQAPGKEREFVAAISSGATTLYADSVKG
204		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	500	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRYAMGWFRQAPGKEREFVALIRIKDGSIYYADSV
205		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	501	EVQLVESGGGLVQPGGSLRLSCAASGHTFNTYPMGWFRQAPGKERELVAAISRSGGKLYYADS
206		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	502	EVQLVESGGGLVQPGGSLRLSCAASGRSFSEYAMGWFRQAPGKEREFLAAISRDGAATYYADSV
207		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	503	EVQLVESGGGLVQPGGSLRLSCAASGRTFTTYPMGWFRQAPGKEREFVAAISSSGSSTVYADSV
208		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	504	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRYAMGWFRQAPGKEREFVAAISWSGGSTLYADSV
209		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	505	EVQLVESGGGLVQPGGSLRLSCAASGSIFTINAMGWFRQAPGKERELVAAINWSGSSTVYADSV
210		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	506	EVQLVESGGGLVQPGGSLRLSCAASGTSISNRVMGWFRQAPGKERELVAGISSGGNLKAYADSV
211		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	507	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEGAGSDTYYADS
212		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQIPGRKWTANGRKDYWGQGTLVTVSS
DKK1-	508	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSEISPSGKKKYYADS
213		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYPKNFDYWGQGTLVTVSS
DKK1-	509	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSAAMSWVRQAPGKGLEWVAAISGGGADTYYADS
214		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	510	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSAIQQRGLKTAYADS
215		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGIRGWIGHDTQPFDYWGQGTLVTVSS
DKK1-	511	EVQLLESGGGLVQPGGSLRLSCAASGFTFDRYRMMWVRQAPGKGLEWVSEISPSGKKKYYADS
216		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYPKNFDYWGQGTLVTVSS
DKK1-	512	EVQLLESGGGLVQPGGSLRLSCAASGFTSNNFAMTWVRQAPGKGLEWVAAISGGGADTYYADS
217		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLQKRGPRFDYWGQGTLVTVSS
DKK1-	513	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSVISSSGGETSYADS
218		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKAPLRSGGVDYWGQGTLVTVSS
DKK1-	514	EVQLLESGGGLVQPGGSLRLSCAASGFTFDRYRMMWVRQAPGKGLEWVSEISPSGKKKYYADS
219		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFPSTHGKFDYWGQGTLVTVSS
DKK1-	515	EVQLLESGGGLVQPGGSLRLSCAASGLTFPNYGMGWVRQAPGKGLEWVSSIDDRGRYTYYADS
220		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVIAAAGAFDYWGQGTLVTVSS
DKK1-	516	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVGYISNSGSTSYNDSV
221		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	517	EVQLLESGGGLVQPGGSLRLSCAASGFTFTHYSMGWVRQAPGKGLEWVSGITRSGSTNYRDSVK
222		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTENRGVSFDYWGQGTLVTVSS
DKK1-	518	EVQLLESGGGLVQPGGSLRLSCAASGFTFEEKEMIWVRQAPGKGLEWVSMISSSGLWTYYADSV
223		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWRRFDYWGQGTLVTVSS
DKK1-	519	EVQLLESGGGLVQPGGSLRLSCAASGFTFDRYRMMWVRQAPGKGLEWVSEISPSGKKKYYADS
224		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYTWNGYWGQGTLVTVSS
DKK1-	520	EVQLLESGGGLVQPGGSLRLSCAASGFTFHKYGMAWVRQAPGKGLEWVSEISPSGKKKYYADS
225		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASLSRGYWGQGTLVTVSS
DKK1-	521	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSSIWPRGQKTYYADS
226		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRGRGFDYWGQGTLVTVSS
DKK1-	522	EVQLLESGGGLVQPGGSLRLSCAASGFTFAKYKMWWVRQAPGKGLEWVSEISPSGKKKYYADS
227		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAHNAFDYWGQGTLVTVSS
DKK1-	523	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYFMSWVRQAPGKGLEWVSAISGGGADTYYADSV
228		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGNYFDYWGQGTLVTVSS
DKK1-	524	EVQLLESGGGLVQPGGSLRLSCAASGFTFDRYRMMWVRQAPGKGLEWVSSISGYGSTTYYADS
229		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRGRGFDYWGQGTLVTVSS
DKK1-	525	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMNWVRQAPGKGLEWVSSIGANGAPTYYADS
230		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDKRYRGSQHYFDYWGQGTLVTVSS
DKK1-	526	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYTMGWVRQAPGKGLEWVSSISNSGGSTYYADSV
231		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAGRKFDYWGQGTLVTVSS
DKK1-	527	EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSDIGASGSATSYADSV
232		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQSGSEDHFDYWGQGTLVTVSS
DKK1-	528	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSEISPSGKKKYYADS
233		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWRREGYTGSKFDYWGQGTLVTVSS
DKK1-	529	EVQLLESGGGLVQPGGSLRLSCAASGGFSLSRYMHWVRQAPGKGLEWVSTINQAGLRTYYADS
234		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSRTGRYFDYWGQGTLVTVSS
DKK1-	530	EVQLLESGGGLVQPGGSLRLSCAASGFTFHKYGMAWVRQAPGKGLEWVGYINPSRGYTYYADS
235		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGYRHFDYWGQGTLVTVSS
DKK1-	531	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSVISSSGGETSYADS
236		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLGQGFDYWGQGTLVTVSS
DKK1-	532	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSYISSSGSSTYYADSV
237		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	533	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
238		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGLPKRGPRFDYWGQGTLVTVSS
DKK1-	534	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMNWVRQAPGKGLEWVSYIGPSGGKTYYADS
239		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPWFDYWGQGTLVTVSS
DKK1-	535	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
240		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPSRRFDYWGQGTLVTVSS
DKK1-	536	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYVMIWVRQAPGKGLEWVSAIQQRGLKTAYADSV
241		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSGPYYFDYWGQGTLVTVSS
DKK1-	537	EVQLLESGGGLVQPGGSLRLSCAASGFTFEDYQMGWVRQAPGKGLEWVSAITGTGGETYYADS
242		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPGHRFDYWGQGTLVTVSS
DKK1-	538	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSGIYPSGGSTVYADS
243		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRYSQVHYALDYWGQGTLVTVSS
DKK1-	539	EVQLLESGGGLVQPGGSLRLSCAASGFTFKAYEIGWVRQAPGKGLEWVSGISPSGGITTYADSVK
244		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRAGSSGWYSDYWGQGTLVTVSS
DKK1-	540	EVQLLESGGGLVQPGGSLRLSCAASGFTFEVYTMAWVRQAPGKGLEWVSAISGRGDNTYYADS
245		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTENRGVSFDYWGQGTLVTVSS
DKK1-	541	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYSMAWVRQAPGKGLEWVSNIWPRGQKTYYADS
246		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVTGRGFDYWGQGTLVTVSS
DKK1-	542	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVADVNPNSGTSIYNDS
247		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPGTRGDYWGQGTLVTVSS
DKK1-	543	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGVSWVRQAPGKGLEWVSSISPSGGWTEYADSV
248		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYGAYFGLDYWGQGTLVTVSS
DKK1-	544	EVQLLESGGGLVQPGGSLRLSCAASGFTFAHEPMVWVRQAPGKGLEWVGKINYAGNTDYNDSV
249		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKKDYDYVWGSPYFDYWGQGTLVTVSS
DKK1-	545	EVQLLESGGGLVQPGGSLRLSCAASGFTFHESTMTWVRQAPGKGLEWVSVISSSGGETSYADSV
250		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS
DKK1-	546	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSEISPSGKKKYYADS
251		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFPSSQFRFDYWGQGTLVTVSS
DKK1-	547	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSEISPSGKKKYYADS
252		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYPKNFNYWGQGTLVTVSS
DKK1-	548	KVQLLESGGGLVQPGGSLRLSCAASGFTFHKYGMAWVRQAPGKGLEWVGKINYAGNTDYNDS
253		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDKRYRGSQHYFDYWGQGTLVTVSS
DKK1-	549	EVQLLESGGGLVQPGGSLRLSCAASGLTFPNYGMGWVRQAPGKGLEWVSEISPSGKKKYYADS
254		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS
DKK1-	550	EVQLLESGGGLVQPGGSLRLSCAASGFTFKAYEIGWVRQAPGKGVEWGSGIIPNGGITTYADSVK
255		GRFTISRDNSXNTLYLLMNSLIAEDAAVYYCGRHRAGSIGWYSDYWGQGTLVTVSS
DKK1-	551	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSDIGASGSATSYADS
256		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	552	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
257		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGRRRFDYWGQGTLVTVSS
DKK1-	553	EVQLLESGGGLVQPGGSLRLSCAASGFTSNNFAMTWVRQAPGKGLEWVAAISGGGADTYYADS
258		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLQKRGPRFDYWGQGTLVTVSS
DKK1-	554	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSTIWARGQKTYYAD
259		SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHLPGRGFEYWGRGTRTPVSS
DKK1-	555	EVQLLESGGGLVQPGGSLRLSCAASGFTFEDETMSWVRQAPGKGLEWVSAIISSGGLTYYADSV
260		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGFRIFDYWGQGTLVTVSS
DKK1-	556	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNSYISWVRQAPGKGLEWVSYITPKGDHTYYADSV
261		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGARRFDYWGQGTLVTVSS
DKK1-	557	EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYDMQWVRQAPGKGLEWVSSIGRHGGRTYYADS
262		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSLGRFDYWGQGTLVTVSS
DKK1-	558	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEGAGSDTYYADS
263		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	559	EVQLLESGGGLVQPGGSLRLSCAASGFTFKSYGMHWVRQAPGKGLEWVSSIWPRGQKTYYADS
264		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSGTRIKQGFDYWGQGTLVTVSS
DKK1-	560	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
265		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	561	EVQLLESGGGLVQPGGSLRLSCAASGFTFVAYNMGWVRQAPGKGLEWVSSISNSGGSTYYADS
266		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKNRAKFDYWGQGTLVTVSS
DKK1-	562	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSVISSSGGETSYADSV
267		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLPKRGPRFDYWGQGTLVTVSS
DKK1-	563	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEGAGSDTYYADS
268		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRGRGFDYWGQGTLVTVSS
DKK1-	564	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVAVISYGGSNKYYADS
269		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGVRKGFDYWGQGTLVTVSS
DKK1-	565	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSAIQQRGLKTAYADS
270		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYRGYFDYWGQGTLVTVSS
DKK1-	566	EVQLLESGGGLVQPGGSLRLSCAASGYSISSGYHWAWVRQAPGKGLEWVSSIDDRGRYTYYAD
271		SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSNGRFDYWGQGTLVTVSS
DKK1-	567	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAISGSGGGTSYADS
272		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYFHGKFDYWGQGTLVTVSS
DKK1-	568	EVQLLESGGGLVQPGGSLRLSCAASGFTFHKYGMAWVRQAPGKGLEWVSEISPSGKKKYYADS
273		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGRWSIFDYWGQGTLVTVSS
DKK1-	569	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVADVNPNSGASIYNDS
274		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGPGTRGDYWGQGTLVTVSS
DKK1-	570	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSGIYPSGGSTVYDDS
275		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSSRAFDYWGQGTLVTVSS
DKK1-	571	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEGAGSDTYYADS
276		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	572	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEGAGSDTYYADS
277		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	573	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYVMIWVRQAPGKGLEWVSEISPSGKKKYYADSV
278		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYPKNFDYWGQGTLVTVSS
DKK1-	574	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
279		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	575	EVQLLESGGGLVQPGGSLRLSCAASGFTSNNFAMTWVRQAPGKGLEWVGYINPSRGYTYYADS
280		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTENRGVSFDYWGQGTLVTVSS
DKK1-	576	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSEISPSGKKKYYADS
281		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRGRGFDYWGQGTLVTVSS
DKK1-	577	EVQLLESGGGLVQPGGSLRLSCAASGFTFFPYAMGWVRQAPGKGLEWVAAISGGGADTYYADS
282		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	578	EVQLLESGGGLVQPGGSLRLSCAASGFTFDQYDMSWVRQAPGKGLEWVSAITGSGGSTYYADS
283		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATAESDDTYDYWGQGTLVTVSS
DKK1-	579	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEGAGSDTYYADS
284		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	580	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYTMVWVRQAPGKGLEWVSAITGTGGETYYADS
285		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	581	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAIEARGGGTYYADS
286		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRGRGFDYWGQGTLVTVSS
DKK1-	582	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSSIWPSGGQTWYAD
287		SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDKRYRGSQHYFDYWGQGTLVTVSS
DKK1-	583	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVGISNSGSTSYNDSVK
288		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	584	EVQLLESGGGLVQPGGSLRLSCAASGFTFHKYGMAWVRQAPGKGLEWVSSIGRHGGRTYYADS
289		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAGSGFDYWGQGTLVTVSS
DKK1-	585	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYWNHWVRQAPGKGLEWVSTIGPSGTSTYYADSV
290		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAESFRSRYFDYWGQGTLVTVSS
DKK1-	586	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSSIWPRGQKTYYADS
291		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASLSRGYWGQGTLVTVSS
DKK1-	587	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYTMGWVRQAPGKGLEWVAAISGGGADTYYADS
292		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLPKRGPRFDYWGQGTLVTVSS
DKK1-	588	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYFMGWVRQAPGKGLEWVSAISGRGDNTYYADS
293		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTENRGVSFDYWGQGTLVTVSS
DKK1-	589	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVGAIQQRGLKTAYAD
294		SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS
DKK1-	590	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYFMGWVRQAPGKGLEWVSEIDALGTDTYYADS
295		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLRRFDYWGQGTLVTVSS
DKK1-	591	EVQLLESGGGLVQPGGSLRLSCAASGFTFDRYRMMWVRQAPGKGLEWVSSISSTGFKTYYADS
296		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRGRGFDYWGQGTLVTVSS
DKK1-	592	EVQLLESGGGLVQPGGSLRLSCAASGFTFTHYSMGWVRQAPGKGLEWVSAINGTGGETYYADS
297		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	593	EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYLMSWVRQAPGKGLEWVSTIGPSGTSTYYADSV
298		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGRRIFDYWGQGTLVTVSS
DKK1-	594	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYFMIWVRQAPGKGLEWVSSIDDRGRYTYYADSV
299		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGDYGSGDYWGQGTLVTVSS
DKK1-	595	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
300		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPPKRGPRFDYWGQGTLVTVSS
DKK1-	596	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSVISSSGGETSYADS
301		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	597	EVQLLESGGGLVQPGGSLRLSCAASGFTFKSYGMHWVRQAPGKGLEWVSSIGRHGGRTYYADS
302		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGDYGSGDYWGQGTLVTVSS
DKK1-	598	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSYIGPSGGKTYYADS
303		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	599	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
304		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPPKRGPRFDYWGQGTLVTVSS
DKK1-	600	EVQLLESGGGLVQPGGSLRLSCAASGFTFEDETMSWVRQAPGKGLEWVSAIISSGGLTYYADSV
305		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGFRIFDYWGQGTLVTVSS
DKK1-	601	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSGITRSGSTNYRDSV
306		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSSRAFDYWGQGTLVTVSS
DKK1-	602	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
307		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHSKSSHRQSFDYWGQGTLVTVSS
DKK1-	603	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSEISPSGKKKYYADS
308		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLTGRFDYWGQGTLVTVSS
DKK1-	604	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYFMGWVRQAPGKGLEWVSEISPSGKKKYYADSV
309		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSGAYFDYWGQGTLVTVSS
DKK1-	605	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKYPMMWVRQAPGKGLEWVSWIEGRGTETYYADS
310		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTRSKFDYWGQGTLVTVSS
DKK1-	606	EVQLLESGGGLVQPGGSLRLSCAASGFTFHKYGMAWVRQAPGKGLEWVSEISPSGKKKYYADS
311		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYPKNFDYWGQGTLVTVSS
DKK1-	607	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSEISPSGKKKYYADS
312		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGVRKKFDYWGQGTLVTVSS
DKK1-	608	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
313		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	609	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMAWVRQAPGKGLEWVSYISPIGPRTYYADSV
314		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRTENRGVSFDYWGQGTLVTVSS
DKK1-	610	EVQLLESGGGLVQPGGSLRLSCAASGFTLDYLAIGWVRQAPGKGLEWVSEISPSGKKKYYADSV
315		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYTGRWEPFDYWGQGTLVTVSS
DKK1-	611	EVQLLESGGGLVQPGGSLRLSCAASGFTFTHYSMGWVRQAPGKGLEWVAAISGGGADTYYADS
316		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	612	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSAITGTGGETYYADS
317		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	613	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVSTISPSGHGTYYADS
318		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS
DKK1-	614	EVQLLESGGGLVQPGGSLRLSCAASGFTFPVYNMAWVRQAPGKGLEWVSSISESGTTTYYADSV
319		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKNRAKFDYWGQGTLVTVSS
DKK1-	615	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYVMGWVRQAPGKGLEWVAAISGGGADTYYADS
320		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPKRGPRFDYWGQGTLVTVSS
DKK1-	616	EVQLLESGGGLVQPGGSLRLSCAASGFSFSAYAMNWVRQAPGKGLEWVSSISTSGGSTYYADSV
321		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRAGADYWGQGTLVTVSS
DKK1-	617	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMSWVRQAPGKGLEWVSAISGSGAYTYYADSV
322		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDIAAASFDYWGQGTLVTVSS
DKK1-	618	EVQLLESGGGLVQPGGSLRLSCAASGFTFTSYAMTWVRQAPGKGLEWVSGVSGSGGTTYYADS
323		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAISYHFDYYFDYWGQGTLVTVSS
DKK1-	619	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAISGGGGATYYADS
324		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARECSGGSCSYYYGMDVWGQGTLVTVSS
DKK1-	620	EVQLLESGGGLVQPGGSLRLSCAASGSTFNNYAMSWVRQAPGKGLEWVSAISGSGSTTYYADS
325		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAVSTSDYYYYGMDVWGQGTLVTVSS
DKK1-	621	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRFAMSWVRQAPGKGLEWVSGITGSGTSTYYADSV
326		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDRVRFSPVRRWFDPWGQGTLVTVSS
DKK1-	622	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYAMGWVRQAPGKGLEWVSAISATGGSTYYADS
327		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRSSSWYGDYWGQGTLVTVSS
DKK1-	623	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMTWVRQAPGKGLEWVSTISGSGVTTYYADSV
328		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARKTGGHYPFDYWGQGTLVTVSS
DKK1-	624	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRSAMSWVRQAPGKGLEWVSSISASGANTYYADSV
329		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQARYYGMDVRGQGTLVTVSS
DKK1-	625	EVQLLESGGGLVQPGGSLRLSCAASGFTFRNYAMSWVRQAPGKGLEWVSTITSSGGSTYYADSV
330		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASGLRARNGFDIWGQGTLVTVSS
DKK1-	626	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMTWVRQAPGKGLEWVSGISGSGGSTYYADS
331		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGAILAYWGQGTLVTVSS
DKK1-	627	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMIWVRQAPGKGLEWVSAVSGTGGTTYYADS
332		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDVGFGELHPWGQGTLVTVSS
DKK1-	628	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVSGISGSGYSTYYADSV
333		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRTGTLYGMDVWGQGTLVTVSS
DKK1-	629	EVQLLESGGGLVQPGGSLRLSCAASGFSFNNYAMSWVRQAPGKGLEWVSAISGGGSNTYYADS
334		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVAASGSYYRAFDQWGQGTLVTVSS
DKK1-	630	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYAMSWVRQAPGKGLEWVSGISSSGGNTYYADS
335		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGFGWFDPWGQGTLVTVSS
DKK1-	631	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYGMTWVRQAPGKGLEWVSTISGSGGRTYYADSV
336		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVSYDSSGYYYDAFDIWGQGTLVTVSS
DKK1-	632	EVQLLESGGGLVQPGGSLRLSCAASGFTFANYAMSWVRQAPGKGLEWVSAISGSGGSAYYADS
337		VKGRFTISRDNSKNTLYLQMNSLRAEDAAVYYCARSGSFLSFDSWGQGTLVTVSS
DKK1-	633	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRFAISWVRQAPGKGLEWVSTISGSGGRTYYADSV
338		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVDYKKKSYYNAMDAWGQGTLVTVSS
DKK1-	634	EVQLLESGGGLVQPGGSLRLSCAASGFTFRTSAMSWVRQAPGKGLEWVSAISSGGGGTYYADSV
339		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPRGRGAFDVWGQGTLVTVSS
DKK1-	635	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSV
340		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDRVRFSPVRRWFDPWGQGTLVTVSS
DKK1-	636	EVQLLESGGGLVQPGGSLRLSCAASGIHLSSYAMSWVRQAPGKGLEWVSTISGGGGGTYYADSV
341		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGHVGIRRPFDVWGQGTLVTVSS
DKK1-	637	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYAMSWVRQAPGKGLEWVSIISGSGGTTYYADSV
342		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHAHGAGSYPFDYWGQGTLVTVSS
DKK1-	638	EVQLLESGGGLVQPGGSLRLSCAASGFPFSSYAMGWVRQAPGKGLEWVSVISGSGGRTHYADS
343		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGRAPRKYYGMDVWGQGTLVTVSS
DKK1-	639	EVQLLESGGGLVQPGGSLRLSCAASGFSFSAYAMSWVRQAPGKGLEWVSAISGRDTSTYYADSV
344		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPLRGSGRLSFDYWGQGTLVTVSS
DKK1-	640	EVQLLESGGGLVQPGGSLRLSCAASGSPFSNYAMSWVRQAPGKGLEWVSAISGSGGSTFYSDSV
345		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAPRSPILGVRRGLDPWGQGTLVTVSS
DKK1-	641	EVQLLESGGGLVQPGGSLRLSCAASGFSFSGYAMNWVRQAPGKGLEWVSAISGSSGRTYYADS
346		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRGGTRGLGYWGQGTLVTVSS
DKK1-	642	EVQLLESGGGLVQPGGSLRLSCAASGFTFRTYGMSWVRQAPGKGLEWVSAISGSGETTYYADSV
347		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLDHDSSGFYEAFDVWGQGTLVTVSS
DKK1-	643	EVQLLESGGGLVQPGGSLRLSCAASGLTFSRYAMSWVRQAPGKGLEWVSSISGRGGNTYYADS
348		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGMRLGKSYYYYGMDVWGQGTLVTVSS
DKK1-	644	EVQLLESGGGLVQPGGSLRLSCAASGFAFSTSAMSWVRQAPGKGLEWVSGISASGGSTHYADSV
349		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLSVARGAYGMDVWGQGTLVTVSS
DKK1-	645	EVQLLESGGGLVQPGGSLRLSCAASGFTFGAYAMSWVRQAPGKGLEWVSAISGSGARTYYADS
350		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGRPPQYYFDSWGQGTLVTVSS
DKK1-	646	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRYAMSWVRQAPGKGLEWVSTVSGSGGTTYYADS
351		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGWEPGIAANWGQGTLVTVSS
DKK1-	647	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKHAMSWVRQAPGKGLEWVSIISGSGDTTYYADSV
352		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHQYSGSGSFRYWGQGTLVTVSS
DKK1-	648	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRSAMSWVRQAPGKGLEWVSAIGGSGDNTYYADS
353		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHRGSFWFDPWGQGTLVTVSS
DKK1-	649	EVQLLESGGGLVQPGGSLRLSCAASGFSFRSYAMNWVRQAPGKGLEWVSAISGSGGNTFYADS
354		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTMFGSGTFYTGFDFWGQGTLVTVSS
DKK1-	650	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSSMSWIRQAPGKGLEWVSGISGSGGTTYYADSVK
355		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAGARFVGFDYWGQGTLVTVSS
DKK1-	651	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMSWVRQAPGKGLEWVSAISGSGRNTYYADSV
356		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATFNPVGLFYWGQGTLVTVSS
DKK1-	652	EVQLLESGGGLVQPGGSLRLSCAASGFSFSTYAMMWVRQAPGKGLEWVSAISGSAVSTYYADS
357		VKGRFTISRDNSKNTLYLQMNSLRAEDAAVYYCARSGSFLSFDSWGQGTLVTVSS
DKK1-	653	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYTMNWVRQAPGKGLEWVSAVSGSGGRTYYADS
358		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSRNGRWFDPWGQGTLVTVSS
DKK1-	654	EVQLLESGGGLVQPGGSLRLSCAASGLTFRSYAMSWVRQAPGKGLEWVSGISGSGGSTYYADSV
359		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGASFDSWGQGTLVTVSS
DKK1-	655	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMKWVRQAPGKGLEWVSGISGSGARTYYADS
360		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRQRQRSTPLGRYWGQGTLVTVSS
DKK1-	656	EVQLLESGGGLVQPGGSLRLSCAASGFNFRDYAMSWVRQAPGKGLEWVSAISGRGSVYYADSV
361		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGDWVAFDYWGQGTLVTVSS
DKK1-	657	EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYVMSWFRQAPGKGLEWVSGISGSGGRTYYADSV
362		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRKGPTYGMDVWGQGTLVTVSS
DKK1-	658	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTFAMAWVRQAPGKGLEWVSALSGSGGRTYYADS
363		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVTRYQGWLSHFDYWGQGTLVTVSS
DKK1-	659	EVQLLESGGGLVQPGGSLRLSCAASGFTLSTYAMSWVRQAPGKGLEWVSTISTSGGSTYYADSV
364		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVFVSSGWYDGMDVWGQGTLVTVSS
DKK1-	660	EVQLLESGGGLVQPGGSLRLSCAASGLTFNNYAMSWVRQAPGKGLEWVSGISGSGARTYYADS
365		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGASLDVWGQGTLVTVSS
DKK1-	661	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRYAMSWVRQAPGKGLEWVSTISGSGTTTYYADSV
366		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAIGGRTAYWGQGTLVTVSS
DKK1-	662	EVQLLESGGGLVQPGGSLRLSCAASGFSFSAYAMSWVRQAPGKGLEWVSAISGRDTSTYYADSV
367		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPLRGSGRLSFDYWGQGTLVTVSS
DKK1-	663	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRYAMNWVRQAPGKGLEWVSTITASGGSTYYADS
368		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVVTAMGYYYGMDVWGQGTLVTVSS
DKK1-	664	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGVSWVRQAPGKGLEWVSAISAGGGNTYYADS
369		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGMRGPYYYYYGMDVWGQGTLVTVSS
DKK1-	665	EVQLLESGGGLVQPGGSLRLSCAASGFTFSYYGMSWVRQAPGKGLEWVSAISGGGAGTYYADS
370		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVASRNYLLDFWGQGTLVTVSS
DKK1-	666	EVQLLESGGGLVQPGGSLRLSCAASGFTFTKYAMSWVRQAPGKGLEWVGAISGRGGSTYYADS
371		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGDLTVTRKYDSWGQGTLVTVSS
DKK1-	667	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYGMTWVRQAPGKGLEWVSAISRSGGNTYYADS
372		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTYSYGSFDYWGQGTLVTVSS
DKK1-	668	EVQLLESGGGLVQPGGSLRLSCAASGFNFRSYAMNWVRQAPGKGLEWVSAISGSGTTTYYADS
373		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASWRAAPFDYWGQGTLVTVSS
DKK1-	669	EVQLLESGGGLVQPGGSLRLSCAASGFSFSAYAMSWVRQAPGKGLEWVSAISGRDTSTYYADSV
374		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPLRGSGRLSFDYWGQGTLVTVSS
DKK1-	670	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYAMTWVRQAPGKGLEWVSSITGSGGSTYYADS
375		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGKFHLDPWGQGTLVTVSS
DKK1-	671	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVGAISGRGGSTYYADS
376		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTDYGAIMDVWGQGTLVTVSS
DKK1-	672	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRFAMSWVRQAPGKGLEWVSGISGSGTSTYYADSV
377		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSRNYFGMGVWGQGTLVTVSS
DKK1-	673	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYALSWVRQAPGKGLEWVSAISRSGGNTYYADSV
378		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGRDGTRFGAFDIWGQGTLVTVSS
DKK1-	674	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKFAMTWVRQAPGKGLEWVSTISGSGSRTYYADSV
379		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRSWYNHWGQGTLVTVSS
DKK1-	675	EVQLLESGGGLVQHGGSLRLSCAASGLTFSSYALSWVRQAPGKGLEWVSDISGSGGNTYYADSV
380		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARFQPRPLRLFDYWGQGTLVTVSS
DKK1-	676	EVQLLESGGGLVQPGGSLRLSCAASGFTLRSYAMTWVRQAPGKGLEWVSAISGSGGYTYYADS
381		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARASYGSGSYPLIHWGQGTLVTVSS
DKK1-	677	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFAMSWVRQAPGKGLEWVSTVSGSGGSTYYADSV
382		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGHRSNIGWDVWGQGTLVTVSS
DKK1-	678	EVQLLESGGGLVQPGGSLRLSCAASGSTFSSYAMSWVRQAPGKGLEWVSTISASGGRTYYADSV
383		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDRVRFSPVRRWFDPWGQGTLVTVSS
DKK1-	679	EVQLLESGGGLVQPGGSLRLSCAASGFTFRRSAMSWVRQAPGKGLEWVSAISGSGSGTYYADSV
384		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSARGRWFDPWGQGTLVTVSS
DKK1-	680	EVQLLESGGGLVQPGGSLRLSCAASGFTFAGYAMSWVRQALGKGLEWVSAISRSGDRTYYADS
385		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGQRAHQQLVRGAMDVWGQGTLVTVSS
DKK1-	681	EVQLLESGGGLVQPGGSLRLSCAASGFTFRTFAMSWVRQAPGKGLEWVSGISASGGTTYYADSV
386		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAHRRRSKFWSGFGVWGQGTLVTVSS
DKK1-	682	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMTWVRQAPGKGLEWVSTISGSGVTTYYADSV
387		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARKTGGHYPFDYWGQGTLVTVSS
DKK1-	683	EVQLLESGGGLVQPGGSLRLSCAASGFTFDNYAMTWVRQAPGKGLEWVSGISGSGGSIYYADSV
388		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKGAPAGYLDSWGQGTLVTVSS
DKK1-	684	EVQLLESGGGLVQPGGSLRLSCAASGFRFSSYAMSWVRQAPGKGLEWVSTISGRGGSTDYADSV
389		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHNRERRAFDIWGQGTLVTVSS
DKK1-	685	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYAMGWVRQAPGKGLEWVSGISGGGGTTYYADS
390		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSRVRGTHDYYYYGMDVWGQGTLVTVSS
DKK1-	686	EVQLLESGGGLVQPGGSLRLSCAASGFTFSKFAMNWVRQAPGKGLEWVSGISASGGRTYYADS
391		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLRFTPWGQGTLVTVSS
DKK1-	687	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSAISPSGGSTYYADSV
392		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLSADRVFAFDIWGQGTLVTVSS
DKK1-	688	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSFAMAWVRQAPGKGLEWVSTISGSGDVTYYADSV
393		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGHRSNIGWDVWGQGTLVTVSS
DKK1-	689	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRFAMSWVRQAPGKGLEWVSGITGSGTSTYYADSV
394		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPLRGSGRLSFDYWGQGTLVTVSS
DKK1-	690	EVQLLESGGGLVQPGGSLRLSCAASGFGFSSYAMSWVRQAPGKGLEWVSGITGSGGNTYYADS
395		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSRRPRYSYGFAFESWGQGTLVTVSS
DKK1-	691	EVQLLESGGGLVQPGGSLRLSCAASGVTFRNYAMSWVRQAPGKGLEWVSAISASGGSPYYADS
396		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTSVGWFDPWGQGTLVTVSS
DKK1-	692	EVQLLESGGGLVQPGGSLRLSCAASGFTFRNYAMSWVRQAPGKGLEWVSSISGGGGRTYYADS
397		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRDLTRRAAMDVWGQGTLVTVSS
DKK1-	693	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSSAMSWVRQAPGKGLEWVSVISGSGRSTYYADSV
398		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNGAGSHYYAMDVWGQGTLVTVSS
DKK1-	694	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMGWVRQAPGKGLEWVSSISGSGGRTYYADSV
399		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSKVTRSALDYWGQGTLVTVSS
DKK1-	695	EVQLLESGGGLVQPGGSLRLSCAASGFTFGNYALSWVRQAPGKGLEWVSAISGSGSSTFYADSV
400		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCGRESGRGSGTWGQGTLVTVSS
DKK1-	696	EVQLLESGGGLVQPGGSLRLSCAASGFTYSSYAMTWVRQAPGKGLEWVSVISGSGGSTYHADS
401		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERELYYFYYGMDVWGQGTLVTVSS
DKK1-	697	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMGWVRQAPGKGLEWVSTITGSGGSTYYADSV
402		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHHNRRSSLDYWGQGTLVTVSS
DKK1-	698	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSGISSTGGTTYYADSV
403		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGRRQLRYYYGMDVWGQGTLVTVSS
DKK1-	699	EVQLLESGGGLVQPGGSLRLSCAASGFSFSSSAMNWVRQAPGKGLEWVAAISGSGGTTYYADSV
404		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARRRSFDWWGQGTLVTVSS
DKK1-	700	EVQLLESGGDLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVSAISGGRVSTYYADS
405		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLRGNAFDIWGQGTLVTVSS
DKK1-	701	EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYAMSWVRQAPGKGLEWVSSIRGSGGSTYYADSV
406		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLQSRGYWGQGTLVTVSS
DKK1-	702	EVQLLESGGGLVQPGGSLRLSCAASGFTFNKFAMSWVRQAPGKGLEWVSGISVSGGNTYYADS
407		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHSRLAALLAWGQGTLVTVSS
DKK1-	703	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSHVMGWVRQAPGKGMEWVSGISGSGAGTYYADS
408		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAVTGTTGWFDPWGQGTLVTVSS
DKK1-	704	EVQLLESGGGLVQPGGSLRLSCAASGFTFGRYAMSWVRQAPGKGLEWVSGISSSRGSTYYADSV
409		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVGIAGRGMDVWGQGTLVTVSS
DKK1-	705	EVQLLESGGGLVQPGGSLRLSCAASGFTFNTYGMSWVRQAPGKGLEWVSAISGRRTYYADSVK
410		GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVSRGYPRRSDSWGQGTLVTVSS
DKK1-	706	EVQLLESGGGLVQPGGSLRLSCAASGFTVSSYAMSWVRQAPGKGLEWVSGISGGGGTTYYADS
411		VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRSSNWKFDQWGQGTLVTVSS
DKK1-	707	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRSAMSWVRQAPGKGLEWVSSISASGANTYYADSV
412		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQARYYGMDVRGQGTLVTVSS
DKK1-	708	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSYDMTWVRQAPGKGLEWVSSISGSGVTTYYADSV
413		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRRLDYWGQGTLVTVSS
DKK1-	709	EVQLLESGGGLVQPGGSLRLSCAASGFAFTTYAMGWVRQAPGKGLEWVSAISGSGSTTYYADS
414		VKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSGSFLSFDSWGQGTLVTVSS
DKK1-	710	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMIWVRQAPRKGLEWVSAISGSGRNTYYADSV
415		KGRFTISRDNSKNTLYLQMNSLRAEDTTVYYCARGGGASNWFDPWGQGTLVTISS
DKK1-	711	EVQLLESGGGLVQPGGSLRLSCAASGFSFSAYAMSWVRQAPGKGLEWVSAISGRDTSTYYADSV
416		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPLRGSGRLSFDYWGQGTLVTVSS
DKK1-	712	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRFAMSWVRQAPGKGLEWVSSISGTGSSTYYADSV
417		KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVPGNWGQGTLVTVSS
DKK1-	2164	EVQLVESGGGLVQPGGSLRLSCAASGIPFSSRTMGWFRQAPGKEREFVAAISRSGTGTYYADSVK
418		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	2165	EVQLVESGGGLVQPGGSLRLSCAASGGIYRVNTMGWFRQAPGKEREFVAAINWSGGSTIYADSV
419		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2166	EVQLVESGGGLVQPGGSLRLSCAASGFLMYDRAMGWFRQAPGKEREIVAAISRTGSSIYYADSV
420		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2167	EVQLVESGGGLVQPGGSLRLSCAASGRTFSRFAMGWFRQAPGKERELVAAISARGMPAYADSV
421		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2168	EVQLVESGGGLVQPGGSLRLSCAASGTTFRINVMGWFRQAPGKEREFVAVVNWNGGSTIYADS
422		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2169	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNNVMGWFRQAPGKEREMVAAMLSGGSTNYADS
423		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYDWGQGTLVTVSS
DKK1-	2170	EVQLVESGGGLVQPGGSLRLSCAASGRTFSDIAMGWFRQAPGKEREFVAAINWSGARTYYADS
424		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFSTSSNYDWGQGTLVTVSS
DKK1-	2171	EVQLVESGGGLVQPGGSLRLSCAASGHTYNTYPMGWFRQAPGKERELVAVILRGGSTVYADSV
425		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	2172	EVQLVESGGGLVQPGGSLRLSCAASGRSLYDRAMGWFRQAPGKEREIVAAISRTGSSIYYADSV
426		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	2173	EVQLVESGGGLVQPGGSLRLSCAASGRTFNNYAMGWFRQAPGKERELVAAISWSTGSTYYADS
427		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	2174	EVQLVESGGGLVQPGGSLRLSCAASGRTLYSYPMGWFRQAPGKEREFVAAISWSAGSTYYADS
428		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGSKYGHSRARYDWGQGTLVTVSS
DKK1-	2175	EVQLVESGGGLVQPGGSLRLSCAASGTFRDYAMGWFRQAPGKERELVAAIYGTGGELVYYADS
429		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2176	EVQLVESGGGLVQPGGSLRLSCAASGGGTFGSYAMGWFRQAPGKEREFVSAITWNGTRTYYAD
430		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	2177	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYPMGWFRQAPGKEREFVAATSWSGGSKYYADS
431		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	2178	EVQLVESGGGLVQPGGSLRLSCAASGRTFTNYAMGWFRQAPGKEREFVATISRGGSATYYADSV
432		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	2179	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTHAMGWFRQAPGKEREFVAHITRLGVTYYADSV
433		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2180	EVQLVESGGGLVQPGGSLRLSCAASGRSFSMYAMGWFRQAPGKEREFVAAISRDGAATYYADS
434		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRLYGHSRARYDWGQGTLVTVSS
DKK1-	2181	EVQLVESGGGLVQPGGSLRLSCAASGLTFRNYAMGWFRQAPGKEREFVAAVSWSLSRTHYADS
435		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRASVQYFSTSSNYDWGQGTLVTVSS
DKK1-	2182	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDRAMGWFRQAPGKERELVAAIRWSGGITWYADS
436		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	2183	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSVMGWFRQAPGKEREFVAAINWSGASTVYADSV
437		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYNHSRTRYEWGQGTLVTVSS
DKK1-	2184	EVQLVESGGGLVQPGGSLRLSCAASGHTFNTYPMGWFRQAPGKEREFVAAINSGGSYTYYADS
438		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYEWGQGTLVTVSS
DKK1-	2185	EVQLVESGGGLVQPGGSLRLSCAASGRIFTMGWFRQAPGKEREFVAAISGSGVYTYYADSVKGR
439		FTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	2186	EVQLVESGGGLVQPGGSLRLSCAASGRSFSEYAMGWFRQAPGKEREFLAAISRDGAATYYADSV
440		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2187	EVQLVESGGGLVQPGGSLRLSCAASGFNSGSYTMGWFRQAPGKEREFVAAISWSLSRTFYADSV
441		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	2188	EVQLVESGGGLVQPGGSLRLSCAASGGTAYAMGWFRQAPGKEREFVAAISWSLTRTHYADSVK
442		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	2189	EVQLVESGGGLVQPGGSLRLSCAASGRTFTSYPMGWFRQAPGKEREFVAAISGSGDDTYYADSV
443		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2190	EVQLVESGGGLVQPGGSLRLSCAASGSTFRINVMGWFRQAPGKEREFVAAISASGSALYADSVK
444		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2191	EVQLVESGGGLVQPGGSLRLSCAASGGTLNNNPMAMGWFRQAPGKEREFVASINWSGARAYYADS
445		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRISVQYFTTSSNYDWGQGTLVTVSS
DKK1-	2192	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTYPMGWFRQAPGKEREFVAGIGTRGAPVYADSVK
446		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2193	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSYPMGWFRQAPGKEREFVAHITRLGVTYYADSVK
447		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	2194	EVQLVESGGGLVQPGGSLRLSCAASGIPFSSRTMGWFRQAPGKEREFVAAVGWYGSTYYADSV
448		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2195	EVQLVESGGGLVQPGGSLRLSCAASGIDVNRNAMGWFRQAPGKERELVAAISWSGGRTYYADS
449		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVHYFSTSSNYDWGQGTLVTVSS
DKK1-	2196	EVQLVESGGGLVQPGGSLRLSCAASGINFSRYGMGWFRQAPGKEREFVAAIDWSGSRSYYADSV
450		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	2197	EVQLVESGGGLVQPGGSLRLSCAASGGTLRGYGMGWFRQAPGKEREFVAAIDWSGSRSYYADS
451		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKYVSVRYFSTSSNYDWGQGTLVTVSS
DKK1-	2198	EVQLVESGGGLVQPGGSLRLSCAASGQTFNMGWFRQAPGKEREFVAAVNWNGDSTYYADSVK
452		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2199	EVQLVESGGGLVQPGGSLRLSCAASGYTFRAYVMGWFRQAPGKEREWVARITSGGSTIYADSV
453		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2200	EVQLVESGGGLVQPGGSLRLSCAASGNIFTLNVMGWFRQAPGKEREFVAAINSGGSYTYYADSV
454		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2201	EVQLVESGGGLVQPGGSLRLSCAASGFRMYDRAMGWFRQAPGKEREFVAAISGRSGNTYYADS
455		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYDWGQGTLVTVSS
DKK1-	2202	EVQLVESGGGLVQPGGSLRLSCAASGFTFSMWPMGWFRQAPGKEREFVAAISRSGGSTIYADSV
456		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYNHSRTRYEWGQGTLVTVSS
DKK1-	2203	EVQLVESGGGLVQPGGSLRLSCAASGFTFRSYPMGWFRQAPGKEREFVALIHTGGGTYYADSVK
457		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYDWGQGTLVTVSS
DKK1-	2204	EVQLVESGGGLVQPGGSLRLSCAASGLPFSTKSMGWFRQAPGKERELVAFSSSGGRTIYADSVK
458		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	2205	EVQLVESGGGLVQPGGSLRLSCAASGNIFRINAMGWFRQAPGKEREWVARINSGGSSTYYADSV
459		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2206	EVQLVESGGGLVQPGGSLRLSCAASGGTFGHYAMGWFRQAPGKEREFVAVISWSLTRTHYADS
460		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSFSYFSTSSNYEWGQGTLVTVSS
DKK1-	2207	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSYPMGWFRQAPGKEREFVAAITWGGSTTLYADSV
461		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGNLVTVSS
DKK1-	2208	EVQLVESGGGLVQPGGSLRLSCAASGITFRRYPMGWFRQAPGKEREFVAGVNWGGGSTKYADS
462		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2209	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKEREMVATISIGGRTSYADSVK
463		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	2210	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKEREFVAAIRSSGGLFYADSVK
464		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2211	EVQLVESGGGLVQPGGSLRLSCAASGPTFSTNTMGWFRQAPGKEREFVAAIYSGVRSGVSAIYA
465		DSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	2212	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYPMGWFRQAPGKEREFVAAIYGTGGELVYYAD
466		SVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2213	EVQLVESGGGLVQPGGSLRLSCAASGRAIGSYAMGWFRQAPGKEREFVATITFSGARTHYADSV
467		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRASVQYFSTSSNYDWGQGTLVTVSS
DKK1-	2214	EVQLVESGGGLVQPGGSLRLSCAASGRTLSRNTMGWFRQAPGKEREFVATIRSGAPVYADSVKG
468		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	2215	EVQLVESGGGLVQPGGSLRLSCAASGRTFIGYHMGWFRQAPGKERELVAIKFSGGTTNYADSVK
469		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYGHSRARYDWGQGTLVTVSS
DKK1-	2216	EVQLVESGGGLVQPGGSLRLSCAASGRTISNYAMGWFRQAPGKEREFVAAISWRGGSTYYADS
470		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKYVSVSYFSTSSNYDWGQGTLVTVSS
DKK1-	2217	EVQLVESGGGLVQPGGSLRLSCAASGRTISNYAMGWFRQAPGKEREFVAAISWALSRTHYADSV
471		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSFSYFSTSSNYEWGQGTLVTVSS
DKK1-	2218	EVQLVESGGGLVQPGGSLRLSCAASGTFTSYPMGWFRQAPGKEREFVAAISWTGGSTVYADSVK
472		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRYYNHSRTRYEWGQGTLVTVSS
DKK1-	2219	EVQLVESGGGLVQPGGSLRLSCAASGRSFSMYAMGWFRQAPGKERELVAAISWSGGSTVYADS
473		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEGGYSGTYYYTGDFDWGQGTLVTVSS
DKK1-	2220	EVQLVESGGGLVQPGGSLRLSCAASGLTFRNYAMGWFRQAPGKEREFVAAINWSGARTYYADS
474		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKSISVRYFSTSSNYEWGQGTLVTVSS
DKK1-	2221	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMGWFRQAPGKEREWVSAISADGSDKRYADS
475		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGKRYGYYDWGQGTLVTVSS
DKK1-	2222	EVQLVESGGGLVQPGGSLRLSCAASGRTHSIYPMGWFRQAPGKEREFVATIRWGTTDTYYADSV
476		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPTRVSVRYFSTRSNYNWGQGTLVTVSS
DKK1-	2223	EVQLVESGGGLVQPGGSLRLSCAASGFSLDYVGMGWFRQAPGKEREGVSTIKPSGDTTNYADSV
477		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKYLSFYSDYEVYDWGQGTLVTVSS
DKK1-	2224	EVQLVESGGGLVQPGGSLRLSCAASGSIFRVNVMGWFRQAPGKEREFVGAISMSGANTYYADSV
478		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2225	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVAALNWSGGNTYYADS
479		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQGTLVTVSS
DKK1-	2226	EVQLVESGGGLVQPGGSLRLSCAASGFLMYDRAMGWFRQAPGKEREIVAAISRTGSSIYYADSV
480		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2227	EVQLVESGGGLVQPGGSLRLSCAASGDISSYVMGWFRQAPGKEREFVARITWNGGTHTYYADS
481		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRKYGHHRARYDWGQSTLVTVSS
DKK1-	2228	EVQLVESGGGLVQPGGSLRLSCAASGRTHSIYPMGWFRQAPGKERELVAAVNWNGDSTYYADS
482		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2229	EVQLVESGGGLVQPGGSLRLSCAASGIPFSSRTMGWFRQAPGKEREFVAAISRSGTGTYYADSVK
483		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2230	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYPMGWFRQAPGKERELVAIIVNGGSTYADSVKG
484		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2231	EVQLVESGGGLVQPGGSLRLSCAASGMTTIGPMGWFRQAPGKEREFVAAISWDGGNTYYADSV
485		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2232	EVQLVESGGGLVQPGGSLRLSCAASGRASGDYAMGWFRQAPGKEREFVAAISWRGGNTYYADS
486		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSFSYFSTSSNYEWGQGTLVTVSS
DKK1-	2233	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYPMGWFRQAPGKEREWVAHLLSGGSTVYADSV
487		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2234	EVQLVESGGGLVQPGGSLRLSCAASGRTFSEVVMGWFRQAPGKERELVAVAHWSGGSTFYADS
488		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	2235	EVQLVESGGGLVQPGGSLRLSCAASGSTFSINRMGWFRQAPGKEREFVARITPRGLTEYADSVKG
489		RFTISADNSKNTTYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2236	EVQLVESGGGLVQPGGSLRLSCAASGRTFSFGWFRQAPGKEREFVAAVIWRGGSTYYADSVKG
490		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2237	EVQLVESGGGLVQPGGSLRLSCAASGGTFSSYPMGWFRQAPGKEREFVAAISWSGSATFYADSV
491		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	2238	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNFAMGWFRQAPGKEREFVAVILRGGSTYADSVKG
492		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	2239	EVQLVESGGGLVQPGGSLRLSCAASGGTFSRYAMGWFRQAPGKEREFVAAISWSLTRTHYADS
493		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFVTSSNYDWGQGTLVTVSS
DKK1-	2240	EVQLVESGGGLVQPGGSLRLSCAASGRTLSRSNMGWFRQAPGKEREHVALIRIKDGSIYYADSV
494		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2241	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSGTMGWFRQAPGKERELVAAISRSGTLKAYADSV
495		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVQYFSTSSNYDWGQGTLVTVSS
DKK1-	2242	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSYPMGWFRQAPGKEREFVAAINVGGGTYYADSV
496		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYDWGQGTLVTVSS
DKK1-	2243	EVQLVESGGGLVQPGGSLRLSCAASGYTLKNYYAMGWFRRAPGKEREFVAAISRSGGTTFYADS
497		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRASVQYFSTSSNYDWGQGTLVTVSS
DKK1-	2244	EVQLVESGGGLVQPGGSLRLSCAASGHTFNTYPMGWFRQAPGKEREFVAAVSYSGSYYADSVK
498		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2245	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDRAMGWFRQAPGKEREFVASISTSGTRTLYADSV
499		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2246	EVQLVESGGGLVQPGGSLRLSCAASGRTLSSYAMGWFRQAPGKEREWVATIGTSGPPRYADSV
500		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2247	EVQLVESGGGLVQPGGSLRLSCAASGRIFTNTAMGWFRQAPGKEREFVAAISWGGGLTVYADS
501		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGSRYGHSRARYDWGQGTLVTVSS
DKK1-	2248	EVQLVESGGGLVQPGGSLRLSCAASGRIFTMGWFRQAPGKEREFVAAISWTAGTTYYADSVKGR
502		FTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHSRARYDWGQGTLVTVSS
DKK1-	2249	EVQLVESGGGLVQPGGSLRLSCAASGNIFTRHIMGWFRQAPGKEREWVARINTGGGSTFYADSV
503		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYGHSRARYEWGQGTLVTVSS
DKK1-	2250	EVQLVESGGGLVQPGGSLRLSCAASGRTFSNYPMGWFRQAPGKEREFVAAISWSSGNAYYADS
504		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2251	EVQLVESGGGLVQPGGSLRLSCAASGRTFTSYPMGWFRQAPGKEREWVATIGTHGTPLYADSV
505		KGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2252	EVQLVESGGGLVQPGGSLRLSCAASGQTFNGWFRQAPGKEREFVATISRSGVLYADSVKGRFTIS
506		ADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRAYGYSRARYEWGQGTLVTVSS
DKK1-	2253	EVQLVESGGGLVQPGGSLRLSCAASGRSFSEYPMGWFRQAPGKEREFVAAITWSGDMSVYADS
507		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRHYGHSRARYDWGQGTLVTVSS
DKK1-	2254	EVQLVESGGGLVQPGGSLRLSCAASGRSFSSYPMGWFRQAPGKEREFVATINTAGWTTYADSVK
508		GRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRSYGHSRARYDWGQGTLVTVSS
DKK1-	2255	EVQLVESGGGLVQPGGSLRLSCAASGLTFRNYAMGWFRQAPGKEREFVAAISWSGGKLYYADS
509		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRISVSYFSTTSNYDWGQGTLVTVSS
DKK1-	2256	EVQLVESGGGLVQPGGSLRLSCAASGSTFSSYPMGWFRQAPGKERELVALIHTGGTYYADSVKG
510		RFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRQYGHSRARYDWGQGTLVTVSS
DKK1-	2257	EVQLVESGGGLVQPGGSLRLSCAASGIDVNRNAMGWFRQAPGKEREFVGAVSWSGGTTVYADS
511		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVSYFSTASNYDWGQGTLVTVSS
DKK1-	2258	EVQLVESGGGLVQPGGSLRLSCAASGGTFNVYAMGWFRQAPGKEREFVAAINRSGKSTYYADS
512		VKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRPKRVSVRYFSTSSNYDWGQGTLVTVSS

TABLE 7
Variable Light Chain Domain Sequences
	SEQ
DKK1	ID
Variant	NO	VH Sequence
DKK1-	713	DIQMTQSPSSLSASVGDRVTITCSGDKLRNKYASWYQQKPGKAPKLLIYGASTLQSGVPSRFSGSG
212		SGTDFTLTISSLQPEDFATYYCQSYDDHDRIVFGQGTKVEIK
DKK1-	714	DIQMTQSPSSLSASVGDRVTITCRASQPIGPDLLWYQQKPGKAPKLLIYSASVLQSGVPSRFSGSGS
213		GTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	715	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLVIYGRNKRPSGVPSRFSGSGS
214		GTDFTLTISSLQPEDFATYYCQQSYSSPLTFGQGTKVEIK
DKK1-	716	DIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAPKLLIYAASDLESGVPSRFSGSGS
215		GTDFTLTISSLQPEDFATYYCQQYYNLPWTFGQGTKVEIK
DKK1-	717	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYAASGLPSGVPSRFSGSG
216		SGTDFTLTISSLQPEDFATYYCASRDRSGHGVFGQGTKVEIK
DKK1-	718	DIQMTQSPSSLSASVGDRVTITCRASQPIGPDLLWYQQKPGKAPKLLIYGASSRATGVPSRFSGSGS
217		GTDFTLTISSLQPEDFATYYCQQSYNTPLTFGQGTKVEIK
DKK1-	719	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYQQKPGKAPKLLIYGRNKRPSGVPSRFSGSGS
218		GTDFTLTISSLQPEDFATYYCQHSYRSGRAFGQGTKVEIK
DKK1-	720	DIQMTQSPSSLSASVGDRVTITCRASQDVSSGVAWYQQKPGKAPKLLIYDASSLHTGVPSRFSGSG
219		SGTDFTLTISSLQPEDFATYYCKQSYTLRTFGQGTKVEIK
DKK1-	721	DIQMTQSPSSLSASVGDRVTITCRPSQRISRYLNWYQQKPGKAPKLLIYGKKNRPSGVPSRFSGSGS
220		GTDFTLTISSLQPEDFATYYCQQSYSPPLTFGQGTKVEIK
DKK1-	722	DIQMTQSPSSLSASVGDRVTITCRASQTIGDYLNWYQQKPGKAPKLLIYHTSRLHSGVPSRFSGSGS
221		GTDFTLTISSLQPEDFATYYCGQDYTSPRTFGQGTKVEIK
DKK1-	723	DIQMTQSPSSLSASVGDRVTITCRASQTIERRLNWYQQKPGKAPKLLIYQDFKRPSGVPSRFSGSGS
222		GTDFTLTISSLQPEDFATYYCQQSRTFGQGTKVEIK
DKK1-	724	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYQQKPGKAPKLLIYGKKNRPSGVPSRFSGSG
223		SGTDFTLTISSLQPEDFATYYCQQSYSTPSFGQGTKVEIK
DKK1-	725	DIQMTQSPSSLSASVGDRVTITCRASQTIERRLNWYQQKPGKAPKLLIYGNNNRPSGVPSRFSGSGS
224		GTDFTLTISSLQPEDFATYYCSSWAGSRSGTVFGQGTKVEIK
DKK1-	726	DIQMTQSPSSLSASVGDRVTITCRASQNIRSYLNWYQQKPGKAPKLLIYATSNLASGVPSRFSGSGS
225		GTDFTLTISSLQPEDFATYYCNSRDTSINHPVIFGQGTKVEIK
DKK1-	727	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDNTNRPSGVPSRFSGSG
226		SGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	728	DIQMTQSPSSLSASVGDRVTITCSGDRLGEKYVSWYQQKPGKAPKLLIYDNTNRPSGVPSRFSGSG
227		SGTDFTLTISSLQPEDFATYYCLAWDTRTSGAVFGQGTKVEIK
DKK1-	729	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLLIYAKNNRPSGVPSRFSGSGS
228		GTDFTLTISSLQPEDFATYYCQSYGSHSNFVVFGQGTKVEIK
DKK1-	730	DIQMTQSPSSLSASVGDRVTITCRASQTIGDYLNWYQQKPGKAPKLLIYAASSLYSGVPSRFSGSGS
229		GTDFTLTISSLQPEDFATYYCQSYDLRYSHVFGQGTKLEIK
DKK1-	731	DIQMTQSPSSLSASVGDRVTITCRASQDIKNYLNWYQQKPGKAPKLLIYGTSYRYSGVPSRFSGSG
230		SGTDFTLTISSLQPEDFATYYCASRSSKGNPHVLFGQGTKVEIK
DKK1-	732	DIQMTQSPSSLSASVGDRVTITCRASQNIRSYLNWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
231		GTDFTLTISSLQPEDFATYYCQQRARHPHTFGQGTKVEIK
DKK1-	733	DIQMTQSPSSLSASVGDRVTITCSGDNLRSYYVHWYQQKPGKAPKLLIYQDFKRPSGVPSRFSGSG
232		SGTDFTLTISSLQPEDFATYYCQSYDDHDRIVFGQGTKVEIK
DKK1-	734	DIQMTQSPSSLSASVGDRVTITCTGDKLAEKYVSWYQQKPGKAPKLLIYDNNIRPSGVPSRFSGSG
233		SGTDFTLTISSLQPEDFATYYCLAWDTRTSGAVFGQGTKVEIK
DKK1-	735	DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKLLIYAASTLQRGVPSRFSGSGS
234		GTDFTLTISSLQPEDFATYYCQQGKTLPLTFGQGTKVEIK
DKK1-	736	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLLIYAVTSLASGVPSRFSGSGS
235		GTDFTLTISSLQPEDFATYYCQQSTILPLTFGQGTKVEIK
DKK1-	737	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYQQKPGKAPKLLIYGRNKRPSGVPSRFSGSGS
236		GTDFTLTISSLQPEDFATYYCQQRARHPHTFGQGTKVEIK
DKK1-	738	DIQMTQSPSSLSASVGDRVTITCRASQTIERRLNWYQQKPGKAPKLLIYDDIDRPSGVPSRFSGSGS
237		GTDFTLTISSLQPEDFATYYCQQGSSLPLTFGQGTKVEIK
DKK1-	739	DIQMTQSPSSLSASVGDRVTITCSGGSGSYGWYQQKPGKAPKLLIYGNNNRPSGVPSRFSGSGSGT
238		DFTLTISSLQPEDFATYYCNSRDTSGNHRVFGQGTKVEIK
DKK1-	740	DIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSG
239		SGTDFTLTISSLQPEDFATYYCNSRDTSGNHLVFGQGTKVEIK
DKK1-	741	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSG
240		SGTDFTLTISSLQPEDFATYYCQQTYSTRTFGQGTKVEIK
DKK1-	742	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLLIYGRNKRPSGVPSRFSGSGS
241		GTDFTLTISSLQPEDFATYYCQAWGSSTVIFGQGTKVEIK
DKK1-	743	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYQQKPGKAPKLLIYRKSNRPSGVPSRFSGSGS
242		GTDFTLTISSLQPEDFATYYCQQRARHPHTFGQGTKVEIK
DKK1-	744	DIQMTQSPSSLSASVGDRVTITCTSSQSLFNVRSQKNYLAWYQQKPGKAPKLLIYDTSKVASGVPS
243		RFSGSGSGTDFTLTISSLQPEDFATYYCSSRDNSDNHLVVFGQGTKVEIK
DKK1-	745	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
244		GTDFTLTISSLQPEDFATYYCQQSYSAPLTFGQGTKVEIK
DKK1-	746	DIQMTQSPSSLSASVGDRVTITCTGDKLAEKYVSWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSG
245		SGTDFTLTISSLQPEDFATYYCQVWDTGTVVFGQGTKVEIK
DKK1-	747	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDNNNRPSGVPSRFSGSG
246		SGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	748	DIQMTQSPSSLSASVGDRVTITCRASQPIAYFLSWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
247		GTDFTLTISSLQPEDFATYYCASRSSKGNPHVLFGQGTKVEIK
DKK1-	749	DIQMTQSPSSLSASVGDRVTITCKASDHIGKFLTWYQQKPGKAPKLLIYAASTLQRGVPSRFSGSG
248		SGTDFTLTISSLQPEDFATYYCQQSYETPLTFGQGTKVEIK
DKK1-	750	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLLIYAVTSLASGVPSRFSGSGS
249		GTDFTLTISSLQPEDFATYYCQQSTIMPLTFGQGTKVEIK
DKK1-	751	DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYQQKPGKAPKLLIYRKSNRPSGVPSRFSGSGS
250		GTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	752	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLAWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSGS
251		GTDFTLTISSLQPEDFATYYCQQRDTTPWTFGQGTKVEIK
DKK1-	753	DIQMTQSPSSLSASVGDRVTITCRASQDIKNYYKWYQQKPGKAPKLLIYENNNRPSGVPSRFSGSG
252		SGTDFTLTISSLQPEDFATYYCQARDRNTYVAFGQGTKVEIK
DKK1-	754	DIQMTQSPSSLSASVGDRVTITCRASQYIGTALNWYQQKPGKAPKLLIYDNNIRPSGVPSRFSGSGS
253		GTDFTLTISSLQPEDFATYYCNSRDTSGLHYVFGQGTKVEIK
DKK1-	755	DIQMTQSPSSLSASVGDRVTITCRASQSISGYLNWYQQKPGKAPKLLIYGQHNRPSGVPSRFSGSGS
254		GTDFTLTISSLQPEDFATYYCQQYDAYPPTFGQGTKVEIK
DKK1-	756	DIQMTQSPSSLSASVGDRVTITCRASQSIGRYMNWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
255		GTDFTLTISSLQPEDFATYYCQQSYSAPLTFGQGTKVEIK
DKK1-	757	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYEDTKRPSGVPSRFSGSG
256		SGTDFTLTISSLQPEDFATYYCLQYASSPFTFGQGTKVEIK
DKK1-	758	DIQMTQSPSSLSASVGDRVTITCRASQPIGPDLLWYQQKPGKALKLLIYAVTSLASGVPSRFSGSGF
257		GTDFTLTISSLQPEDFATYYCQQSFSVPAFGQGTKVEIK
DKK1-	759	DIQMTQSPSSLSASVGDRVTITCRASQPIGPDLLWYQQKPGKAPKLLIYGASSRATGVPSRFSGSGS
258		GTDFTLTISSLQPEDFATYYCQQSYNTPLTFGQGTKVEIK
DKK1-	760	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAHKLMIYDNNNRPSGVPSRFSGS
259		GCGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	761	DIQMTQSPSSLSASVGDRVTITCRASQRISSFLNWYQQKPGKAPKLLIYRKSNRPSGVPSRFSGSGS
260		GTDFTLTISSLQPEDFATYYCSQSTRVPPTFGQGTKVEIK
DKK1-	762	DIQMTQSPSSLSASVGDRVTITCRPNQNIATYINWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGS
261		GTDFTLTISSLQPEDFATYYCSSWAGSRSGTVFGQGTKVEIK
DKK1-	763	DIQMTQSPSSLSASVGDRVTITCSGDLRNKYASWYQQKPGKAPKLLIYGQHNRPSGVPSRFSGSGS
262		GTDFTLTISSLQPEDFATYYCSSGSRSGTVFGQGTKVEIK
DKK1-	764	DIQMTQSPSSLSASVGDRVTITCRASQPIGPDLLWYQQKPGKAPKLLIYANTNGPSGVPSRFSGSGS
263		GTDFTLTISSLQPEDFATYYCQQSYSAPYTFGQGTKVEIK
DKK1-	765	DIQMTQSPSSLSASVGDRVTITCQASQSIYSFLSWYQQKPGKAPKLLIYRKSNRPSGVPSRFSGSGS
264		GTDFTLTISSLQPEDFATYYCQQTATWPFTFGQGTKVEIK
DKK1-	766	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDNTNRPSGVPSRFSGSG
265		SGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	767	DIQMTQSPSSLSASVGDRVTITCKASDHIGKFLTWYQQKPGKAPKLLIYHTSRLHSGVPSRFSGSGS
266		GTDFTLTISSLQPEDFATYYCQQSYKYPLTFGQGTKVEIK
DKK1-	768	DIQMTQSPSSLSASVGDRVTITCRASHNINSYLNWYQQKPGKAPKLLIYQDFKRPSGVPSRFSGSGS
267		GTDFTLTISSLQPEDFATYYCQQSYSSPLTFGQGTKVEIK
DKK1-	769	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDNTNRPSGVPSRFSGSG
268		SGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	770	DIQMTQSPSSLSASVGDRVTITCRTSQDISNYLNWYQQKPGKAPKLLIYGTSYRYSGVPSRFSGSGS
269		GTDFTLTISSLQPEDFATYYCQQGYTLPWTFGQGTKVEIK
DKK1-	771	DIQMTQSPSSLSASVGDRVTITCRANQNIGNFLNWYQQKPGKAPKLLIYHTSRLHSGVPSRFSGSG
270		SGTDFTLTISSLQPEDFATYYCQQSYSAPLTFGQGTKVEIK
DKK1-	772	DIQMTQSPSSLSASVGDRVTITCSASSSVTYMHWYQQKPGKAPKLLIYHDNKRPSGVPSRFSGSGS
271		GTDFTLTISSLQPEDFATYYCQQSYDNPLTFGQGTKVEIK
DKK1-	773	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSG
272		SGTDFTLTISSLQPEDFATYYCLQFDHTPFTFGQGTKVEIK
DKK1-	774	DIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAPKLLIYHTSRLHSGVPSRFSGSGS
273		GTDFTLTISSLQPEDFATYYCQQGYRFPLTFGQGTKVEIK
DKK1-	775	DIQMTQSPSSLSASVGDRVTITCRASQPIAYFLSWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
274		GTDFTLTISSLQPEDFATYYCASRSSKGNPHVLFGQGTKVEIK
DKK1-	776	DIQMTQSPSSLSASVGDRVTITCSGDNLRGYYASWYQQKPGKAPKLLIYQDFKRPSGVPSRFSGSG
275		SGTDFTLTISSLQPEDFATYYCQQSYSPLTFGQGTKVEIK
DKK1-	777	DIQMTQSPSSLSASVGDRVTITCRSSQLVHSTGNTYLHWYQQKPGKAPKLLIYGASSRATGVPSRF
276		SGSGSGTDFTLTISSLQPEDFATYYCSQSTHVPTFGQGTKVEIK
DKK1-	778	DIQMTQSPSSLSASVGDRVTITCQGASLRNYYASWYQQKPGKAPKLLIYENNNRPSGVPSRFSGSG
277		SGTDFTLTISSLQPEDFATYYCSTRSRKGNPHVLFGQGTKVEIK
DKK1-	779	DIQMTQSPSSLSASVGDRVTITCRASQDIKNYLNWYQQKPGKAPKLLIYQASSLQSGVPSRFSGSG
278		SGTDFTLTISSLQPEDFATYYCQQSYSPPLTFGQGTKVEIK
DKK1-	780	DIQMTQSPSSLSASVGDRVTITCRASQDVSSGVAWYQQKPGKAPKLLIYDDIDRPSGVPSRFSGSG
279		SGTDFTLTISSLQPEDFATYYCHQRSSYPWTFGQGTKVEIK
DKK1-	781	DIQMTQSPSSLSASVGDRVTITCRASQGVRTSLAWYQQKPGKAPKLLIYSASVLQSGVPSRFSGSG
280		SGTDFTLTISSLQPEDFATYYCQAWDNSAVIFGQGTKVEIK
DKK1-	782	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDNTNRPSGVPSRFSGSG
281		SGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	783	DIQMTQSPSSLSASVGDRVTITCTGDKLAEKNVSWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSG
282		SGTDFTLTISSLQPEDFATYYCQQTYSTPLTFGQGTKVEIK
DKK1-	784	DIQMTQSPSSLSASVGDRVTITCRASQTIGDYLNWYQQKPGKAPKLLIYAASGLQSGVPSRFSGSG
283		SGTDFTLTISSLQPEDFATYYCQQSNSWPYTFGQGTKVEIK
DKK1-	785	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLLIYLSSDLQSGVPSRFSGSGS
284		GTDFTLTISSLQPEDFATYYCAQTGTHPTTFGQGTKVEIK
DKK1-	786	DIQMTQSPSSLSASVGDRVTITCRTSQSLSSYLHWYQQKPGKAPKLLIYEDTKRPSGVPSRFSGSGS
285		GTDFTLTISSLQPEDFATYYCHTWHHNPHTGETNHFGQGTKVEIK
DKK1-	787	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDNTNRPSGVPSRFSGSG
286		SGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	788	DIQMTQSPSSLSASVGDRVTITCRASQDVSSGVAWYQQKPGKAPKLLIYGASRLQRGVPSRFSGSG
287		SGTDFTLTISSLQPEDFATYYCNSRDTSGLHYVFGQGTKVEIK
DKK1-	789	DIQMTQSPSSLSASVGDRVTITCRASQTIERRLNWYQQKPGKAPKLLIYENNNRPSGVPSRFSGSGS
288		GTDFTLTISSLQPEDFATYYCQQTYSPPLTFGQGTKVEIK
DKK1-	790	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYGASSRATGVPSRFSGSG
289		SGTDFTLTISSLQPEDFATYYCQQSYSSPLTFGQGTKVEIK
DKK1-	791	DIQMTQSPSSLSASVGDRVTITCRATQSIRSFLNWYQQKPGKAPKLLIYGQHNRPSGVPSRFSGSGS
290		GIDFTLTISSLQPEDFATYYCQQYYDWPLTFGQGTKVEIK
DKK1-	792	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
291		GTDFTLTISSLQPEDFATYYCQQYYSGWTFGQGTKVEIK
DKK1-	793	DIQMTQSPSSLSASVGDRVTITCRTSQSLSSYLHWYQQKPGKAPKLLIYGRNKRPSGVPSRFSGSGS
292		GTDFTLTISSLQPEDFATYYCQNVLSTPYTFGQGTKVEIK
DKK1-	794	DIQMTQSPSSLSASVGDRVTITCSGDLRNKYASWYQQKPGKAPKLLIYGTSNLESGVPSRFSGSGS
293		GTDFTLTISSLQPEDFATYYCQAWVSSTVVFGQGTKVEIK
DKK1-	795	DIQMTQSPSSLSASVGDRVTITCRASQSVDRYFNWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSG
294		SGTDFTLTISSLQPEDFATYYCSQSTHVPLTFGQGTKVEIK
DKK1-	796	DIQMTQSPSSLSASVGDRVTITCRASQFIGRYFNWYQQKPGKAPKLLIYGRNKRPSGVPSRFSGSGS
295		GTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	797	DIQMTQSPSSLSASVGDRVTITCRASQPIGPDLLWYQQKPGKAPKLLIYGKKNRPSGVPSRFSGSGS
296		GTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK
DKK1-	798	DIQMTQSPSSLSASVGDRVTITCRASQTIGDYLNWYQQKPGKAPKLLIYGASRLQRGVPSRFSGSG
297		SGTDFTLTISSLQPEDFATYYCSQSTHVPTFGQGTKVEIK
DKK1-	799	DIQMTQSPSSLSASVGDRVTITCRASQTIERRLNWYQQKPGKAPKLLIYGQHNRPSGVPSRFSGSGS
298		GTDFTLTISSLQPEDFATYYCQQYHSYPPTFGQGTKVEIK
DKK1-	800	DIQMTQSPSSLSASVGDRVTITCRASQSIRRFLNWYQQKPGKAPKLLIYGASSRATGVPSRFSGSGS
299		GTDFTLTISSLQPEDFATYYCQQSFSVPAFGQGTKVEIK
DKK1-	801	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYGNNNRPSGVPSRFSGSG
300		SGTDFTLTISSLQPEDFATYYCQQSYSAPLTFGQGTKVEIK
DKK1-	802	DIQMTQSPSSLSASVGDRVTITCRPNQNIATYINWYQQKPGKAPKLLIYHDNKRPSGVPSRFSGSGS
301		GTDFTLTISSLQPEDFATYYCLQDYNYPLTFGQGTKVEIK
DKK1-	803	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYGRNKRPSGVPSRFSGSG
302		SGTDFTLTISSLQPEDFATYYCQQTYNVPPTFGQGTKVEIK
DKK1-	804	DIQMTQSPSSLSASVGDRVTITCRANQNIGNFLNWYQQKPGKAPKLLIYNAKTLPEGVPSRFSGSG
303		SGTDFTLTISSLQPEDFATYYCASRDRSGHGVFGQGTKVEIK
DKK1-	805	DIQMTQSPSSLSASVGDRVTITCRASQTIERRLNWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSGS
304		GTDFTLTISSLQPEDFATYYCSSRDRSGNHRVFGQGTKVEIK
DKK1-	806	DIQMTQSPSSLSASVGDRVTITCRASQRISSFLNWYQQKPGKAPKLLIYQNDKRPSGVPSRFSGSGS
305		GTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	807	DIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQQKPGKAPKLLIYHDNKRPSGVPSRFSGSGS
306		GTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVEIK
DKK1-	808	DIQMTQSPSSLSASVGDRVTITCSGDKLGDKYAYWYQQKPGKAPKLLIYHDNKRPSGVPSRFSGS
307		GSGTDFTLTISSLQPEDFATYYCQPSFYFPYTFGQGTKVEIK
DKK1-	809	DIQMTQSPSSLSASVGDRVTITCRASQDIYQNLDWYQQKPGKAPKLLIYGKNIRPSGVPSRFSGSGS
308		GTDFTLTISSLQPEDFATYYCQQYYSGWTFGQGTKVEIK
DKK1-	810	DIQMTQSPSSLSASVGDRVTITCQASQSISSYLAWYQQKPGKAPKLLIYGASTLQSGVPSRFSGSGS
309		GTDFTLTISSLQPEDFATYYCQQYWAFPVTFGQGTKVEIK
DKK1-	811	DIQMTQSPSSLSASVGDRVTITCRASQSISGYLNWYQQKPGKAPKLLIYAKNNRPSGVPSRFSGSGS
310		GTDFTLTISSLQPEDFATYYCQQSYSSPRTFGQGTKVEIK
DKK1-	812	DIQMTQSPSSLSASVGDRVTITCSASQDINKYLNWYQQKPGKAPKLLIYDTSKVASGVPSRFSGSG
311		SGTDFTLTISSLQPEDFATYYCQQSYSTPNTFGQGTKVEIK
DKK1-	813	DIQMTQSPSSLSASVGDRVTITCRASQNIRSYLNWYQQKPGKAPKLLIYDNNIRPSGVPSRFSGSGS
312		GTDFTLTISSLQPEDFATYYCLQDYNLWTFGQGTKVEIK
DKK1-	814	DIQMTQSPSSLSASVGDRVTITCRASQSIREYLHWYQQKPGKAPKLLIYATSNLASGVPSRFSGSGS
313		GTDFTLTISSLQPEDFATYYCQAWDTSTAVFGQGTKVEIK
DKK1-	815	DIQMTQSPSSLSASVGDRVTITCSGDLGEKYVSWYQQKPGKAPKLLIYATSTLQSGVPSRFSGSGS
314		GTDFTLTISSLQPEDFATYYCQAWASSTVVFGQGTKVEIK
DKK1-	816	DIQMTQSPSSLSASVGDRVTITCRPNQNIATYINWYQQKPGKAPKLLIYGNNNRPSGVPSRFSGSGS
315		GTDFTLTISSLQPEDFATYYCSTRSSKGNPHVLFGQGTKVEIK
DKK1-	817	DIQMTQSPSSLSASVGDRVTITCRASKVSTSGYVYMHWYQQKPGKAPKLLIYENNNRPSGVPSRF
316		SGSGSGTDFTLTISSLQPEDFATYYCQQYWAFPVTFGQGTKVEIK
DKK1-	818	DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKLLIYGENSRPSGVPSRFSGSGS
317		GTDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK
DKK1-	819	DIQMTQSPSSLSASVGDRVTITCRASQDVSSGVAWYQQKPGKAPKLLIYGSSLQSGVPSRFSGSGS
318		GTDFTLTISSLQPEDFATYYCQQYHSYPPTFGQGTKVEIK
DKK1-	820	DIRMTQSPSSLSASVGDRVTITCRASQSVDRYFNWYQQKPGKAPKLLIYHTSRLHSGVPSRFSGSG
319		SGTDFTLTISSLQPEDFATYYCQAWDNRAVVFGQGTKVEIK
DKK1-	821	DIQMTQSPSSLSASVGDRVTITCQSSQSVYSNNELSWYQQKPGKAPKLLIYGNNNRPSGVPSRFSG
320		SGSGTDFTLTISSLQPEDFATYYCQQSYSTPTFGQGTKVEIK
DKK1-	822	DIQMTQSPSSLSASVGDRVTITCRSSQSISTYLNWYQQKPGKAPKLLIYAASRSQSGVPSRFSGSGS
321		GTDFTLTISSLQPEDFATYYCQQNYIIPWTFGGGTKVEIK
DKK1-	823	DIQMTQSPSSLSASVGDRVTITCRASHSISSYLNWYQQKPGKAPKLLIYTASRLRSGVPSRFSGSGS
322		GTDFTLTISSLQPEDFATYYCQQNYNTPFTFGGGTKVEIK
DKK1-	824	DIQMTQSPSSLSASVGDRVTITCRASQSIHSYLNWYQQKPGKAPKLLIYTASALQTGVPSRFSGSGS
323		GTDFTLTISSLQPEDFATYYCQQSFSSPLTFGQGTKVEIK
DKK1-	825	DIQMTQSPSSLSASVGDRVTITCRAGQSVSRFLNWYQQKPGKAPKLLIYAAATLQSGVPSRFSGSG
324		SGTDFTLTISSLQPEDFATYYCQQSYDTPFTFGGGTKVEIK
DKK1-	826	DIQMTQSPSSLSASVGDRVTITCRTSQSIGTYLNWYQQKPGKSPKLLIYDASILQSGVPSRFSGSGS
325		GTDFTLTISSLQPEDFATYYCQQNYNTPLTFGGGTKVEIK
DKK1-	827	DIQMTQSPSSLSASVGDRVTITCRASQSIGIHLNWYQQKPGKAPKLLIYGATSLESGVPSRFSGSGS
326		GTDFTLTISSLQPEDFATYYCQQSYNTPPYTFGGGTKVEIK
DKK1-	828	DIQMTQSPSSLSASVGDRVTITCRASQSIRSYLNWYQQKPGKAPKLLIYATSRLESGVPSRFSGSGS
327		GTDFTLTISSLQPEDFATYYCQQGYTSPLTFGGGTKVEIK
DKK1-	829	DIQMAQSPSSLSASVGDRVTITCRASQGIATYLNWYQQKPGKAPKLLIYGASTLRTGVPSRFSGSG
328		SGTDFTLTISSLQPEDFATYYCQQTFTNTPLTFGGGTKVEIK
DKK1-	830	DIQMTQSPSSLSASVGDRVTITCRASQSIGSYLNWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGS
329		GTDFTLTISSLQPEDFATYYCQQSHNIPRTFGGGTKVEIK
DKK1-	831	DIQMTQSPSSLSASVGDRVTITCRASQSISRNLNWYQQKPGKAPKLLIYGASRLHSGVPSRFSGSGS
330		GTDFTLTISSLQPEDFATYYCQQGYITPQTFGGGTKVEIK
DKK1-	832	DIQMTQSPSSLSASVGDRVTITCRASQSVRTYLNWYQQKPGKAPKLLIYRASRLQSGVPSRFSGSG
331		SGTDFTLTISSLQPEDFATYYCQQSFTTPLTFGGGTKVEIK
DKK1-	833	DIQMTQSPSSLSASVGDRVTITCRASQSIGSHLSWYQQKPGKAPKLLIYRASRLQSGVPSRFSGSGS
332		GTDFTLTISSLQPEDFATYYCQQSYSPPITFGGGTKVEIK
DKK1-	834	DIQMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYGASKLQRGVPSRFSGSGS
333		GTDFTLTISSLQPEDFATYYCQQSSSVPWTFGGGTKVEIK
DKK1-	835	DIQMTQSPSSLSASVGDRVTITCRASQNIGNYLNWYQQKPGKAPKLLIYAASTLASGVPSRFSGSG
334		SGTDFTLTISSLQPEDFATYYCQQNYNTPLTFGGGTKVEIK
DKK1-	836	DIQMTQSPSSLSASVGDRVTITCRSSQSISTYLNWYQQKPGKAPKLLIYAASRLESGVPSRFSGSGS
335		GTDFTLTISSLQPEDFATYYCQQSYTPPITFGGGTKVEIK
DKK1-	837	DIQMTQSPSSLSASVGDRVTITCRASQNIGSYLNWYQQKPGKAPKLLIYAASKLHSGVPSRFSGSG
336		SGTDFTLTISSLQPEDFATYYCQQSYNTPVTFGGGTKVEIK
DKK1-	838	DIQMTQSPSSLSASVGDRVTITCRASQSISRFLNWYQQKPGKAPKLLIYGASALQTGVPSRFSGSGS
337		GTDFTLTISSLQPEDFATYYCQQSYIPPLTFGGGTKVEIK
DKK1-	839	DIQMTQSPSSLSASVGDRVTITCRASESITTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGS
338		GTDFTLTISSLQPEDFATYYCQQNYITPLTFGGGTKVEIK
DKK1-	840	DIQMTQSPSSLSASVGDRVTITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLHSGVPSRFSGSGS
339		GTDFTLTISSLQPEDFATYYCQQSYNSITFGGGTKVEIK
DKK1-	841	DIQMTQSPSSLSASVGDRVTITCRSSQSIGSNLNWYQQKPGKAPKLLIYATSNLQSGVPSRFSGSGS
340		GTDFTLTISSLQPEDFATYYCQQSYRIPRTFGGGTKVEIK
DKK1-	842	DIQMTQSPSSLPASVGDRVTITCRASQSISRYLSWYQQKPGKAPKLLIYAASRLRSGVPSRFSGSGS
341		GTDFTLTISSLQPEDFATYYCQQSYSTPTTFGGGTKVEIK
DKK1-	843	DIQMTQSPSSLSASVGDRVTITCRASQYIGTYLNWYQQKPGKAPKLLIYAASNLQRGVPSRFSGSG
342		SGTDFTLTISSLQPEDFATYYCQQSYSDLTFGGGTKVEIK
DKK1-	844	DIQMTQSPSSLSASVGDRVTITCRASESISRNLNWYQQKPGKAPKLLIYAASSLRSGVPSRFSGSGS
343		GTDFTLTISSLQPEDFATYYCQQSYSGPPYTFGGGTKVEIK
DKK1-	845	DIQMTQSPSSLSASVGDRVTITCRSSQSISTYLNWYQQKPGKAPKLLIYAASRSQSGVPSRFSGSGS
344		GTDFTLTISSLQPEDFATYYCQQNYIIPWTFGGGTKVEIK
DKK1-	846	DIQMTQSPSSLSASVGDRVTITCRASQSVSNFLNWYQQKPGKAPKLLIYGASNLHSGVPSRFSGSG
345		SGTDFTLTISSLQPEDFATYYCQQSYSFPFSFGGGTKVEIK
DKK1-	847	DIQMTQSPSSLSASVGDRVTITCRASRNIRTYLNWYQQKPGKAPKLLIYRASTLQSGVPSRFSGSGS
346		GTDFTLTISSLQPEDFATYYCQQSYKTPVTFGGGTKVEIK
DKK1-	848	DIQMTQSPSSLSASVGDRVTITCRASQSIGNFLNWYQQKPGKAPKLLIYRASRLQSGVPSRFSGSGS
347		GTDFTLTISSLQPEDFATYYCQQSYNTPITFGGGTKVEIK
DKK1-	849	DIQMTQSPSSLSASVGDRVTITCRASQSIRSYLNWYQQKPGKAPKLLIYGATNLQSGVPSRFSGSGS
348		GTDFTLTISSLQPEDFATYYCQQSYSTLPFTFGGGTKVEIK
DKK1-	850	DIQMTQSPSSLSASVGDRVTITCRASQSIRTYLNWYQQKPGKAPKLLIYGAVNLQSGVPSRFSGSG
349		SGTDFTLTISSLQPEDFATYYCQQRDTFGGGTKVEIK
DKK1-	851	DIQMTQSPSSLSASVGDRVTITCRASQNIYTYLNWYQQKPGKAPKPLIYLASSLQSGVPSRFSGSGS
350		GTDFTLTISSLQPEDFATYYCQQSYSTRFTFGGGTKVEIK
DKK1-	852	DIQMTQSPSSLSASVGDRVTITCRASQSISRYLSWYQQKPGKAPKLLIYGSSNLQSGVPSRFSGSGS
351		GTDFTLTISSLQPEDFATYYCQQSYSSPTFGGGTKVEIK
DKK1-	853	DIQMTQSPSSLSASVGDRVTITCRASQNIGRYLNWYQQKPGKAPKLLIYSASKLQSGVPSRFSGSG
352		SGTDFTLTISSLQPEDFATYYCQQTYSPPLTFGGGTKVEIK
DKK1-	854	DIQMTQSPSSLSASVGDRVTITCRASQTISAYLNWYQQKPGKAPKLLIYGASSVQSGVPSRFSGSGS
353		GTDFTLTISSLQPEDFATYYCQQSYSGLTFGGGTKVEIK
DKK1-	855	DIQMTQSPSSLSASVGDRVTITCRASQSIRGYLNWYQQKPGKAPKLLIYSTSSLQSGVPSRFSGSGS
354		GTDFTLTISSLQPEDFATYYCQQNYNTPLTFGGGTKVEIK
DKK1-	856	DIQMTQYPSSLSASVGDRVTITCRASQSVSYYLNWYQQKPGKAPKLLIYGSSNLQSGVPSRFSGSGS
355		GTDFTLTISSLQPEDFATYYCQQTYSSPVTFGGGTKVEIK
DKK1-	857	DIQMTQSPSSLSASVGDRVTITCRASQPISSYLNWYQQKPGKAPKLLIYSASSLRSGVPSRFSGSGS
356		GTDFTLTISSLQPEDFATYYCQQGYSAPLTFGGGTKVEIK
DKK1-	858	DIQMTQSPSSLSASVGDRVTITCQTSQSIGKYLNWYQQKPGKAPKLLIYGASRVQSGVPSRFSGSGS
357		GTDFTLTISSLQPEDFATYYCQQTYSTPLTFGGGTKVEIK
DKK1-	859	DIQMTQSPSSLSASVGDRVTITCRASQSIGAYLNWYQQKPGKAPKLLIYGTSSLQGGVPSRFSGSGS
358		GTDFTLTISSLQPEDFATYYCQQSYGTLITFGGGTKVEIK
DKK1-	860	DIQMTQSPSSLSASVGDRVTITCRASQTISTFLNWYQQKPGKAPKLLIYGASRLQGGVPSRFSGSGS
359		GTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK
DKK1-	861	DIQMTQSPSSLSASVGDRVTITCRASQSIGRYLNWYQQKPGKAPKLLIYAVSNLRSGVPSRFSGSGS
360		GTDFTLTISSLQPEDFATYYCQQSYSTPSFGGGTKVEIK
DKK1-	862	DIQMTQSPSSLSASVGDRVTITCRSSQSISNYLNWYQQKPGKAPKLLIYGASRLESGVPSRFSGSGS
361		GTDFTLTISSLQPEDFATYYCQQSYSLPLTFGGGTKVEIK
DKK1-	863	DIQMTQSPSSLSASVGDRVTITCRASQTISRSLNWYQQKPGKAPKLLIYGASRLQSGVPSRFSGSGS
362		GTDFTLTISSLQPEDFATYYCQQSFTTPYTFGGGTKVEIK
DKK1-	864	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLDWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGS
363		GTDFTLTISSLQPEDFATYYCQQNYRSPLTFGGGTKVEIK
DKK1-	865	DIQMTQSPSSLSASVGDRVTITCRASRSIGTYLNWYQQKPGKAPKLLIYAASKLQSGVPSRFSGSGS
364		GTDFTLTISSLQPEDFATYYCQQNYITPLTFGGGTKVEIK
DKK1-	866	DIQMTQSPSSLSASVGDRVTITCRASQNINRYLNWYQQKPGKAPKLLIYASSRLQSGVPSRFSGSGS
365		GTDFTLTISSLQPEDFATYYCQQSYSSPITFGGGTKVEIK
DKK1-	867	DIQMTQSPSSLSASVGDRVTITCRASQSVSSYLSWYQQKPGKAPKLLIYATSNLQRGVPSRFSGSGS
366		GTDFTLTISSLQPEDFATYYCHQTYSTPRTFGGGTKVEIK
DKK1-	868	DIQMTQSPSSLSASVGDRVTITCRASQSIGIHLNWYQQKPGKAPKLLIYGATSLESGVPSRFSGSGS
367		GTDFTLTISSLQPEDFATYYCQQSYNTPPYTFGGGTKVEIK
DKK1-	869	DIQMTQSPSSLSASVGDRVTITCRASRSISTYLNWYQQKPGKAPKLLIYEVSSLQSGVPSRFSGSGS
368		GTDFTLTISSLQPEDFATYYCQQNYITPLTFGGGTKVEIK
DKK1-	870	DIQMTQSPSSLSASVGDRVTITCRASQSISRYLSWYQQKPGKAPKLLIYAASRLQRGVPSRFSGSGS
369		GTDFTLTISSLQPEDFATYYCQQGYSSPLTFGGGTKVEIK
DKK1-	871	DIQMTQSPSSLSASVGDRVTITCRASQSISNFLSWYQQKPGKAPKLLIYGTSSLQGGVPSRFSGSGS
370		GTDFTLTISSLQPEDFATYYCQQSYSIPFTFGGGTKVEIK
DKK1-	872	DIQMTQSPSSLSASVGDRVTITCRASQGISFYLNWYQQKPGKAPKLLIYAASRLQRGVPSRFSGSGS
371		GTDFTLTISSLQPEDFATYYCQQSYSTPQITFGGGTKVEIK
DKK1-	873	DIQMTQSPSSLSASVGDRVTITCRASQNIKTYLNWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGS
372		GTDFTLTISSLQPEDFATYYCLQTYSVPLTFGGGTKVEIK
DKK1-	874	DIQMTQSPSSLSASVGDRVTITCRASQYISNYLNWYQQKPGKAPKLLIYGASSIQNGVPSRFSGSGS
373		GTDFTLTISSLQPEDFATYYCQQTYSLPLTFGGGTKVEIK
DKK1-	875	DIQMTQSPSSLSASVGDRVTITCRASQTISTFLNWYQQKPGKAPKLLIYGASRLQGGVPSRFSGSGS
374		GTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK
DKK1-	876	DIQMTQSPSSLSASVGDRVTITCRASQSISRFLNWYQQKPGKAPKLLIYGASRLESGVPSRFSGSGS
375		GTDFTLTISSLQPEDFATYYCQQSYKTPRTFGGGTKVEIK
DKK1-	877	DIQMTQSPSSLSASVGDRVTITCRASESIDNYLNWYQQKPGKAPKLLIYGATSLESGVPSRFSGSGS
376		GTDFTLTISSLQPEDFATYYCQQNYNIPFTFGGGTKVEIK
DKK1-	878	DIQMTQSPSSLSASVGDRVTITCRTSQSISNFLNWYQQKPGKAPKLLIYTASKLQSGVPSRFSGSGS
377		GTDFTLTISSLQPEDFATYYCQQSYRVPRTFGGGTKVEIK
DKK1-	879	DIQMTQSPSSLSASVGDRVTITCRASQSIGTNLNWYQQKPGKAPKLLIYAASALQGGVPSRFSGSG
378		SGTDFTLTISSLQPEDFATYYCQQSYSIPLTFGGGTKVEIK
DKK1-	880	DIQMTQSPSSLSASVGDRVTITCRASQTITRYLNWYQQKPGKAPKLLIYAATSLHSGVPSRFSGSGS
379		GTDFTLTISSLQPEDFATYYCQQSYSTPETFGGGTKVEIK
DKK1-	881	DIQMTQSPSSLSASVGDRVTITCRASQSIGNFLNWYQQKPGKAPKLLIYDASSLQSGVPSRFSGSGS
380		GTDFTLTISSLQPEDFATYYCQQSYSIPPTFGGGTKVEIK
DKK1-	882	DIQMTQSPSSLSASVGDRVTITCRASHSISRYLNWYQQKPGKAPKLLIYGASNLPSGVPSRFSGSGS
381		GTDFTLTISSLQPEDFATYYCQQSYSTHTFGGGTKVEIK
DKK1-	883	DIQMTQSPSSLSASVGDRVTITCRASQGISFYLNWYQQKPGKAPKLLIYGASILQTGVPSRFSGSGS
382		GTDFTLTISSLQPEDFATYYCQQSYSPPLTFGGGTKVEIK
DKK1-	884	DIQMTQSPSSLSASVGDRVTITCRASQSVSNYLNWYQQKPGKAPKLLIYGASTLQAGVPSRFSGSG
383		SGTDFTLTISSLQPEDFATYYCQQSYVTPPTFGGGTKVEIK
DKK1-	885	DIQMTQSPSSLSASVGDRVTITCRASQSIGSFLNWYQQKPGKAPKLLIYAAFRLQSGVPSRFSGSGS
384		GTDFTLTISSLQPEDFATYYCQQTYSPPFTFGGGTKVEIK
DKK1-	886	DIQMTQSPSSLSASVGDRVTITCRASQSITRHLNWYQQKPGKAPKLLIYAASRLQTGVPSRFSGSGS
385		GTDFTLTISSLQPEDFATYYCQQSYSTPGTFGGGTKVEIK
DKK1-	887	DIQMTQSPSSLSASVGDRVTITCRASQRISRYLNWYQQKPGKAPKLLIYGASNLQGGVPSRFSGSG
386		SGTDFTLTISSLQPEDFATYYCQQSYRTPITFGGGTKVEIK
DKK1-	888	DIQMTQSPSSLSASVGDRVTITCRASQYIGNYLNWYQQKPGKAPKLLIYAVSRLQSGVPSRFSGSG
387		SGTDFTLTISSLQPEDFATYYCQQSFSAPYTFGGGTKVEIK
DKK1-	889	DIQMTQSPSSLSASVGDRVTITCRASQYISTFLNWYQQKPGKAPKLLIYSASRLQNGVPSRFSGSGS
388		GTDFTLTISSLQPEDFATYYCQQSYSPLTFGGGTKVEIK
DKK1-	890	DIQMTQSPSSLSASVGDRVTITCRASRSISRYLNWYQQKPGKAPKLLIYGASILQTGVPSRFSGSGS
389		GTDFTLTISSLQPEDFATYYCQQSYTPPRTFGGGTKVETK
DKK1-	891	DIQMTQSPSSLSASVGDRVTITCRASQSISRSLNWYQQKPGKAPKLLIYGASSLRSGVPSRFSGSGS
390		GTDFTLTISSLQPEDFATYYCQQSFTIPWTFGGGTKVEIK
DKK1-	892	DIQMTQSPSSLSASAGDRVTITCRASQSITSYLNWYQQKPGKAPKLLIYAASRLRSGVPSRFSGSGS
391		GTDFTLTISSLQPEDFATYYCQQSYNTPVTFGGGTKVEIK
DKK1-	893	DIQMTQSPSSLSASVGDRVTITCRASQNIAGYLNWYQQKPGKAPKLLIYAASRLHSGVPSRFSGSG
392		SGTDFTLTISSLQPEDFATYYCQQSSSTPITFGGGTKVEIK
DKK1-	894	DIQMTQSPSSLSASVGDRVTITCRASQTIRTYLNWYQQKPGKAPKLLIYATSSLQTGVPSRFSGSGS
393		GTDFTLTISSLQPEDFATYYCQQSYRPPLTFGGGTKVEIK
DKK1-	895	DIQMTQSPSSLSASVGDRVTITCRASQSIGIHLNWYQQKPGKAPKLLIYGATSLESGVPSRFSGSGS
394		GTDFTLTISSLQPEDFATYYCQQSYNTPPYTFGGGTKVEIK
DKK1-	896	DIQMTQSPSSLSASVGDRVTITCRSSQSISTYLHWYQQKPGKAPKLLIYGASKLQSGVPSRFSGSGS
395		GTDFTLTISSLQPEDFATYYCQQTYSAPRTFGGGTKVEIK
DKK1-	897	DIQMTQSPSSLSASVGDRVTITCRASQSIGRYLNWYQQKPGKAPKLLIYGASRLQSGVPSRFSGSGS
396		GTDFTLTISSLQPEDFATYYCQQSYRTPLTFGGGTKVEIK
DKK1-	898	DIQMTQSPSSLSASVGDRVTITCRASHTISRYLNWYQQKPGKAPRLLIYAASDLQTGVPSRFSGGG
397		SGTDFTLTISSLQPEDFATYYCQQSFTAPDTFGGGTKVEIK
DKK1-	899	DIQMTQSPSSLSASVGDRVTITCRTSQSISRYLNWYQQKPGKAPKLLIYTTSDLQSGVPSRFSGSGS
398		GTDFTLTISSLQPEDFATYYCQQSYSDLTFGGGTKVEIK
DKK1-	900	DIQMTQSPSSLSASVGDRVTITCRASQRINTYLNWYQQKPGKAPKLLIYGAFRLQSGVPSRFSGSG
399		SGTDFTLTISSLQPEDFATYYCQQSYRVPRTFGGGTKVEIK
DKK1-	901	DIQMTQSPSSLSASVGDRVTITCRASQSINHYLNWYQQKPGKAPKLLIYGASRLQSGVPSRFSGSG
400		SGTDFTLTISSLQPEDFATYYCQQSYSLPRTFGGGTKVEIK
DKK1-	902	DIQMTQSPSSLSASVGDRVTITCRASQTIGRYLNWYQQKPGKAPKLLIYATSSLRSGVPSRFSGSGS
401		GTDFTLTISSLQPEDFATYYCQQTYSTPYTFGGGTKVEIK
DKK1-	903	DIQMTQSPSSLSASVGDRVTITCRASQSIGEYLNWYQQKPGKAPKLLIYAASRLQRGVPSRFSGSG
402		SGTDFTLTISSLQPEDFATYYCQQNYRSPLTFGGGTKVEIK
DKK1-	904	DIQMTQSPSSLSASVGDRVTITCRASQSIYRYLNWYQQKPGKAPKLLIYAATTLQSGVPSRFSGSGS
403		GTDFTLTISSLQPEDFATYYCQQSYSPPLTFGGGTKVEIK
DKK1-	905	DIQMTQSPSSLSASVGDRVTITCRASQNIGRYLNWYQQKPGKAPKLLIYEVSSLRSGVPSRFSGSGS
404		GTDFTLTISSLQPEDFATYYCQQSYRTPGTFGGGTKVEIK
DKK1-	906	DIQMTQSPSSLSASVGDRVTITCRAGQSIRNYLNWYQQKPGKAPKLLIYAATTLQSGVPSRFSGSG
405		SGTDFTLTISSLQPEDFATYYCQQSFLTPWTFGGGTKVEIK
DKK1-	907	DIQMTQSPSSLSASVGDRVTITCRASQSISRHLNWYQQKPGKAPKLLIYGATRLQSGVPSRFSGSGS
406		GTDFTLTISSLQPEDFATYYCQQSYSKPYTFGGGTKVEIK
DKK1-	908	DIQMTQSPSSLSASVGDRVTITCRASQSISRYLHWYQQKPGKAPKLLIYAATSLQSGVPSRFSGSGS
407		GTDFTLTISSLQPEDFATYYCQQSYSTPLSFGGGTKVEIK
DKK1-	909	DIQMTQSPSSLSASVGDRVTITCRTSQSIGTYLNWYQQKPGKAPKLLIYDTSNLQGGVPSRFSGSGS
408		GTDFTLAISSLQPEDFATYYCQQSFTSPLTFGGGTKVEIK
DKK1-	910	DIQMTQSPSSLSASVGDRVTITCRASQGIATYLNWYQQKPGKAPKLLIYAASSLQRGVPSRFSGSG
409		SGTDFTLTISSLQPEDFATYYCQQTHSTPLTFGGGTKVEIK
DKK1-	911	DIQMTQSPSSLSASVGDRVTITCRASQNIGGYLNWYQQKPGKAPKLLIYRASRLQSGVPSRFSGSG
410		SGTDFTLTISSLQPEDFATYYCQQSYSTPLLTFGGGTKVEIK
DKK1-	912	DIQMTQSPSSLSASVGDRVTITCRASQYIGNYLNWYQQKPGKAPKLLIYASSTLQRGVPSRFSGSG
411		SGTDFTLTISSLQPEDFATYYCQQTSSTPLTFGGGTKVEIK
DKK1-	913	DIQMTQSPSSLSASVGDRVTITCRTSQSIGTYLNWYQQKPGKSPKLLIYDASILQSGVPSRFSGSGS
412		GTDFTLTISSLQPEDFATYYCQQNYNTPLTFGGGTKVEIK
DKK1-	914	DIQMTQSPSSLSASVGDRVTITCQASQNIGRYLNWYQQKPGKAPKLLIYAASALQGGVPSRFSGSG
413		SGTDFTLTISSLQPEDFATYYCQQSYTPPRTFGGGTKVEIK
DKK1-	915	DIQMTQSPSSLSASVGDRVTITCRASQSISRHLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGS
414		GTDFTLTISSLQPEDFATYYCQQTYRTPLTFGGGTKVEIK
DKK1-	916	DIQMTQSPSSLSASVGDRVTITCRASQSIHNYLNWYQQKPGKAPKLLIYAASSLHDGVPSRFSGSG
415		SGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGGGTKVEIK
DKK1-	917	DIQMAQSPSSLSASVGDRVTITCRASQGIATYLNWYQQKPGKAPKFLIYGASTLRTGVPSRFSGSG
416		SGTDFTLTISSLQPEDFATYYCQQTFTNTPLTFGGGTKVEIK
DKK1-	918	DIQMTQSPSSLSASVGDRVTITCRASQTITKYLNWYQQKPGKAPKLLIYATSNLQTGVPSRFSGSGS
417		GTDFTLTISSLQPEDFATYYCQQSYSAPVTFGGGTKVEIK

TABLE 8
Variable Light Chain CDRs
	SEQ		SEQ	CDR2	SEQ
DKK1	ID	CDR1	ID	Se-	ID	CDR3
Variant	NO	Sequence	NO	quence	NO	Sequence
DKK1-212	2259	KLRNKY		GAS	2522	QSYDDHDRIV
DKK1-213	2260	QPIGPD		SAS	2523	QQSYSTPT
DKK1-214	2261	QSISSY		GRN	2524	QQSYSSPLT
DKK1-215	2262	QDISNY		AAS	2525	QQYYNLPWT
DKK1-216	2263	QDIYQN		AAS	2526	ASRDRSGHGV
DKK1-217	2264	QPIGPD		GAS	2527	QQSYNTPLT
DKK1-218	2265	QSIRRY		GRN	2528	QHSYRSGRA
DKK1-219	2266	QDVSSG		DAS	2529	KQSYTLRT
DKK1-220	2267	QRISRY		GKK	2530	QQSYSPPLT
DKK1-221	2268	QTIGDY		HTS	2531	GQDYTSPRT
DKK1-222	2269	QTIERR		QDF	2532	QQSRT
DKK1-223	2270	QSIRRY		GKK	2533	QQSYSTPS
DKK1-224	2271	QTIERR		GNN	2534	SSWAGSRSGTV
DKK1-225	2272	QNIRSY		ATS	2535	NSRDTSINHPVI
DKK1-226	2273	QDINKY		DNT	2536	QQSYSTPT
DKK1-227	2274	DRLGEKY		DNT	2537	LAWDTRTSGAV
DKK1-228	2275	QSISSY		AKN	2538	QSYGSHSNFVV
DKK1-229	2276	QTIGDY		AAS	2539	QSYDLRYSHV
DKK1-230	2277	QDIKNY		GTS	2540	ASRSSKGNPHVL
DKK1-231	2278	QNIRSY		GKN	2541	QQRARHPHT
DKK1-232	2279	DNLRSYY		QDF	2542	QSYDDHDRIV
DKK1-233	2280	KLAEKY		DNN	2543	LAWDTRTSGAV
DKK1-234	2281	SSVSY		AAS	2544	QQGKTLPLT
DKK1-235	2282	QSISSY		AVT	2545	QQSTILPLT
DKK1-236	2283	QSIRRY		GRN	2546	QQRARHPHT
DKK1-237	2284	QTIERR		DDI	2547	QQGSSLPLT
DKK1-238	2285	SGS		GNN	2548	NSRDTSGNHRV
DKK1-239	2286	QDISNY		QND	2549	NSRDTSGNHLV
DKK1-240	2287	QDIYQN		QND	2550	QQTYSTRT
DKK1-241	2288	QSISSY		GRN	2551	QAWGSSTVI
DKK1-242	2289	QSIRRY		RKS	2552	QQRARHPHT
DKK1-243	2290	QSLFNVRS		DTS	2553	SSRDNSDNHLVV
		QKNY
DKK1-244	2291	QSIRRY		GKN	2554	QQSYSAPLT
DKK1-245	2292	KLAEKY		HTS	2555	QVWDTGTVV
DKK1-246	2293	QDINKY		DNN	2556	QQSYSTPT
DKK1-247	2294	QPIAYF		GKN	2557	ASRSSKGNPHVL
DKK1-248	2295	DHIGKF		AAS	2558	QQSYETPLT
DKK1-249	2296	QSISSY		AVT	2559	QQSTIMPLT
DKK1-250	2297	QSIRRY		RKS	2560	QQSYSTPT
DKK1-251	2298	QSISSY		QND	2561	QQRDTTPWT
DKK1-252	2299	QDIKNY		ENN	2562	QARDRNTYVA
DKK1-253	2300	QYIGTA		DNN	2563	NSRDTSGLHYV
DKK1-254	2301	QSISGY		GQH	2564	QQYDAYPPT
DKK1-255	2302	QSIGRY		GK	2565	QQSYSAPLT
DKK1-256	2303	QDIYQN		EDT	2566	LQYASSPFT
DKK1-257	2304	QPIGPD		AVT	2567	QQSFSVPA
DKK1-258	2305	QPIGPD		GAS	2568	QQSYNTPLT
DKK1-259	2306	QDINKY		DNN	2569	QQSYSTPT
DKK1-260	2307	QRISSF		RKS	2570	SQSTRVPPT
DKK1-261	2308	QNIATY		HTS	2571	SSWAGSRSGTV
DKK1-262	2309	GDLRNKY		GQH	2572	SSGSRSGTV
DKK1-263	2310	QPIGPD		ANT	2573	QQSYSAPYT
DKK1-264	2311	QSIYSF		RKS	2574	QQTATWPFT
DKK1-265	2312	QDINKY		DNT	2575	QQSYSTPT
DKK1-266	2313	DHIGKF		HTS	2576	QQSYKYPLT
DKK1-267	2314	HNINSY		QDF	2577	QQSYSSPLT
DKK1-268	2315	QDINKY		DNT	2578	QQSYSTPT
DKK1-269	2316	QDISNY		GTS	2579	QQGYTLPWT
DKK1-270	2317	QNIGNF		HTS	2580	QQSYSAPLT
DKK1-271	2318	SSVTY		HDN	2581	QQSYDNPLT
DKK1-272	2319	QDIYQN		QND	2582	LQFDHTPFT
DKK1-273	2320	QDIGNY		HTS	2583	QQGYRFPLT
DKK1-274	2321	QPIAYF		GKN	2584	ASRSSKGNPHVL
DKK1-275	2322	DNLRGYY		QDF	2585	QQSYSPLT
DKK1-276	2323	QLVHSTG		GAS	2586	SQSTHVPT
		NTY
DKK1-277	2324	SLRNYY		ENN	2587	STRSRKGNPHVL
DKK1-278	2325	QDIKNY		QAS	2588	QQSYSPPLT
DKK1-279	2326	QDVSSG		DDI	2589	HQRSSYPWT
DKK1-280	2327	QGVRTS		SAS	2590	QAWDNSAVI
DKK1-281	2328	QDINKY		DNT	2591	QQSYSTPT
DKK1-282	2329	KLAEKN		QND	2592	QQTYSTPLT
DKK1-283	2330	QTIGDY		AAS	2593	QQSNSWPYT
DKK1-284	2331	QSISSY		LSS	2594	AQTGTHPTT
DKK1-285	2332	QSLSSY		EDT	2595	HTWHHNPHTGE
						TNH
DKK1-286	2333	QDINKY		DNT	2596	QQSYSTPT
DKK1-287	2334	QDVSSG		GAS	2597	NSRDTSGLHYV
DKK1-288	2335	QTIERR		ENN	2598	QQTYSPPLT
DKK1-289	2336	QDINKY		GAS	2599	QQSYSSPLT
DKK1-290	2337	QSIRSF		GQH	2600	QQYYDWPLT
DKK1-291	2338	QDIYQN		GKN	2601	QQYYSGWT
DKK1-292	2339	QSLSSY		GRN	2602	QNVLSTPYT
DKK1-293	2340	GDLRNKY		GTS	2603	QAWVSSTVV
DKK1-294	2341	QSVDRY		SAS	2604	SQSTHVPLT
DKK1-295	2342	QFIGRY		GRN	2605	QQSYSTPT
DKK1-296	2343	QPIGPD		GKK	2606	QQSYSTPRT
DKK1-297	2344	QTIGDY		GAS	2607	SQSTHVPT
DKK1-298	2345	QTIERR		GQH	2608	QQYHSYPPT
DKK1-299	2346	QSIRRF		GAS	2609	QQSFSVPA
DKK1-300	2347	QDIYQN		GNN	2610	QQSYSAPLT
DKK1-301	2348	QNIATY		HDN	2611	LQDYNYPLT
DKK1-302	2349	QDINKY		GRN	2612	QQTYNVPPT
DKK1-303	2350	QNIGNF		NAK	2613	ASRDRSGHGV
DKK1-304	2351	QTIERR		QND	2614	SSRDRSGNHRV
DKK1-305	2352	QRISSF		QND	2615	QQSYSTPT
DKK1-306	2353	QSISSY		HDN	2616	AQNLEIPRT
DKK1-307	2354	DKLGDKY		HDN	2617	QPSFYFPYT
DKK1-308	2355	QDIYQN		GKN	2618	QQYYSGWT
DKK1-309	2356	QSISSY		GAS	2619	QQYWAFPVT
DKK1-310	2357	QSISGY		AKN	2620	QQSYSSPRT
DKK1-311	2358	QDINKY		DTS	2621	QQSYSTPNT
DKK1-312	2359	QNIRSY		DNN	2622	LQDYNLWT
DKK1-313	2360	QSIREY		ATS	2623	QAWDTSTAV
DKK1-314	2361	GDLGEKY		ATS	2624	QAWASSTVV
DKK1-315	2362	QNIATY		GNN	2625	STRSSKGNPHVL
DKK1-316	2363	KVSTSGYVY		ENN	2626	QQYWAFPVT
DKK1-317	2364	SSVSY		GEN	2627	QQSYSTPWT
DKK1-318	2365	QDVSSG		GS	2628	QQYHSYPPT
DKK1-319	2366	QSVDRY		HTS	2629	QAWDNRAVV
DKK1-320	2367	QSVYSNNE		GNN	2630	QQSYSTPT
DKK1-321	2368	QSISTY		AAS	2631	QQNYIIPWT
DKK1-322	2369	HSISSY		TAS	2632	QQNYNTPFT
DKK1-323	2370	QSIHSY		TAS	2633	QQSFSSPLT
DKK1-324	2371	QSVSRF		AAA	2634	QQSYDTPFT
DKK1-325	2372	QSIGTY		DAS	2635	QQNYNTPLT
DKK1-326	2373	QSIGIH		GAT	2636	QQSYNTPPYT
DKK1-327	2374	QSIRSY		ATS	2637	QQGYTSPLT
DKK1-328	2375	QGIATY		GAS	2638	QQTFTNTPLT
DKK1-329	2376	QSIGSY		AAS	2639	QQSHNIPRT
DKK1-330	2377	QSISRN		GAS	2640	QQGYITPQT
DKK1-331	2378	QSVRTY		RAS	2641	QQSFTTPLT
DKK1-332	2379	QSIGSH		RAS	2642	QQSYSPPIT
DKK1-333	2380	QSISRY		GAS	2643	QQSSSVPWT
DKK1-334	2381	QNIGNY		AAS	2644	QQNYNTPLT
DKK1-335	2382	QSISTY		AAS	2645	QQSYTPPIT
DKK1-336	2383	QNIGSY		AAS	2646	QQSYNTPVT
DKK1-337	2384	QSISRF		GAS	2647	QQSYIPPLT
DKK1-338	2385	ESITTY		TAS	2648	QQNYITPLT
DKK1-339	2386	QSISTY		AAS	2649	QQSYNSIT
DKK1-340	2387	QSIGSN		ATS	2650	QQSYRIPRT
DKK1-341	2388	QSISRY		AAS	2651	QQSYSTPTT
DKK1-342	2389	QYIGTY		AAS	2652	QQSYSDLT
DKK1-343	2390	ESISRN		AAS	2653	QQSYSGPPYT
DKK1-344	2391	QSISTY		AAS	2654	QQNYIIPWT
DKK1-345	2392	QSVSNF		GAS	2655	QQSYSFPFS
DKK1-346	2393	RNIRTY		RAS	2656	QQSYKTPVT
DKK1-347	2394	QSIGNF		RAS	2657	QQSYNTPIT
DKK1-348	2395	QSIRSY		GAT	2658	QQSYSTLPFT
DKK1-349	2396	QSIRTY		GAV	2659	QQRDT
DKK1-350	2397	QNIYTY		LAS	2660	QQSYSTRFT
DKK1-351	2398	QSISRY		GSS	2661	QQSYSSPT
DKK1-352	2399	QNIGRY		SAS	2662	QQTYSPPLT
DKK1-353	2400	QTISAY		GAS	2663	QQSYSGLT
DKK1-354	2401	QSIRGY		STS	2664	QQNYNTPLT
DKK1-355	2402	QSVSYY		GSS	2665	QQTYSSPVT
DKK1-356	2403	QPISSY		SAS	2666	QQGYSAPLT
DKK1-357	2404	QSIGKY		GAS	2667	QQTYSTPLT
DKK1-358	2405	QSIGAY		GTS	2668	QQSYGTLIT
DKK1-359	2406	QTISTF		GAS	2669	QQSYSTPLT
DKK1-360	2407	QSIGRY		AVS	2670	QQSYSTPS
DKK1-361	2408	QSISNY		GAS	2671	QQSYSLPLT
DKK1-362	2409	QTISRS		GAS	2672	QQSFTTPYT
DKK1-363	2410	QSISSY		AAS	2673	QQNYRSPLT
DKK1-364	2411	RSIGTY		AAS	2674	QQNYITPLT
DKK1-365	2412	QNINRY		ASS	2675	QQSYSSPIT
DKK1-366	2413	QSVSSY		ATS	2676	HQTYSTPRT
DKK1-367	2414	QSIGIH		GAT	2677	QQSYNTPPYT
DKK1-368	2415	RSISTY		EVS	2678	QQNYITPLT
DKK1-369	2416	QSISRY		AAS	2679	QQGYSSPLT
DKK1-370	2417	QSISNF		GTS	2680	QQSYSIPFT
DKK1-371	2418	QGISFY		AAS	2681	QQSYSTPQIT
DKK1-372	2419	QNIKTY		GAS	2682	LQTYSVPLT
DKK1-373	2420	QYISNY		GAS	2683	QQTYSLPLT
DKK1-374	2421	QTISTF		GAS	2684	QQSYSTPLT
DKK1-375	2422	QSISRF		GAS	2685	QQSYKTPRT
DKK1-376	2423	ESIDNY		GAT	2686	QQNYNIPFT
DKK1-377	2424	QSISNF		TAS	2687	QQSYRVPRT
DKK1-378	2425	QSIGTN		AAS	2688	QQSYSIPLT
DKK1-379	2426	QTITRY		AAT	2689	QQSYSTPET
DKK1-380	2427	QSIGNF		DAS	2690	QQSYSIPPT
DKK1-381	2428	HSISRY		GAS	2691	QQSYSTHT
DKK1-382	2429	QGISFY		GAS	2692	QQSYSPPLT
DKK1-383	2430	QSVSNY		GAS	2693	QQSYVTPPT
DKK1-384	2431	QSIGSF		AAF	2694	QQTYSPPFT
DKK1-385	2432	QSITRH		AAS	2695	QQSYSTPGT
DKK1-386	2433	QRISRY		GAS	2696	QQSYRTPIT
DKK1-387	2434	QYIGNY		AVS	2697	QQSFSAPYT
DKK1-388	2435	QYISTF		SAS	2698	QQSYSPLT
DKK1-389	2436	RSISRY		GAS	2699	QQSYTPPRT
DKK1-390	2437	QSISRS		GAS	2700	QQSFTIPWT
DKK1-391	2438	QSITSY		AAS	2701	QQSYNTPVT
DKK1-392	2439	QNIAGY		AAS	2702	QQSSSTPIT
DKK1-393	2440	QTIRTY		ATS	2703	QQSYRPPLT
DKK1-394	2441	QSIGIH		GAT	2704	QQSYNTPPYT
DKK1-395	2442	QSISTY		GAS	2705	QQTYSAPRT
DKK1-396	2443	QSIGRY		GAS	2706	QQSYRTPLT
DKK1-397	2444	HTISRY		AAS	2707	QQSFTAPDT
DKK1-398	2445	QSISRY		TTS	2708	QQSYSDLT
DKK1-399	2446	QRINTY		GAF	2709	QQSYRVPRT
DKK1-400	2447	QSINHY		GAS	2710	QQSYSLPRT
DKK1-401	2448	QTIGRY		ATS	2711	QQTYSTPYT
DKK1-402	2449	QSIGEY		AAS	2712	QQNYRSPLT
DKK1-403	2450	QSIYRY		AAT	2713	QQSYSPPLT
DKK1-404	2451	QNIGRY		EVS	2714	QQSYRTPGT
DKK1-405	2452	QSIRNY		AAT	2715	QQSFLTPWT
DKK1-406	2453	QSISRH		GAT	2716	QQSYSKPYT
DKK1-407	2454	QSISRY		AAT	2717	QQSYSTPLS
DKK1-408	2455	QSIGTY		DTS	2718	QQSFTSPLT
DKK1-409	2456	QGIATY		AAS	2719	QQTHSTPLT
DKK1-410	2457	QNIGGY		RAS	2720	QQSYSTPLLT
DKK1-411	2458	QYIGNY		ASS	2721	QQTSSTPLT
DKK1-412	2459	QSIGTY		DAS	2722	QQNYNTPLT
DKK1-413	2460	QNIGRY		AAS	2723	QQSYTPPRT
DKK1-414	2461	QSISRH		GAS	2724	QQTYRTPLT
DKK1-415	2462	QSIHNY		AAS	2725	QQSYSTPYT
DKK1-416	2463	QGIATY		GAS	2726	QQTFTNTPLT
DKK1-417	2464	QTITKY		ATS	2727	QQSYSAPVT

Example 5: DKK1 Variants

In this experiment, the antibodies were tested for their yield, SPR affinity, and enrichment from eluted phage (Tables 9-10).

Variable heavy chain and light chain domains of anti-DKK1 antibodies were reformatted to IgG2, or VHH-Fc based on IgG2 Fc for nanobody leads. Reformatted leads were then DNA back-translated, synthesized, and cloned into mammalian expression vector pTwist CMV BG WPRE Neo. Light chain variable domains were reformatted into kappa and lambda frameworks accordingly. Clonal genes were delivered as purified plasmid DNA ready for transient transfection in HEK Expi293 cells (Thermo Fisher Scientific). Cultures in a volume of 1.2 mL were grown to four days, harvested, and purified using Protein A resin (PhyNexus) on the Hamilton Microlab STAR platform into 43 mM Citrate 148 mM HEPES, pH 6. 1.2 ml. Yield was calculated by measuring absorbance at 280 nm on Lunatic instrumentation (UNCLE). Results are depicted in FIG. 10A.

SPR experiments were performed on a Carterra LSA SPR biosensor equipped with a HC30M chip at 25° C. in HBS-TE. Antibodies were diluted to 10 μg/mL and amine-coupled to the sensor chip by EDC/NHS activation, followed by ethanolamine HCl quenching. Increasing concentrations of analyte were flowed over the sensor chip in HBS-TE with 0.5 mg/mL BSA with 5-minute association and 15-minute dissociation. Following each injection cycle the surface was regenerated with 2×30-second injections of IgG elution buffer (Thermo). Data were analyzed in Carterra's Kinetics Tool software with 1:1 binding model. Results are depicted in FIGS. 10B-C and 11A-B.

Long-read NGS sequencing was performed by submitting PCR amplicons of DNA corresponding to the scFv or VHH of each clone to Loop Genomics for processing. Returned contiguous FASTQ files were processed by the AIRR Python API to extract and annotate antibody sequences. “NGS enrichment” refers to the number of instances that specific antibody appeared in round 4 sequencing. “Cluster enrichment” refers to the number of instances that the exact antibody appeared in round 4 or a variant within a Levenshtein distance of 3 appeared in round 4 sequencing. “Cluster rank” lists the antibody rank order of the antibody belonging to the largest size cluster enrichment to the lowest. Results can be seen in FIGS. 9A-C

TABLE 9
Antibody Yield, SPR Affinity, and Enrichment of Antibodies
DKK1	1.2 ml	ka (M−1	kd	KD	Rmax	NGS	Cluster	Cluster
Variant	yield (ug)	s−1)	(s−1)	(M)	(RU)	Enrichment	Enrichment	Rank
DKK1-1	73.0	—	—	—	—	—	—	—
DKK1-2	166.0	—	—	—	—	—	—	—
DKK1-3	56.0	—	—	—	—	—	—	—
DKK1-4	98.0	—	—	—	—	—	—	—
DKK1-5	147.0	—	—	—	—	—	—	—
DKK1-6	96.0	2.24E+05	8.60E−04	3.84E−09	90.1	48	53	5
DKK1-7	131.0	—	—	—	—	—	—	—
DKK1-8	232.0	—	—	—	—	3	—	—
DKK1-9	n/a	n/a	n/a	n/a	n/a	3	—	—
DKK1-10	105.0	4.51E+05	4.02E−04	8.92E−10	32.5	16	17	41
DKK1-11	56.0	—	—	—	—	46	49	6
DKK1-12	82.0	—	—	—	—	44	53	4
DKK1-13	267.0	—	—	—	—	53	62	1
DKK1-14	119.0	—	—	—	—	2	—	—
DKK1-15	117.0	—	—	—	—	2	—	—
DKK1-16	243.0	—	—	—	—	2	—	—
DKK1-17	51.0	—	—	—	—	2	—	—
DKK1-18	131.0	3.76E+04	1.29E−04	3.42E−09	18.5	—	—	—
DKK1-19	96.0	—	—	—	—	5	—	—
DKK1-20	5.0	—	—	—	—	—	—	—
DKK1-21	307.0	—	—	—	—	1	—	—
DKK1-22	211.0	—	—	—	—	1	—	—
DKK1-23	89.0	—	—	—	—	—	—	—
DKK1-24	40.0	4.21E+05	3.00E−04	7.13E−10	126.5	1	—	—
DKK1-25	129.0	—	—	—	—	—	—	—
DKK1-26	77.0	8.82E+05	1.00E−06	1.13E−12	18.8	—	—	—
DKK1-27	192.0	—	—	—	—	33	40	13
DKK1-28	84.0	6.27E+05	1.00E−05	1.59E−11	68.7	2	—	—
DKK1-29	47.0	—	—	—	—	—	—	—
DKK1-30	37.0	4.15E+05	3.03E−04	7.29E−10	95.1	3	—	—
DKK1-31	42.0	—	—	—	—	9	17	40
DKK1-32	157.0	—	—	—	—	8	—	—
DKK1-33	68.0	—	—	—	—	12	13	84
DKK1-34	180.0	3.46E+05	6.04E−04	1.75E−09	163.7	3	—	—
DKK1-35	89.0	—	—	—	—	4	12	92
DKK1-36	370.0	—	—	—	—	7	13	68
DKK1-37	260.0	9.13E+04	9.16E−05	1.00E−09	42.5	24	30	15
DKK1-38	61.0	—	—	—	—	—	—	—
DKK1-39	28.0	—	—	—	—	—	—	—
DKK1-40	7.0	1.10E+05	6.43E−04	5.86E−09	47.3	—	—	—
DKK1-41	140.4	1.02E+05	8.28E−04	8.13E−09	224.6	9	17	40
DKK1-42	124.0	8.91E+04	2.59E−03	2.91E−08	81.1	3	17	39
DKK1-43	147.4	2.01E+05	3.93E−03	1.96E−08	230.7	10	17	38
DKK1-44	110.0	1.78E+05	1.24E−04	6.93E−10	173.7	13	17	37
DKK1-45	142.7	6.63E+04	1.72E−03	2.60E−08	218.5	12	18	36
DKK1-46	124.0	1.27E+05	2.90E−03	2.27E−08	186.7	13	18	35
DKK1-47	88.9	2.73E+05	6.68E−03	2.45E−08	161.5	11	19	34
DKK1-48	72.5	9.94E+04	3.06E−03	3.08E−08	202.1	6	19	33
DKK1-49	28.1	4.11E+04	3.18E−03	7.75E−08	88.4	16	19	32
DKK1-50	138.1	9.14E+04	1.74E−03	1.90E−08	80.7	12	19	31
DKK1-51	107.6	4.91E+04	4.25E−03	8.66E−08	161.0	18	19	30
DKK1-52	152.1	8.29E+04	2.99E−03	3.60E−08	120.4	15	20	29
DKK1-53	154.4	8.72E+04	3.54E−03	4.05E−08	187.4	15	20	28
DKK1-54	152.1	1.06E+05	3.72E−04	3.51E−09	486.9	19	20	27
DKK1-55	131.0	2.29E+05	8.89E−04	3.89E−09	535.3	16	21	26
DKK1-56	163.8	4.34E+04	2.05E−03	4.72E−08	114.9	15	22	25
DKK1-57	128.7	9.24E+04	3.06E−03	3.31E−08	232.1	11	22	24
DKK1-58	79.6	9.61E+04	3.31E−03	3.44E−08	249.1	18	22	23
DKK1-59	67.9	1.29E+05	1.40E−02	1.08E−07	230.6	9	23	22
DKK1-60	42.1	1.02E+05	1.79E−03	1.75E−08	213.3	22	25	21
DKK1-61	32.8	7.00E+04	4.39E−03	6.26E−08	170.1	13	25	20
DKK1-62	65.5	1.26E+05	2.19E−03	1.74E−08	93.5	20	26	19
DKK1-63	28.1	n.b.	n.b.	n.b.	n.b.	24	27	18
DKK1-64	49.1	n.b.	n.b.	n.b.	n.b.	22	28	17
DKK1-65	124.0	3.61E+04	2.26E−03	6.27E−08	133.1	23	28	16
DKK1-66	49.1	1.23E+05	4.92E−03	3.99E−08	4450.4	24	30	15
DKK1-67	81.9	2.17E+05	1.47E−03	6.77E−09	180.3	29	34	14
DKK1-68	58.5	5.61E+04	2.42E−03	4.31E−08	77.9	33	40	13
DKK1-69	51.5	1.08E+05	7.22E−04	6.68E−09	237.0	19	40	12
DKK1-70	37.4	2.05E+05	2.14E−03	1.04E−08	333.0	29	42	11
DKK1-71	42.1	1.13E+05	3.45E−03	3.06E−08	292.4	29	42	10
DKK1-72	100.6	2.06E+05	3.62E−03	1.76E−08	133.7	35	42	9
DKK1-73	51.5	1.03E+05	1.77E−03	1.71E−08	45.7	41	44	8
DKK1-74	63.2	1.65E+05	4.31E−03	2.61E−08	205.2	34	16	7
DKK1-75	74.9	1.05E+06	8.32E−03	7.90E−09	118.5	46	49	6
DKK1-76	51.5	1.23E+05	2.03E−03	1.66E−08	240.7	48	53	5
DKK1-77	28.1	1.26E+05	1.26E−03	1.00E−08	197.8	44	53	4
DKK1-78	39.8	2.09E+05	3.52E−03	1.68E−08	290.0	43	54	3
DKK1-79	53.8	1.58E+05	1.19E−03	7.55E−09	148.7	50	55	2
DKK1-80	81.9	4.40E+05	7.60E−05	1.73E−10	190.9	53	62	1
DKK1-81	79.6					—	—	—
DKK1-82	7.0					—	—	—
DKK1-83	98.3					—	—	—
DKK1-84	67.9					—	—	—
DKK1-85	4.7					—	—	—
DKK1-86	16.4					—	—	—
DKK1-87	149.8					—	—	—
DKK1-88	238.7	5.94E+04	1.81E−03	3.06E−08	637.9	5	—	—
DKK1-89	126.4	5.09E+04	4.35E−03	8.55E−08	405.5	—	—	—
DKK1-90	322.9	3.73E+04	3.07E−03	8.23E−08	359.2	—	—	—
DKK1-91	114.7	8.07E+04	1.03E−02	1.27E−07	439.7	—	—	—
DKK1-92	152.1	9.36E+04	3.62E−03	3.87E−08	142.0	—	—	—
DKK1-93	117.0	6.25E+04	4.13E−04	6.62E−09	422.2	—	—	—
DKK1-94	98.3	7.24E+04	2.01E−03	2.78E−08	418.1	—	—	—
DKK1-95	133.4	9.41E+04	2.69E−03	2.85E−08	491.0	—	—	—
DKK1-96	163.8	6.03E+04	1.54E−03	2.54E−08	661.4	—	—	—
DKK1-97	156.8	6.57E+04	1.00E−05	1.52E−10	411.3	—	—	—
DKK1-98	154.4	1.34E+05	2.02E−01	1.50E−06	83.7	—	—	—

TABLE 10
Antibody Yield, SPR Affinity, and Enrichment of Antibodies
						100 nM	EC50
TSLP		kon	koff	KD	Rmax	FACS (MFI	FACS
Variant	yield	(M−1 s−1)	(s−1)	(M)	(RU)	Ratio)	(nM)
DKK1-99	154.44	1.34E+05	2.02E−01	1.50E−06	83.7	1.70
DKK1-100	156.78	6.57E+04	1.00E−05	1.52E−10	411.3	5.30
DKK1-101	163.8	6.03E+04	1.54E−03	2.54E−08	661.4	16.90
DKK1-102	133.38	9.41E+04	2.69E−03	2.85E−08	491.0	8.00
DKK1-103	98.28	7.24E+04	2.01E−03	2.78E−08	418.1	9.10
DKK1-104	117	6.25E+04	4.13E−04	6.62E−09	422.2	6.90
DKK1-105	152.1	9.36E+04	3.62E−03	3.87E−08	142.0	2.10
DKK1-106	114.66	8.07E+04	1.03E−02	1.27E−07	439.7	4.20
DKK1-107	322.92	3.73E+04	3.07E−03	8.23E−08	359.2	1.30
DKK1-108	126.36	5.09E+04	4.35E−03	8.55E−08	405.5	1.10
DKK1-109	238.68	5.94E+04	1.81E−03	3.06E−08	637.9	15.50
DKK1-110	149.76					6.50
DKK1-111	16.38
DKK1-112	4.68
DKK1-113	67.86					2.20
DKK1-114	98.28					4.40
DKK1-115	7.02
DKK1-116	79.56					3.50
DKK1-117	81.9	4.40E+05	7.60E−05	1.73E−10	190.9	45.10
DKK1-118	53.82	1.58E+05	1.19E−03	7.55E−09	148.7
DKK1-119	39.78	2.09E+05	3.52E−03	1.68E−08	290.0
DKK1-120	28.08	1.26E+05	1.26E−03	1.00E−08	197.8
DKK1-121	51.48	1.23E+05	2.03E−03	1.66E−08	240.7
DKK1-122	74.88	1.05E+06	8.32E−03	7.90E−09	118.5
DKK1-123	63.18	1.65E+05	4.31E−03	2.61E−08	205.2
DKK1-124	51.48	1.03E+05	1.77E−03	1.71E−08	45.7
DKK1-125	100.62	2.06E+05	3.62E−03	1.76E−08	133.7
DKK1-126	42.12	1.13E+05	3.45E−03	3.06E−08	292.4
DKK1-127	37.44	2.05E+05	2.14E−03	1.04E−08	333.0
DKK1-128	51.48	1.08E+05	7.22E−04	6.68E−09	237.0
DKK1-129	58.5	5.61E+04	2.42E−03	4.31E−08	77.9
DKK1-130	81.9	2.17E+05	1.47E−03	6.77E−09	180.3	30.00
DKK1-131	49.14	1.23E+05	4.92E−03	3.99E−08	4450.4
DKK1-132	124.02	3.61E+04	2.26E−03	6.27E−08	133.1
DKK1-133	49.14	n.b.	n.b.	n.b.	n.b.
DKK1-134	28.08	n.b.	n.b.	n.b.	n.b.
DKK1-135	65.52	1.26E+05	2.19E−03	1.74E−08	93.5
DKK1-136	32.76	7.00E+04	4.39E−03	6.26E−08	170.1
DKK1-137	42.12	1.02E+05	1.79E−03	1.75E−08	213.3
DKK1-138	67.86	1.29E+05	1.40E−02	1.08E−07	230.6
DKK1-139	79.56	9.61E+04	3.31E−03	3.44E−08	249.1
DKK1-140	128.7	9.24E+04	3.06E−03	3.31E−08	232.1
DKK1-141	163.8	4.34E+04	2.05E−03	4.72E−08	114.9
DKK1-142	131.04	2.29E+05	8.89E−04	3.89E−09	535.3	4.20
DKK1-143	152.1	1.06E+05	3.72E−04	3.51E−09	486.9	22.40
DKK1-144	154.44	8.72E+04	3.54E−03	4.05E−08	187.4
DKK1-145	152.1	8.29E+04	2.99E−03	3.60E−08	120.4
DKK1-146	107.64	4.91E+04	4.25E−03	8.66E−08	161.0
DKK1-147	138.06	9.14E+04	1.74E−03	1.90E−08	80.7
DKK1-148	28.08	4.11E+04	3.18E−03	7.75E−08	88.4
DKK1-149	72.54	9.94E+04	3.06E−03	3.08E−08	202.1
DKK1-150	88.92	2.73E+05	6.68E−03	2.45E−08	161.5
DKK1-151	124.02	1.27E+05	2.90E−03	2.27E−08	186.7
DKK1-152	142.74	6.63E+04	1.72E−03	2.60E−08	218.5
DKK1-153	109.98	1.78E+05	1.24E−04	6.93E−10	173.7	7.20
DKK1-154	147.42	2.01E+05	3.93E−03	1.96E−08	230.7
DKK1-155	124.02	8.91E+04	2.59E−03	2.91E−08	81.1
DKK1-156	140.4	1.02E+05	8.28E−04	8.13E−09	224.6
DKK1-157	180.18	1.23E+04	3.73E−03	3.03E−07	196.2
DKK1-158	58.5	4.77E+05	1.01E−02	2.12E−08	175.5
DKK1-159	72.54	8.09E+04	1.93E−03	2.39E−08	266.8
DKK1-160	93.6	1.02E+05	3.08E−04	3.03E−09	295.9
DKK1-161	58.5	2.61E+05	4.68E−03	1.79E−08	231.9
DKK1-162	105.3	6.41E+04	2.95E−03	4.60E−08	224.6
DKK1-163	44.46	1.38E+02	1.77E−02	1.28E−04	16396.4
DKK1-164	168.48	2.00E+04	2.14E−03	1.07E−07	293.9
DKK1-165	163.8	1.55E+05	2.83E−03	1.83E−08	70.4
DKK1-166	152.1	9.84E+04	2.58E−03	2.62E−08	321.8
DKK1-167	39.78	1.65E+04	2.83E−02	1.71E−06	950.7
DKK1-168	74.88	1.88E+05	7.97E−03	4.23E−08	165.5
DKK1-169	140.4	7.50E+04	4.68E−03	6.23E−08	261.2
DKK1-170	128.7	n.b.	n.b.	n.b.	n.b.
DKK1-171	18.72	5.83E+04	2.06E−03	3.54E−08	67.4
DKK1-172	86.58	2.29E+04	3.05E−03	1.33E−07	264.4
DKK1-173	147.42	1.59E+05	2.62E−03	1.65E−08	217.9
DKK1-174	42.12	9.10E+04	3.53E−03	3.88E−08	250.0
DKK1-175	65.52	1.74E+05	3.45E−03	1.98E−08	129.8
DKK1-176	51.48	6.53E+04	4.68E−03	7.17E−08	154.3
DKK1-177	100.62	5.92E+04	1.70E−02	2.87E−07	178.9
DKK1-178	156.78	1.93E+05	1.27E−03	6.61E−09	277.4	7.00
DKK1-179	77.22	6.18E+04	5.17E−03	8.36E−08	213.3
DKK1-180	42.12	6.27E+04	3.49E−03	5.56E−08	164.6
DKK1-181	35.1	1.66E+05	7.46E−03	4.48E−08	181.8
DKK1-182	65.52	3.44E+05	3.24E−03	9.40E−09	231.3
DKK1-183	35.1	7.32E+04	2.53E−03	3.46E−08	41.7
DKK1-184	65.52	1.12E+05	2.35E−04	2.11E−09	386.0	13.80
DKK1-185	49.14	1.56E+05	5.80E−03	3.73E−08	245.3
DKK1-186	67.86	9.26E+04	4.76E−03	5.14E−08	194.5
DKK1-187	86.58	2.06E+05	3.44E−03	1.67E−08	168.1
DKK1-188	49.14	1.37E+05	1.49E−03	1.08E−08	435.0
DKK1-189	49.14	2.64E+05	9.14E−03	3.47E−08	231.2
DKK1-190	65.52	8.99E+04	8.75E−04	9.74E−09	149.6
DKK1-191	70.2	1.10E+05	5.76E−05	5.26E−10	378.2	4.40
DKK1-192	91.26	4.78E+04	1.76E−03	3.68E−08	167.7
DKK1-193	74.88	2.03E+05	7.54E−03	3.71E−08	183.7
DKK1-194	79.56	n.b.	n.b.	n.b.	n.b.
DKK1-195	70.2	4.34E+04	3.05E−03	7.04E−08	271.6
DKK1-196	149.76	9.80E+04	2.01E−03	2.05E−08	438.6
DKK1-197	124.02	2.81E+05	2.41E−03	8.58E−09	112.5
DKK1-198	86.58	1.15E+05	3.42E−03	2.97E−08	228.1
DKK1-199	63.18	7.56E+04	5.46E−03	7.23E−08	200.8
DKK1-200	133.38	4.66E+04	1.63E−03	3.49E−08	112.0
DKK1-201	58.5	1.45E+05	9.81E−03	6.74E−08	141.5
DKK1-202	58.5	1.57E+05	1.09E−02	6.92E−08	248.8
DKK1-203	112.32	6.07E+04	6.57E−04	1.08E−08	317.8
DKK1-204	114.66	8.36E+04	1.95E−03	2.33E−08	280.2
DKK1-205	105.3	n.b.	n.b.	n.b.	n.b.
DKK1-206	147.42	n.b.	n.b.	n.b.	n.b.
DKK1-207	147.42	3.42E+05	2.46E−03	7.19E−09	158.5
DKK1-208	154.44	9.36E+04	2.24E−04	2.39E−09	310.2
DKK1-209	159.12	1.82E+05	1.03E−03	5.64E−09	260.8	18.00
DKK1-210	128.7	n.b.	n.b.	n.b.	n.b.
DKK1-211	91.26	n.b.	n.b.	n.b.	n.b.
DKK1-212	9.36
DKK1-213	0					0.70
DKK1-214	7.02					0.20
DKK1-215	28.08					0.20
DKK1-216	7.02					0.10
DKK1-217	44.46					0.20
DKK1-218	7.02
DKK1-219	7.02					0.60
DKK1-220	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-221	18.72	n.b.	n.b.	n.b.	n.b.	1.00
DKK1-222	18.72	n.b.	n.b.	n.b.	n.b.	1.60
DKK1-223	14.04	n.b.	n.b.	n.b.	n.b.	2.20
DKK1-224	21.06
DKK1-225	16.38					1.20
DKK1-226	14.04	1.25E+05	8.99E−02	7.17E−07	42.1	2.60
DKK1-227	25.74					0.40
DKK1-228	11.7	4.50E+05	1.06E−02	2.35E−08	94.0	1.10
DKK1-229	25.74	n.b.	n.b.	n.b.	n.b.	1.50
DKK1-230	18.72					0.20
DKK1-231	4.68
DKK1-232	56.16					36.50
DKK1-233	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-234	25.74					1.30
DKK1-235	35.1					6.50
DKK1-236	9.36					0.10
DKK1-237	21.06	n.b.	n.b.	n.b.	n.b.	4.10
DKK1-238	14.04	n.b.	n.b.	n.b.	n.b.	0.30
DKK1-239	11.7					0.70
DKK1-240	4.68
DKK1-241	102.96					0.70
DKK1-242	4.68
DKK1-243	35.1					10.30
DKK1-244	7.02					2.90
DKK1-245	11.7	n.b.	n.b.	n.b.	n.b.	319.70
DKK1-246	4.68					0.30
DKK1-247	4.68	1.83E+04	8.02E−03	4.39E−07	58.1	0.20
DKK1-248	112.32	3.73E+05	4.63E−03	1.24E−08	541.0	26.00
DKK1-249	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-250	9.36					0.70
DKK1-251	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-252	4.68
DKK1-253	18.72	n.b.	n.b.	n.b.	n.b.	0.20
DKK1-254	53.82	1.39E+05	2.36E−02	1.70E−07	256.8	2.50
DKK1-255	2.34
DKK1-256	49.14	n.b.	n.b.	n.b.	n.b.	0.10
DKK1-257	11.7	n.b.	n.b.	n.b.	n.b.	0.10
DKK1-258
DKK1-259	0
DKK1-260	16.38	n.b.	n.b.	n.b.	n.b.
DKK1-261	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-262	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-263	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-264	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-265	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-266	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-267	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-268	42.12	n.b.	n.b.	n.b.	n.b.
DKK1-269	14.04	n.b.	n.b.	n.b.	n.b.
DKK1-270	25.74	n.b.	n.b.	n.b.	n.b.
DKK1-271	21.06	n.b.	n.b.	n.b.	n.b.
DKK1-272	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-273	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-274	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-275	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-276	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-277	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-278	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-279	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-280	21.06	n.b.	n.b.	n.b.	n.b.
DKK1-281	16.38	n.b.	n.b.	n.b.	n.b.
DKK1-282	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-283	25.74	1.30E+05	3.35E−03	2.58E−08	355.6
DKK1-284	51.48	n.b.	n.b.	n.b.	n.b.
DKK1-285	49.14	n.b.	n.b.	n.b.	n.b.
DKK1-286	16.38	n.b.	n.b.	n.b.	n.b.
DKK1-287	14.04	n.b.	n.b.	n.b.	n.b.
DKK1-288	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-289	70.2	n.b.	n.b.	n.b.	n.b.
DKK1-290	35.1	9.25E+04	2.42E−03	2.61E−08	123.8
DKK1-291	25.74	n.b.	n.b.	n.b.	n.b.
DKK1-292	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-293	28.08	n.b.	n.b.	n.b.	n.b.
DKK1-294	23.4	2.23E+04	4.74E−03	2.12E−07	135.9
DKK1-295	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-296	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-297		n.b.	n.b.	n.b.	n.b.
DKK1-298		n.b.	n.b.	n.b.	n.b.
DKK1-299		n.b.	n.b.	n.b.	n.b.
DKK1-300		n.b.	n.b.	n.b.	n.b.
DKK1-301		n.b.	n.b.	n.b.	n.b.
DKK1-302	21.06	n.b.	n.b.	n.b.	n.b.
DKK1-303	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-304	14.04	n.b.	n.b.	n.b.	n.b.
DKK1-305	53.82	n.b.	n.b.	n.b.	n.b.
DKK1-306		n.b.	n.b.	n.b.	n.b.
DKK1-307		n.b.	n.b.	n.b.	n.b.
DKK1-308		n.b.	n.b.	n.b.	n.b.
DKK1-309		n.b.	n.b.	n.b.	n.b.
DKK1-310		n.b.	n.b.	n.b.	n.b.
DKK1-311		n.b.	n.b.	n.b.	n.b.
DKK1-312	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-313		n.b.	n.b.	n.b.	n.b.
DKK1-314	32.76	n.b.	n.b.	n.b.	n.b.
DKK1-315	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-316	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-317	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-318	32.76	n.b.	n.b.	n.b.	n.b.
DKK1-319	23.4	n.b.	n.b.	n.b.	n.b.
DKK1-320	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-321	63.18	3.72E+05	3.04E−03	8.17E−09	154.1	92.00
DKK1-322	74.88	4.82E+05	8.51E−03	1.77E−08	387.2	38.70
DKK1-323	56.16	n.b.	n.b.	n.b.	n.b.	3.40
DKK1-324	79.56	n.b.	n.b.	n.b.	n.b.	0.80
DKK1-325	21.06	5.04E+05	4.22E−03	8.39E−09	93.7	17.90
DKK1-326	58.5	3.34E+05	2.98E−03	8.92E−09	58.8
DKK1-327	32.76	4.66E+05	4.80E−03	1.03E−08	75.1
DKK1-328	21.06	n.b.	n.b.	n.b.	n.b.
DKK1-329	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-330	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-331	16.38	n.b.	n.b.	n.b.	n.b.
DKK1-332	28.08	1.55E+05	6.92E−04	4.48E−09	619.7	13.30
DKK1-333	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-334	16.38	1.31E+05	7.03E−03	5.36E−08	144.8
DKK1-335	70.2	1.01E+05	1.37E−03	1.36E−08	48.7
DKK1-336	44.46	5.67E+04	1.75E−01	3.10E−06	76.9
DKK1-337	30.42	4.83E+05	1.74E−03	3.61E−09	314.7	3.30
DKK1-338	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-339	35.1	4.23E+05	4.81E−03	1.14E−08	60.1
DKK1-340	42.12	n.b.	n.b.	n.b.	n.b.
DKK1-341	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-342	9.36	4.85E+05	1.98E−03	4.09E−09	72.2	1.90
DKK1-343	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-344	23.4	n.b.	n.b.	n.b.	n.b.
DKK1-345	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-346	4.68	3.28E+06	4.85E−02	1.48E−08	51.5
DKK1-347	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-348	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-349	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-350	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-351	16.38	n.b.	n.b.	n.b.	n.b.
DKK1-352	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-353	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-354	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-355	11.7	2.26E+05	1.31E−02	5.79E−08	127.4
DKK1-356	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-357	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-358	30.42	4.66E+04	2.22E−03	4.77E−08	94.2
DKK1-359	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-360	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-361	7.02	3.93E+05	5.20E−03	1.32E−08	53.5
DKK1-362	16.38	n.b.	n.b.	n.b.	n.b.
DKK1-363	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-364	7.02	2.36E+05	3.16E−03	1.34E−08	47.4
DKK1-365	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-366	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-367	14.04	n.b.	n.b.	n.b.	n.b.
DKK1-368	7.02	4.23E+03	2.53E−02	5.97E−06	2264.0
DKK1-369	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-370	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-371	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-372	7.02	5.47E+04	3.29E−03	6.01E−08	71.5
DKK1-373	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-374	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-375	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-376	9.36	3.77E+05	3.05E−03	8.08E−09	286.0	4.00
DKK1-377	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-378	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-379	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-380	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-381	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-382	46.8	4.16E+05	1.10E−03	2.65E−09	301.7	7.10
DKK1-383	63.18	n.b.	n.b.	n.b.	n.b.
DKK1-384	14.04	n.b.	n.b.	n.b.	n.b.
DKK1-385	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-386	25.74	n.b.	n.b.	n.b.	n.b.
DKK1-387	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-388	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-389	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-390	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-391	4.68	1.25E+06	4.17E−02	3.34E−08	86.0
DKK1-392	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-393	16.38	3.34E+05	1.97E−03	5.92E−09	190.4	15.90
DKK1-394	7.02	n.b.	n.b.	n.b.	n.b.
DKK1-395	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-396	37.44	6.22E+05	9.97E−03	1.60E−08	121.9
DKK1-397	63.18	n.b.	n.b.	n.b.	n.b.
DKK1-398	39.78	n.b.	n.b.	n.b.	n.b.
DKK1-399	18.72	n.b.	n.b.	n.b.	n.b.
DKK1-400	51.48	n.b.	n.b.	n.b.	n.b.
DKK1-401	39.78	n.b.	n.b.	n.b.	n.b.
DKK1-402	39.78	n.b.	n.b.	n.b.	n.b.
DKK1-403	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-404	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-405	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-406	9.36	n.b.	n.b.	n.b.	n.b.
DKK1-407	35.1	n.b.	n.b.	n.b.	n.b.
DKK1-408	32.76	2.04E+05	3.91E−03	1.91E−08	405.1
DKK1-409	25.74	n.b.	n.b.	n.b.	n.b.
DKK1-410	4.68	n.b.	n.b.	n.b.	n.b.
DKK1-411	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-412	32.76	n.b.	n.b.	n.b.	n.b.
DKK1-413	2.34	n.b.	n.b.	n.b.	n.b.
DKK1-414	18.72	9.75E+04	1.82E−03	1.87E−08	126.3
DKK1-415	14.04	n.b.	n.b.	n.b.	n.b.
DKK1-416	11.7	n.b.	n.b.	n.b.	n.b.
DKK1-417	28.08	n.b.	n.b.	n.b.	n.b.

Example 5: Panning and Screening for Identification of Antibodies for DKK1

This example describes identification of antibodies for DKK1. Phage displayed libraries were panned for biding to DKK1. Panning was performed as shown in FIG. 21.

Carterra kinetics results showed that VHH-Fc hits bind with high affinity to DKK1 (FIGS. 12A-12D).

FIG. 13 shows the results of a TCF/LEF reporter (Wnt signaling) assay. Wnt signaling activation was plotted with SPR binding affinity.

FIGS. 14A-14B show the results of an immune cell activation assay.

A tumor cell killing assay was performed as depicted in FIG. 15A. Results showed that high affinity binders that were also Wnt signaling activators were not always the same as strong immune cell activators and tumor killers (FIGS. 15B-15G).

FIG. 16 depicts antibody yield results from 1 mL Expi293 cell culture. It took 31 days to create 113 anti DKK1 VHH-Fc from DNA synthesis to antibody production.

Example 6: Testing DKK1 Antibodies

This example describes assays used to determine the efficacy of anti-DKK1 leads identified in Example 5.

As seen in FIG. 17A, two epitope bins were apparent among top anti-DKK1 leads. These leads bound to two distinct cysteine-rich domains (CRDs) in hDKK1 (CRD1 or CRD2), resulting in different activation pathways (FIGS. 17B-17C).

Anti-DKK1 VHH leads were found to block DKK1 binding to the receptor (FIGS. 18A-18C) DKK1 binding to LRP5/6 blocks Wnt TCF/LEF signaling; however anti-DKK1 leads blocked DKK1 binding to the receptor, which resulted in TCF/LEF signal activation.

Dual functional activity of DKK1-100 and DKK1-99 was tested in signaling assays, immune cell activation, and tumor cell killing (FIGS. 19A-19C). FIGS. 22A-22C showed that antagonism of DKK1 inhibition of WNT in TCF/LEF assays is biphasic. Transient and cell line TCF/LEF reporter rankings were found to match in functional assays (FIGS. 23A-23B).

DKK1 antibodies were tested for binding to LRP6 (FIG. 24 and FIGS. 25A-25C) and for activation of immune cells (FIGS. 26A-26B and FIGS. 27A-27C). Signaling titration assays were used to identify antagonists (FIGS. 28A-28D). Additional immune assays were also performed (FIGS. 28A-28B).

Example 7: In Vivo Efficacy of DKK1 Antibodies

Preclinical studies in tumor regression are described in FIG. 20A, using a mouse model. Results of in vivo efficacy in PC3 tumor regression in SCID mice is shown in FIG. 20B-20D.

Lung tumor organoid killing by immune cells with DKK1 inhibition is shown in FIG. 30.

While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

1-9. (canceled)

10. An antibody or antibody fragment comprising a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 295-392, 394-712, or 2164-2258.

11. The antibody or antibody fragment of claim 10, wherein the antibody or antibody fragment binds to a spike glycoprotein.

12. The antibody or antibody fragment of claim 10, wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein.

13. The antibody or antibody fragment of claim 10, wherein the antibody or antibody fragment comprises a KD of less than 50 nM.

14. The antibody or antibody fragment of claim 10, wherein the antibody or antibody fragment comprises a KD of less than 25 nM.

15. The antibody or antibody fragment of claim 10, wherein the antibody or antibody fragment comprises a KD of less than 10 nM.

16. The antibody or antibody fragment of claim 10, wherein the antibody or antibody fragment comprises a KD of less than 5 nM.

17. The antibody or antibody fragment of claim 10, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.

18. The antibody or antibody fragment of claim 10, wherein the antibody is a single domain antibody.

19. A nucleic acid composition comprising: a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-98 or 919-1332; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 99-196 or 1333-1746; and (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 197-294 or 1747-2160; and an excipient.

20-29. (canceled)

30. An antibody or antibody fragment comprising a variable domain, light chain region (VL) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 713-918.

31. The antibody or antibody fragment of claim 30, wherein the antibody or antibody fragment binds to a spike glycoprotein.

32. The antibody or antibody fragment of claim 30, wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein.

33. The antibody or antibody fragment of claim 30, wherein the antibody or antibody fragment comprises a KD of less than 50 nM.

34. The antibody or antibody fragment of claim 30, wherein the antibody or antibody fragment comprises a KD of less than 25 nM.

35. The antibody or antibody fragment of claim 30, wherein the antibody or antibody fragment comprises a KD of less than 10 nM.

36. The antibody or antibody fragment of claim 30, wherein the antibody or antibody fragment comprises a KD of less than 5 nM.

37. The antibody or antibody fragment of claim 30, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.

38. The antibody or antibody fragment of claim 30, wherein the antibody is a single domain antibody.

39. (canceled)

40. (canceled)

41. The nucleic acid composition of claim 19, further comprising a second nucleic acid encoding a variable domain, light chain region (VL) comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 2259-2464; (b) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 2465-2521; and (c) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 2522-2727.